imidazolidines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	imidazolidines	go back to main search page
Accession:	CHEBI:38261	browse the term

show annotations for term's descendants Sort by:
Rat (1007) Mouse (1004) Human (1007) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (1007)

4-hydroxyphenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions

[CYP2C9 protein results in increased hydroxylation of Phenytoin] which results in increased abundance of hydroxyphenytoin; Miconazole inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Phenytoin] which results in increased abundance of hydroxyphenytoin]

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

UGT1A1 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

UDP glucuronosyltransferase family 1 member A4

multiple interactions

UGT1A4 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 2:233,718,736...233,773,300
Ensembl chr 2:233,718,736...233,773,300

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

UGT1A6 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300

G

UDP glucuronosyltransferase family 1 member A9

multiple interactions

UGT1A9 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300

G

UDP glucuronosyltransferase family 2 member B15

increases metabolic processing

UGT2B15 protein results in increased metabolism of hydroxyphenytoin

NCBI chr 4:68,646,597...68,670,652
Ensembl chr 4:68,646,597...68,670,652

7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin D2 receptor

multiple interactions

BW 245C binds to and results in increased activity of PTGDR protein
BW 245C binds to and results in increased activity of PTGDR protein; BW 245C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

PMID:9579725 PMID:15528449 PMID:20719937

NCBI chr14:52,267,698...52,280,914
Ensembl chr14:52,267,698...52,276,724

G

transforming growth factor beta 1

decreases response to substance

BW 245C results in decreased susceptibility to TGFB1 protein

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

allantoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]

NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554

G

interleukin 1 beta

decreases secretion
increases secretion

Allantoin results in decreased secretion of IL1B protein
Allantoin results in increased secretion of IL1B protein

PMID:30654793 PMID:32382552

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

increases secretion
decreases secretion

Allantoin results in increased secretion of IL6 protein
Allantoin results in decreased secretion of IL6 protein

PMID:30654793 PMID:32382552

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

leptin receptor

affects abundance

LEPR affects the abundance of Allantoin

NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559

G

nitric oxide synthase 2

decreases expression
increases expression

Allantoin results in decreased expression of NOS2 protein
Allantoin results in increased expression of NOS2 protein

PMID:30654793 PMID:32382552

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

prostaglandin-endoperoxide synthase 2

decreases expression

Allantoin results in decreased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

transforming growth factor beta 1

increases expression

Allantoin results in increased expression of TGFB1 protein

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

tumor necrosis factor

increases secretion
decreases secretion

Allantoin results in increased secretion of TNF protein
Allantoin results in decreased secretion of TNF protein

PMID:30654793 PMID:32382552

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

vascular endothelial growth factor A

increases expression
affects secretion

Allantoin results in increased expression of VEGFA protein
Allantoin affects the secretion of VEGFA protein

PMID:30654793 PMID:32382552

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

xanthine dehydrogenase

multiple interactions

[2,2,5,7,8-pentamethyl-1-hydroxychroman results in decreased activity of XDH protein] which results in decreased abundance of Allantoin

NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742

Azimilide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

azimilide results in decreased activity of KCNH2 protein
Acids inhibits the reaction [azimilide results in decreased activity of KCNH2 protein]; azimilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [azimilide results in decreased activity of KCNH2 protein]; Potassium inhibits the reaction [azimilide results in decreased activity of KCNH2 protein]

PMID:15821840 PMID:16960444 PMID:18057881

NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321

BW A868C

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin D2 receptor

multiple interactions

BW A868C binds to and results in increased activity of PTGDR protein; BW A868C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]
BW A868C binds to and results in decreased activity of PTGDR protein

PMID:9579725 PMID:15528449

NCBI chr14:52,267,698...52,280,914
Ensembl chr14:52,267,698...52,276,724

creatinine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Creatinine

NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]

NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Creatinine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Creatinine]

NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477

G

leptin receptor

affects abundance
multiple interactions
increases abundance

LEPR affects the abundance of Creatinine
Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]; swietenine inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]

PMID:20567778 PMID:29988851 PMID:36066211

NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559

G

NFE2 like bZIP transcription factor 2

multiple interactions

[NFE2L2 protein affects the susceptibility to ochratoxin A] which results in increased abundance of Creatinine

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[SC 560 results in decreased activity of PTGS1 protein] which results in increased abundance of Creatinine

NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703

G

solute carrier family 47 member 1

multiple interactions

Creatinine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034

G

solute carrier family 47 member 2

multiple interactions

Creatinine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979

G

superoxide dismutase 2

decreases abundance

SOD2 protein results in decreased abundance of Creatinine

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

dantrolene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2 (JR blood group)

affects transport

ABCG2 protein affects the transport of Dantrolene

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

angiotensin converting enzyme 2

increases expression

Dantrolene results in increased expression of ACE2 mRNA

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

activating transcription factor 4

decreases expression
multiple interactions

Dantrolene results in decreased expression of ATF4 protein
Dantrolene affects the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein]; Dantrolene promotes the reaction [Thapsigargin results in increased expression of ATF4 mRNA]

PMID:15921666 PMID:32578922

NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683

G

BCL2 associated X, apoptosis regulator

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of BAX mRNA]

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

increases expression

Dantrolene results in increased expression of BCL2 protein

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 11

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of BCL2L11 mRNA]

NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444

G

brain derived neurotrophic factor

multiple interactions

Dantrolene inhibits the reaction [Oxygen deficiency results in increased secretion of BDNF protein]

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

calpain 1

decreases expression

Dantrolene results in decreased expression of CAPN1 mRNA; Dantrolene results in decreased expression of CAPN1 protein

NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006

G

calpain 2

decreases expression

Dantrolene results in decreased expression of CAPN2 mRNA; Dantrolene results in decreased expression of CAPN2 protein

NCBI chr 1:223,701,597...223,776,018
Ensembl chr 1:223,701,593...223,776,018

G

calpain 3

decreases expression

Dantrolene results in decreased expression of CAPN3 mRNA; Dantrolene results in decreased expression of CAPN3 protein

NCBI chr15:42,359,501...42,412,317
Ensembl chr15:42,359,498...42,412,949

G

caspase 3

multiple interactions

Dantrolene inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]

PMID:17079870 PMID:23022152

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

C-C motif chemokine ligand 2

decreases expression

Dantrolene results in decreased expression of CCL2 mRNA

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 5

affects expression

Dantrolene affects the expression of CCL5 protein

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

C-X-C motif chemokine ligand 2

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of CXCL2 mRNA]

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

multiple interactions

Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

DNA damage inducible transcript 3

decreases phosphorylation
multiple interactions

Dantrolene results in decreased phosphorylation of DDIT3 protein
Dantrolene inhibits the reaction [Halothane results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 protein]

PMID:15921666 PMID:32578922 PMID:32795494

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

endothelin 1

decreases activity

Dantrolene results in decreased activity of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

eukaryotic translation initiation factor 2 alpha kinase 3

decreases phosphorylation

Dantrolene results in decreased phosphorylation of EIF2AK3 protein

NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518

G

eukaryotic translation initiation factor 2 subunit alpha

decreases phosphorylation
multiple interactions

Dantrolene results in decreased phosphorylation of EIF2S1 protein
Dantrolene inhibits the reaction [tributyltin results in increased phosphorylation of EIF2S1 protein]

PMID:15921666 PMID:23743301

NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516

G

FKBP prolyl isomerase 1A

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of FKBP1A mRNA]

NCBI chr20:1,368,978...1,393,054
Ensembl chr20:1,368,977...1,393,164

G

FKBP prolyl isomerase 1B

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of FKBP1B mRNA]

NCBI chr 2:24,033,206...24,063,681
Ensembl chr 2:24,049,701...24,063,681

G

glial fibrillary acidic protein

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein]

PMID:21863293 PMID:21879721

NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937

G

glutamic--pyruvic transaminase

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of GPT protein]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

heme oxygenase 1

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of HMOX1 mRNA]

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

homer scaffold protein 1

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of HOMER1 mRNA]

NCBI chr 5:79,372,636...79,514,134
Ensembl chr 5:79,372,636...79,514,134

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Dantrolene inhibits the reaction [tributyltin results in increased expression of HSPA5 protein]

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

interferon gamma

multiple interactions

Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

insulin like growth factor 1

decreases response to substance

Dantrolene results in decreased susceptibility to IGF1 protein

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

insulin like growth factor 2

decreases response to substance

Dantrolene results in decreased susceptibility to IGF2 protein

NCBI chr11:2,129,117...2,149,566
Ensembl chr11:2,129,112...2,158,391

G

interleukin 10

multiple interactions
affects expression

Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]
Dantrolene affects the expression of IL10 protein

PMID:17707769 PMID:25051504

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 beta

affects expression
multiple interactions

Dantrolene affects the expression of IL1B mRNA
Dantrolene inhibits the reaction [Halothane results in increased expression of IL1B mRNA]

PMID:25051504 PMID:32795494

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions

Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Dantrolene results in decreased activity of KCNH2 protein

NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321

G

potassium inwardly rectifying channel subfamily J member 11

multiple interactions

Dantrolene inhibits the reaction [KCNJ11 protein mutant form results in increased abundance of Calcium]

NCBI chr11:17,385,248...17,389,346
Ensembl chr11:17,365,172...17,389,331

G

leptin

decreases expression

Dantrolene results in decreased expression of LEP protein

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

myocyte enhancer factor 2A

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein]

NCBI chr15:99,565,417...99,716,488
Ensembl chr15:99,565,417...99,716,488

G

myocyte enhancer factor 2C

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein]

NCBI chr 5:88,717,117...88,904,105
Ensembl chr 5:88,717,117...88,904,257

G

myosin heavy chain 7

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]

NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660

G

neurofilament light chain

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein]

PMID:21863293 PMID:21879721

NCBI chr 8:24,950,955...24,956,612
Ensembl chr 8:24,950,955...24,956,721

G

neurofilament medium chain

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein]

PMID:21863293 PMID:21879721

NCBI chr 8:24,913,761...24,919,093
Ensembl chr 8:24,913,758...24,919,098

G

natriuretic peptide A

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPA mRNA]

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

natriuretic peptide B

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPB mRNA]

NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945

G

ryanodine receptor 1

multiple interactions

Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]; Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium]

NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273

G

ryanodine receptor 2

multiple interactions

Dantrolene inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]]

NCBI chr 1:237,042,184...237,833,988
Ensembl chr 1:237,042,184...237,833,988

G

S100 calcium binding protein A8

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of S100A8 mRNA]

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

S100 calcium binding protein A9

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of S100A9 mRNA]

NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023

G

steroidogenic acute regulatory protein

multiple interactions

Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

tumor necrosis factor

decreases expression
multiple interactions

Dantrolene results in decreased expression of TNF protein
Dantrolene inhibits the reaction [Halothane results in increased expression of TNF mRNA]

PMID:11236903 PMID:32795494

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

vascular cell adhesion molecule 1

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of VCAM1 mRNA]

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

vimentin

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein]

PMID:21863293 PMID:21879721

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

X-box binding protein 1

multiple interactions

Dantrolene inhibits the reaction [perfluorooctanoic acid results in increased expression of XBP1 mRNA alternative form]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form]

NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597

enzalutamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases expression

enzalutamide results in decreased expression of AADAT mRNA

NCBI chr 4:170,060,222...170,094,292
Ensembl chr 4:170,060,222...170,091,699

G

ATP binding cassette subfamily C member 4 (PEL blood group)

decreases expression

enzalutamide results in decreased expression of ABCC4 mRNA

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

acyl-CoA synthetase medium chain family member 1

decreases expression

enzalutamide results in decreased expression of ACSM1 mRNA

NCBI chr16:20,623,235...20,697,680
Ensembl chr16:20,623,235...20,698,890

G

ADAM metallopeptidase domain 10

affects expression

enzalutamide affects the expression of ADAM10 mRNA

NCBI chr15:58,588,809...58,749,707
Ensembl chr15:58,588,809...58,749,791

G

ADAM metallopeptidase domain 17

affects expression

enzalutamide affects the expression of ADAM17 mRNA

NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732

G

ADP-ribose/CDP-alcohol diphosphatase, manganese dependent

decreases expression

enzalutamide results in decreased expression of ADPRM mRNA

NCBI chr17:10,697,594...10,711,558
Ensembl chr17:10,697,594...10,711,558

G

ALF transcription elongation factor 3

decreases expression

enzalutamide results in decreased expression of AFF3 mRNA

NCBI chr 2:99,545,419...100,142,590
Ensembl chr 2:99,545,419...100,192,428

G

aldehyde dehydrogenase 1 family member A3

decreases expression

enzalutamide results in decreased expression of ALDH1A3 mRNA

NCBI chr15:100,879,831...100,916,626
Ensembl chr15:100,877,714...100,916,626

G

alpha kinase 2

decreases expression

enzalutamide results in decreased expression of ALPK2 mRNA

NCBI chr18:58,481,247...58,629,091
Ensembl chr18:58,481,247...58,629,091

G

annexin A4

affects expression

enzalutamide affects the expression of ANXA4 mRNA

NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112

G

aph-1 homolog A, gamma-secretase subunit

affects expression

enzalutamide affects the expression of APH1A mRNA

NCBI chr 1:150,265,404...150,269,016
Ensembl chr 1:150,265,399...150,269,580

G

aph-1 homolog B, gamma-secretase subunit

affects expression

enzalutamide affects the expression of APH1B mRNA

NCBI chr15:63,277,605...63,309,126
Ensembl chr15:63,276,018...63,309,126

G

amyloid beta precursor protein

affects expression

enzalutamide affects the expression of APP mRNA

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

androgen receptor

decreases response to substance
decreases expression
decreases activity
multiple interactions

AR alternative form results in decreased susceptibility to enzalutamide; AR protein alternative form results in decreased susceptibility to enzalutamide; AR protein results in decreased susceptibility to enzalutamide
enzalutamide results in decreased expression of AR protein; enzalutamide results in decreased expression of AR protein alternative form
enzalutamide results in decreased activity of AR protein
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; [enzalutamide co-treated with Niclosamide] results in decreased expression of AR protein; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR mRNA alternative form; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR protein; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR protein alternative form; [nirogacestat results in increased susceptibility to enzalutamide] which results in decreased expression of AR protein; enzalutamide binds to and results in decreased localization of and results in decreased activity of AR protein; enzalutamide inhibits the reaction [Dihydrotestosterone affects the localization of AR protein]; enzalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; enzalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; enzalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Niclosamide inhibits the reaction [AR protein alternative form results in decreased susceptibility to enzalutamide]

PMID:19359544 PMID:24740322 PMID:24759320 PMID:25908785 PMID:25970160 More...

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

alpha-2-glycoprotein 1, zinc-binding

decreases expression

enzalutamide results in decreased expression of AZGP1 mRNA

NCBI chr 7:99,966,730...99,976,031
Ensembl chr 7:99,966,720...99,976,042

G

baculoviral IAP repeat containing 5

multiple interactions

enzalutamide promotes the reaction [Niclosamide results in decreased expression of BIRC5 protein]

NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636

G

bone morphogenetic protein receptor type 1B

decreases expression

enzalutamide results in decreased expression of BMPR1B mRNA

NCBI chr 4:94,757,955...95,158,450
Ensembl chr 4:94,757,955...95,158,448

G

chromosome 1 open reading frame 116

decreases expression

enzalutamide results in decreased expression of C1ORF116 mRNA

NCBI chr 1:207,018,522...207,032,756
Ensembl chr 1:207,018,522...207,032,756

G

caspase 3

multiple interactions
decreases expression

enzalutamide promotes the reaction [NVP-BHG712 results in increased cleavage of CASP3 protein]
enzalutamide results in decreased expression of CASP3 protein

PMID:32184358 PMID:32805266

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 8

decreases expression

enzalutamide results in decreased expression of CASP8 protein

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

cyclin B1

decreases expression

enzalutamide results in decreased expression of CCNB1 protein

NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245

G

CD46 molecule

increases expression

enzalutamide results in increased expression of CD46 protein

NCBI chr 1:207,752,038...207,795,516
Ensembl chr 1:207,752,037...207,795,513

G

cell division cycle 25C

multiple interactions

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of CDC25C mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of CDC25C protein

NCBI chr 5:138,285,265...138,338,355
Ensembl chr 5:138,285,269...138,338,355

G

cyclin dependent kinase inhibitor 1B

affects expression

enzalutamide affects the expression of CDKN1B mRNA

NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369

G

CCAAT enhancer binding protein alpha

affects expression

enzalutamide affects the expression of CEBPA mRNA

NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534

G

CREB binding protein

affects expression

enzalutamide affects the expression of CREBBP mRNA

NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713

G

cysteine rich secretory protein 3

decreases expression

enzalutamide results in decreased expression of CRISP3 mRNA

NCBI chr 6:49,727,376...49,744,388
Ensembl chr 6:49,727,376...49,744,437

G

crystallin mu

decreases expression
multiple interactions

enzalutamide results in decreased expression of CRYM mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of CRYM mRNA]

NCBI chr16:21,258,521...21,303,062
Ensembl chr16:21,238,874...21,303,083

G

chondroitin sulfate N-acetylgalactosaminyltransferase 1

decreases expression

enzalutamide results in decreased expression of CSGALNACT1 mRNA

NCBI chr 8:19,404,161...19,757,908
Ensembl chr 8:19,404,161...19,758,029

G

dipeptidyl peptidase 4

decreases expression

enzalutamide results in decreased expression of DPP4 mRNA

NCBI chr 2:161,992,245...162,074,215
Ensembl chr 2:161,992,245...162,074,394

G

deltex E3 ubiquitin ligase 2

affects expression

enzalutamide affects the expression of DTX2 mRNA

NCBI chr 7:76,461,709...76,505,991
Ensembl chr 7:76,461,676...76,505,995

G

deltex E3 ubiquitin ligase 3

affects expression

enzalutamide affects the expression of DTX3 mRNA

NCBI chr12:57,604,824...57,609,802
Ensembl chr12:57,604,622...57,609,804

G

deltex E3 ubiquitin ligase 4

affects expression

enzalutamide affects the expression of DTX4 mRNA

NCBI chr11:59,171,430...59,208,588
Ensembl chr11:59,171,430...59,208,588

G

ER degradation enhancing alpha-mannosidase like protein 3

decreases expression

enzalutamide results in decreased expression of EDEM3 mRNA

NCBI chr 1:184,690,237...184,754,858
Ensembl chr 1:184,690,237...184,754,907

G

embryonic ectoderm development

decreases expression
multiple interactions

enzalutamide results in decreased expression of EED protein
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; enzalutamide promotes the reaction [GSK-2816126 results in decreased expression of EED protein]; GSK-2816126 promotes the reaction [enzalutamide results in decreased expression of EED protein]

NCBI chr11:86,244,753...86,287,615
Ensembl chr11:86,201,212...86,278,813

G

EF-hand calcium binding domain 12

decreases expression

enzalutamide results in decreased expression of EFCAB12 mRNA

NCBI chr 3:129,401,321...129,428,636
Ensembl chr 3:129,401,321...129,428,636

G

elongation factor for RNA polymerase II 2

decreases expression

enzalutamide results in decreased expression of ELL2 mRNA

NCBI chr 5:95,885,098...95,961,851
Ensembl chr 5:95,885,098...95,961,851

G

ELOVL fatty acid elongase 7

decreases expression

enzalutamide results in decreased expression of ELOVL7 mRNA

NCBI chr 5:60,751,791...60,844,269
Ensembl chr 5:60,751,791...60,844,274

G

E1A binding protein p300

affects expression

enzalutamide affects the expression of EP300 mRNA

NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077

G

EPH receptor B4

affects response to substance
multiple interactions

EPHB4 protein affects the susceptibility to enzalutamide
enzalutamide promotes the reaction [EPHB4 protein affects the expression of KLK3 protein]; EPHB4 protein affects the reaction [enzalutamide results in decreased cleavage of PARP1 protein]

NCBI chr 7:100,802,565...100,827,523
Ensembl chr 7:100,802,565...100,827,523

G

epsin 1

affects expression

enzalutamide affects the expression of EPN1 mRNA

NCBI chr19:55,675,226...55,709,533
Ensembl chr19:55,675,226...55,709,858

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

decreases expression
multiple interactions

enzalutamide results in decreased expression of EZH2 protein
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]

NCBI chr 7:148,807,383...148,884,291
Ensembl chr 7:148,807,257...148,884,321

G

FKBP prolyl isomerase 5

decreases expression
multiple interactions

enzalutamide results in decreased expression of FKBP5 mRNA
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of FKBP5 mRNA; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of FKBP5 mRNA]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of FKBP5 mRNA]

NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583

G

forkhead box A1

affects expression

enzalutamide affects the expression of FOXA1 mRNA

NCBI chr14:37,589,552...37,595,249
Ensembl chr14:37,589,552...37,596,059

G

polypeptide N-acetylgalactosaminyltransferase 11

affects expression

enzalutamide affects the expression of GALNT11 mRNA

NCBI chr 7:152,025,674...152,122,340
Ensembl chr 7:152,025,674...152,122,340

G

GDP-mannose 4,6-dehydratase

affects expression

enzalutamide affects the expression of GMDS mRNA

NCBI chr 6:1,623,806...2,245,605
Ensembl chr 6:1,623,806...2,245,605

G

glycine N-methyltransferase

decreases expression

enzalutamide results in decreased expression of GNMT mRNA

NCBI chr 6:42,960,754...42,963,880
Ensembl chr 6:42,960,754...42,963,880

G

glutamic-oxaloacetic transaminase 1

affects expression

enzalutamide affects the expression of GOT1 mRNA

NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624

G

growth regulating estrogen receptor binding 1

decreases expression

enzalutamide results in decreased expression of GREB1 mRNA

NCBI chr 2:11,482,888...11,642,788
Ensembl chr 2:11,482,341...11,642,788

G

hes family bHLH transcription factor 1

affects expression

enzalutamide affects the expression of HES1 mRNA

NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732

G

HNF1 homeobox B

affects expression

enzalutamide affects the expression of HNF1B mRNA

NCBI chr17:37,686,431...37,745,059
Ensembl chr17:37,686,431...37,745,059

G

HOX transcript antisense RNA

affects response to substance

HOTAIR mRNA affects the susceptibility to enzalutamide

NCBI chr12:53,962,312...53,974,954
Ensembl chr12:53,962,308...53,974,956

G

intraflagellar transport 172

affects expression

enzalutamide affects the expression of IFT172 mRNA

NCBI chr 2:27,444,377...27,489,743
Ensembl chr 2:27,444,377...27,489,805

G

intraflagellar transport 74

affects expression

enzalutamide affects the expression of IFT74 mRNA

NCBI chr 9:26,947,110...27,066,134
Ensembl chr 9:26,947,039...27,066,134

G

insulin like growth factor 1

decreases expression

enzalutamide results in decreased expression of IGF1 mRNA

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

insulin like growth factor 1 receptor

decreases expression

enzalutamide results in decreased expression of IGF1R mRNA

NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530

G

interleukin 6

decreases response to substance
multiple interactions

IL6 protein results in decreased susceptibility to enzalutamide
Niclosamide inhibits the reaction [IL6 protein results in decreased susceptibility to enzalutamide]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

IQ motif containing GTPase activating protein 2

decreases expression

enzalutamide results in decreased expression of IQGAP2 mRNA

NCBI chr 5:76,403,285...76,708,132
Ensembl chr 5:76,403,285...76,708,132

G

itchy E3 ubiquitin protein ligase

affects expression

enzalutamide affects the expression of ITCH mRNA

NCBI chr20:34,363,273...34,511,773
Ensembl chr20:34,363,235...34,511,773

G

integrin subunit beta 1 binding protein 1

affects expression

enzalutamide affects the expression of ITGB1BP1 mRNA

NCBI chr 2:9,403,475...9,423,569
Ensembl chr 2:9,403,475...9,423,528

G

jagged canonical Notch ligand 1

affects expression

enzalutamide affects the expression of JAG1 mRNA

NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999

G

jagged canonical Notch ligand 2

affects expression

enzalutamide affects the expression of JAG2 mRNA

NCBI chr14:105,140,995...105,168,776
Ensembl chr14:105,140,982...105,168,824

G

lysine acetyltransferase 2B

affects expression

enzalutamide affects the expression of KAT2B mRNA

NCBI chr 3:20,040,446...20,154,404
Ensembl chr 3:20,040,446...20,154,404

G

lysine demethylase 1A

multiple interactions

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of CRYM mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of LCP1 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MAP2 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MYO1B mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of SLC22A3 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of TMCC3 mRNA]

NCBI chr 1:23,019,468...23,083,689
Ensembl chr 1:23,019,443...23,083,689

G

kinesin family member 5C

decreases expression

enzalutamide results in decreased expression of KIF5C mRNA

NCBI chr 2:148,875,227...149,026,759
Ensembl chr 2:148,875,227...149,026,759

G

kallikrein related peptidase 2

decreases expression

enzalutamide results in decreased expression of KLK2 mRNA

NCBI chr19:50,873,439...50,880,567
Ensembl chr19:50,861,568...50,880,567

G

kallikrein related peptidase 3

increases expression
multiple interactions
decreases expression

enzalutamide results in increased expression of KLK3 mRNA
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of KLK3 mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of KLK3 protein; [nirogacestat results in increased susceptibility to enzalutamide] which results in decreased expression of KLK3 protein; enzalutamide promotes the reaction [EPHB4 protein affects the expression of KLK3 protein]; enzalutamide promotes the reaction [Niclosamide results in decreased expression of KLK3 protein]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of KLK3 mRNA]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of KLK3 protein]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]
enzalutamide results in decreased expression of KLK3 mRNA; enzalutamide results in decreased expression of KLK3 protein

PMID:19359544 PMID:23704919 PMID:25970160 PMID:29581250 PMID:30940724 More...

NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764

G

keratin 19

affects expression

enzalutamide affects the expression of KRT19 mRNA

NCBI chr17:41,523,617...41,528,308
Ensembl chr17:41,523,617...41,528,308

G

LCK proto-oncogene, Src family tyrosine kinase

decreases expression

enzalutamide results in decreased expression of LCK mRNA

NCBI chr 1:32,251,265...32,286,165
Ensembl chr 1:32,251,244...32,286,165

G

lymphocyte cytosolic protein 1

decreases expression
multiple interactions

enzalutamide results in decreased expression of LCP1 mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of LCP1 mRNA]

NCBI chr13:46,125,923...46,182,177
Ensembl chr13:46,125,920...46,211,871

G

MAF bZIP transcription factor

decreases expression

enzalutamide results in decreased expression of MAF mRNA

NCBI chr16:79,202,622...79,600,737
Ensembl chr16:79,585,843...79,600,737

G

mastermind like transcriptional coactivator 1

affects expression

enzalutamide affects the expression of MAML1 mRNA

NCBI chr 5:179,732,822...179,777,283
Ensembl chr 5:179,732,822...179,777,283

G

mastermind like transcriptional coactivator 3

affects expression

enzalutamide affects the expression of MAML3 mRNA

NCBI chr 4:139,716,753...140,154,184
Ensembl chr 4:139,716,753...140,154,184

G

microtubule associated protein 1 light chain 3 beta

multiple interactions

[enzalutamide co-treated with GSK-2816126] results in increased expression of MAP1LC3B protein modified form

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

microtubule associated protein 2

decreases expression
multiple interactions

enzalutamide results in decreased expression of MAP2 mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MAP2 mRNA]

NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,147

G

midkine

affects expression

enzalutamide affects the expression of MDK mRNA

NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837

G

MIB E3 ubiquitin protein ligase 1

affects expression

enzalutamide affects the expression of MIB1 mRNA

NCBI chr18:21,704,916...21,870,953
Ensembl chr18:21,704,957...21,870,953

G

MIB E3 ubiquitin protein ligase 2

affects expression

enzalutamide affects the expression of MIB2 mRNA

NCBI chr 1:1,613,731...1,630,605
Ensembl chr 1:1,615,454...1,630,605

G

marker of proliferation Ki-67

multiple interactions

enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of MKI67 protein]

NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423

G

mitochondrial pyruvate carrier 2

decreases expression

enzalutamide results in decreased expression of BRP44 mRNA

NCBI chr 1:167,916,675...167,937,072
Ensembl chr 1:167,916,675...167,937,072

G

microseminoprotein beta

decreases expression

enzalutamide results in decreased expression of MSMB mRNA

NCBI chr10:46,033,313...46,046,269
Ensembl chr10:46,033,307...46,048,180

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression
affects expression

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of MYC protein; enzalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; enzalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC mRNA]; enzalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC protein]; enzalutamide promotes the reaction [Niclosamide results in decreased expression of MYC protein]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of MYC protein]
enzalutamide results in decreased expression of MYC protein
enzalutamide affects the expression of MYC mRNA

PMID:24759320 PMID:25970160 PMID:30940724 PMID:32184358

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

myosin IB

decreases expression
multiple interactions

enzalutamide results in decreased expression of MYO1B mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MYO1B mRNA]

NCBI chr 2:191,245,404...191,425,386
Ensembl chr 2:191,245,185...191,425,389

G

nicastrin

affects expression

enzalutamide affects the expression of NCSTN mRNA

NCBI chr 1:160,343,383...160,358,949
Ensembl chr 1:160,343,294...160,358,952

G

neuralized E3 ubiquitin protein ligase 1B

affects expression

enzalutamide affects the expression of NEURL1B mRNA

NCBI chr 5:172,641,263...172,691,540
Ensembl chr 5:172,641,263...172,691,540

G

NFKB activating protein

affects expression

enzalutamide affects the expression of NKAP mRNA

NCBI chr X:119,920,672...119,943,751
Ensembl chr X:119,920,672...119,943,751

G

NK3 homeobox 1

multiple interactions
decreases expression

enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of NKX3-1 mRNA]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of NKX3-1 mRNA]

PMID:29581250 PMID:32184358

NCBI chr 8:23,678,693...23,682,938
Ensembl chr 8:23,678,697...23,682,938

G

notchless homolog 1

affects expression

enzalutamide affects the expression of NLE1 mRNA

NCBI chr17:35,128,730...35,142,303
Ensembl chr17:35,128,730...35,142,304

G

notch receptor 1

affects response to substance
multiple interactions
affects expression

NOTCH1 protein affects the susceptibility to enzalutamide
[NOTCH1 protein affects the susceptibility to enzalutamide] which affects the cleavage of PARP1 protein
enzalutamide affects the expression of NOTCH1 mRNA

NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048

G

notch receptor 2

affects expression

enzalutamide affects the expression of NOTCH2 mRNA

NCBI chr 1:119,911,553...120,069,662
Ensembl chr 1:119,911,553...120,100,779

G

notch receptor 3

affects expression

enzalutamide affects the expression of NOTCH3 mRNA

NCBI chr19:15,159,038...15,200,995
Ensembl chr19:15,159,038...15,200,995

G

poly(ADP-ribose) polymerase 1

decreases cleavage
multiple interactions

enzalutamide results in decreased cleavage of PARP1 protein
[enzalutamide co-treated with GSK-2816126] results in increased cleavage of PARP1 protein; [nirogacestat results in increased susceptibility to enzalutamide] which results in increased cleavage of PARP1 protein; [NOTCH1 protein affects the susceptibility to enzalutamide] which affects the cleavage of PARP1 protein; enzalutamide promotes the reaction [NVP-BHG712 results in increased cleavage of PARP1 protein]; EPHB4 protein affects the reaction [enzalutamide results in decreased cleavage of PARP1 protein]

PMID:30940724 PMID:32184358 PMID:32805266

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

p53 apoptosis effector related to PMP22

affects expression

enzalutamide affects the expression of PERP mRNA

NCBI chr 6:138,088,505...138,107,419
Ensembl chr 6:138,088,505...138,107,419

G

phospholipase A2 group V

decreases expression

enzalutamide results in decreased expression of PLA2G5 mRNA

NCBI chr 1:20,028,408...20,091,911
Ensembl chr 1:20,028,179...20,091,911

G

polo like kinase 1

multiple interactions

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of PLK1 mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of PLK1 protein; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of PLK1 mRNA]

NCBI chr16:23,678,889...23,690,367
Ensembl chr16:23,677,656...23,690,367

G

procollagen-lysine,2-oxoglutarate 5-dioxygenase 2

decreases expression

enzalutamide results in decreased expression of PLOD2 mRNA

NCBI chr 3:146,069,440...146,161,184
Ensembl chr 3:146,035,139...146,163,725

G

protein O-fucosyltransferase 1

affects expression

enzalutamide affects the expression of POFUT1 mRNA

NCBI chr20:32,207,880...32,238,658
Ensembl chr20:32,207,855...32,238,658

G

presenilin 1

affects expression

enzalutamide affects the expression of PSEN1 mRNA

NCBI chr14:73,136,417...73,223,691
Ensembl chr14:73,136,418...73,223,691

G

presenilin 2

affects expression

enzalutamide affects the expression of PSEN2 mRNA

NCBI chr 1:226,870,616...226,903,668
Ensembl chr 1:226,870,184...226,927,726

G

presenilin enhancer, gamma-secretase subunit

affects expression

enzalutamide affects the expression of PSENEN mRNA

NCBI chr19:35,745,651...35,747,519
Ensembl chr19:35,745,600...35,747,519

G

prostaglandin E receptor 4

decreases expression

enzalutamide results in decreased expression of PTGER4 mRNA

NCBI chr 5:40,679,915...40,746,800
Ensembl chr 5:40,679,915...40,693,735

G

RNA binding motif protein 15

affects expression

enzalutamide affects the expression of RBM15 mRNA

NCBI chr 1:110,339,377...110,346,677
Ensembl chr 1:110,338,506...110,346,681

G

recombination signal binding protein for immunoglobulin kappa J region

affects expression

enzalutamide affects the expression of RBPJ mRNA

NCBI chr 4:26,105,449...26,435,131
Ensembl chr 4:26,163,455...26,435,131

G

regulator of G protein signaling 2

decreases expression

enzalutamide results in decreased expression of RGS2 mRNA

NCBI chr 1:192,809,039...192,812,275
Ensembl chr 1:192,809,039...192,812,275

G

ras homolog family member U

decreases expression

enzalutamide results in decreased expression of RHOU mRNA

NCBI chr 1:228,644,647...228,746,669
Ensembl chr 1:228,735,479...228,746,664

G

ribosomal protein S19

affects expression

enzalutamide affects the expression of RPS19 mRNA

NCBI chr19:41,860,255...41,872,925
Ensembl chr19:41,860,255...41,872,925

G

ribosomal protein S27a

affects expression

enzalutamide affects the expression of RPS27A mRNA

NCBI chr 2:55,231,903...55,235,853
Ensembl chr 2:55,231,903...55,235,853

G

sphingosine-1-phosphate receptor 3

affects expression

enzalutamide affects the expression of S1PR3 mRNA

NCBI chr 9:88,990,863...89,005,155
Ensembl chr 9:88,990,863...89,005,155

G

SEL1L adaptor subunit of SYVN1 ubiquitin ligase

affects expression

enzalutamide affects the expression of SEL1L mRNA

NCBI chr14:81,471,547...81,533,853
Ensembl chr14:81,471,547...81,533,853

G

selenoprotein P

decreases expression

enzalutamide results in decreased expression of SELENOP mRNA

NCBI chr 5:42,799,880...42,811,892
Ensembl chr 5:42,799,880...42,887,392

G

solute carrier family 22 member 3

decreases expression
multiple interactions

enzalutamide results in decreased expression of SLC22A3 mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of SLC22A3 mRNA]

NCBI chr 6:160,348,378...160,452,577
Ensembl chr 6:160,348,378...160,452,577

G

SNW domain containing 1

affects expression

enzalutamide affects the expression of SNW1 mRNA

NCBI chr14:77,717,599...77,761,156
Ensembl chr14:77,717,599...77,761,207

G

suppressor of cytokine signaling 2

decreases expression

enzalutamide results in decreased expression of SOCS2 mRNA

NCBI chr12:93,569,969...93,626,236
Ensembl chr12:93,569,814...93,583,487

G

SRY-box transcription factor 9

affects expression

enzalutamide affects the expression of SOX9 mRNA

NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416

G

spen family transcriptional repressor

affects expression

enzalutamide affects the expression of SPEN mRNA

NCBI chr 1:15,847,707...15,940,456
Ensembl chr 1:15,836,095...15,940,456

G

SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1

decreases expression

enzalutamide results in decreased expression of SPOCK1 mRNA

NCBI chr 5:136,975,298...137,499,326
Ensembl chr 5:136,975,298...137,598,379

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1

decreases expression

enzalutamide results in decreased expression of ST6GALNAC1 mRNA

NCBI chr17:76,617,407...76,643,757
Ensembl chr17:76,624,761...76,643,786

G

signal transducer and activator of transcription 3

decreases response to substance
multiple interactions

STAT3 protein results in decreased susceptibility to enzalutamide
enzalutamide promotes the reaction [Niclosamide results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Niclosamide inhibits the reaction [STAT3 protein results in decreased susceptibility to enzalutamide]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

sushi domain containing 5

affects expression

enzalutamide affects the expression of SUSD5 mRNA

NCBI chr 3:33,150,043...33,218,810
Ensembl chr 3:33,150,043...33,218,810

G

SUZ12 polycomb repressive complex 2 subunit

multiple interactions
decreases expression

[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; enzalutamide promotes the reaction [GSK-2816126 results in decreased expression of SUZ12 protein]; GSK-2816126 promotes the reaction [enzalutamide results in decreased expression of SUZ12 protein]

NCBI chr17:31,937,007...32,001,038
Ensembl chr17:31,937,007...32,001,038

G

teneurin transmembrane protein 1

decreases expression

enzalutamide results in decreased expression of TENM1 mRNA

NCBI chr X:124,375,903...125,204,312
Ensembl chr X:124,375,903...125,204,312

G

transmembrane and coiled-coil domain family 3

decreases expression
multiple interactions

enzalutamide results in decreased expression of TMCC3 mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of TMCC3 mRNA]

NCBI chr12:94,567,122...94,650,557
Ensembl chr12:94,567,122...94,650,557

G

transmembrane serine protease 2

decreases expression

enzalutamide results in decreased expression of TMPRSS2 mRNA

NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116

G

tumor protein D52

decreases expression

enzalutamide results in decreased expression of TPD52 mRNA

NCBI chr 8:80,031,082...80,171,564
Ensembl chr 8:80,034,745...80,231,232

G

transient receptor potential cation channel subfamily M member 8

decreases expression

enzalutamide results in decreased expression of TRPM8 mRNA

NCBI chr 2:233,917,373...234,019,522
Ensembl chr 2:233,917,373...234,019,522

G

ubiquitin A-52 residue ribosomal protein fusion product 1

affects expression

enzalutamide affects the expression of UBA52 mRNA

NCBI chr19:18,563,766...18,577,550
Ensembl chr19:18,571,730...18,577,550

G

ubiquitin B

affects expression

enzalutamide affects the expression of UBB mRNA

NCBI chr17:16,380,779...16,382,745
Ensembl chr17:16,380,798...16,382,745

G

ubiquitin C

affects expression

enzalutamide affects the expression of UBC mRNA

NCBI chr12:124,911,646...124,914,650
Ensembl chr12:124,911,604...124,917,368

G

ubiquitin conjugating enzyme E2 C

multiple interactions

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of UBE2C mRNA

NCBI chr20:45,812,644...45,816,952
Ensembl chr20:45,812,576...45,816,957

G

WD repeat domain 12

affects expression

enzalutamide affects the expression of WDR12 mRNA

NCBI chr 2:202,874,261...202,911,673
Ensembl chr 2:202,874,261...203,014,798

G

WW domain containing transcription regulator 1

decreases expression

enzalutamide results in decreased expression of WWTR1 mRNA

NCBI chr 3:149,517,235...149,724,788
Ensembl chr 3:149,517,235...149,736,714

ethotoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1 group I member 2

multiple interactions

ethotoin binds to and results in increased activity of NR1I2 protein

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

Ethylenethiourea

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase (Yt blood group)

decreases expression
decreases activity

Ethylenethiourea results in decreased expression of ACHE protein
Ethylenethiourea results in decreased activity of ACHE protein

PMID:3868355 PMID:21251949

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

actin like 7A

decreases expression

Ethylenethiourea results in decreased expression of ACTL7A mRNA

NCBI chr 9:108,862,266...108,863,756
Ensembl chr 9:108,862,266...108,863,756

G

anti-Mullerian hormone

decreases expression

Ethylenethiourea results in decreased expression of AMH protein

NCBI chr19:2,249,323...2,252,073
Ensembl chr19:2,249,309...2,252,073

G

ATPase Na+/K+ transporting subunit alpha 2

decreases expression

Ethylenethiourea results in decreased expression of ATP1A2 mRNA

NCBI chr 1:160,115,759...160,143,591
Ensembl chr 1:160,115,759...160,143,591

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of BCL2 mRNA
Ethylenethiourea results in decreased expression of BCL2 mRNA

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

brain expressed X-linked 2

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of BEX2 mRNA
Ethylenethiourea results in decreased expression of BEX2 mRNA

NCBI chr X:103,309,346...103,310,990
Ensembl chr X:103,309,346...103,311,007

G

bone morphogenetic protein 4

decreases expression

Ethylenethiourea results in decreased expression of BMP4 mRNA

PMID:17161201 PMID:18082712

NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761

G

cytochrome P450 family 19 subfamily A member 1

increases expression
multiple interactions
decreases expression

Ethylenethiourea results in increased expression of CYP19A1 mRNA
Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]
Ethylenethiourea results in decreased expression of CYP19A1 mRNA; Ethylenethiourea results in decreased expression of CYP19A1 protein

NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601

G

DNA damage inducible transcript 4

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of DDIT4 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of DDIT4 mRNA

NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036

G

iodothyronine deiodinase 1

decreases expression

Ethylenethiourea results in decreased expression of DIO1 mRNA

NCBI chr 1:53,894,187...53,911,086
Ensembl chr 1:53,891,239...53,911,086

G

iodothyronine deiodinase 2

multiple interactions
decreases expression
affects expression

[Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA
Ethylenethiourea results in decreased expression of DIO2 mRNA
Ethylenethiourea affects the expression of DIO2 mRNA

NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757

G

iodothyronine deiodinase 3

multiple interactions
affects expression
increases expression
decreases expression

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of DIO3 mRNA]
Ethylenethiourea affects the expression of DIO3 protein
Ethylenethiourea results in increased expression of DIO3 mRNA
Ethylenethiourea results in decreased expression of DIO3 mRNA

NCBI chr14:101,561,495...101,563,452
Ensembl chr14:101,560,139...101,563,452

G

early growth response 1

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of EGR1 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of EGR1 mRNA

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

endoplasmic reticulum-golgi intermediate compartment 1

decreases expression

Ethylenethiourea results in decreased expression of ERGIC1 mRNA

NCBI chr 5:172,834,251...172,952,683
Ensembl chr 5:172,834,251...172,952,792

G

estrogen receptor 1

multiple interactions

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of ESR1 mRNA]

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

flavin containing dimethylaniline monoxygenase 2

decreases oxidation
increases oxidation

FMO2 gene polymorphism results in decreased oxidation of Ethylenethiourea
FMO2 protein results in increased oxidation of Ethylenethiourea

NCBI chr 1:171,185,208...171,212,686
Ensembl chr 1:171,185,249...171,212,686

G

fascin actin-bundling protein 2, retinal

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of FSCN2 mRNA
Ethylenethiourea results in decreased expression of FSCN2 mRNA

NCBI chr17:81,515,062...81,537,130
Ensembl chr17:81,528,377...81,537,130

G

FUS RNA binding protein

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of FUS mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of FUS mRNA

NCBI chr16:31,180,110...31,194,871
Ensembl chr16:31,180,138...31,191,605

G

frizzled class receptor 5

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of FZD5 mRNA
Ethylenethiourea results in decreased expression of FZD5 mRNA

NCBI chr 2:207,762,598...207,769,906
Ensembl chr 2:207,762,598...207,769,906

G

gap junction protein alpha 1

multiple interactions
increases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in increased expression of GJA1 mRNA
Ethylenethiourea results in increased expression of GJA1 mRNA

NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727

G

G protein subunit alpha o1

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of GNAO1 mRNA

NCBI chr16:56,191,489...56,357,444
Ensembl chr16:56,191,390...56,357,444

G

general transcription factor IIIC subunit 6

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of GTF3C6 mRNA

NCBI chr 6:110,958,706...110,967,872
Ensembl chr 6:110,958,706...110,967,890

G

H2A.X variant histone

increases phosphorylation

Ethylenethiourea results in increased phosphorylation of H2AX protein

NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465

G

H2B clustered histone 26

decreases expression

Ethylenethiourea results in decreased expression of H2BU1 mRNA

NCBI chr 1:228,458,103...228,458,558
Ensembl chr 1:228,458,103...228,463,104

G

HEXIM P-TEFb complex subunit 2

decreases expression

Ethylenethiourea results in decreased expression of HEXIM2 mRNA

NCBI chr17:45,160,174...45,170,040
Ensembl chr17:45,160,700...45,170,040

G

high mobility group AT-hook 1

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of HMGA1 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of HMGA1 mRNA

NCBI chr 6:34,236,873...34,246,231
Ensembl chr 6:34,236,873...34,246,231

G

homeobox A13

decreases expression

Ethylenethiourea results in decreased expression of HOXA13 mRNA

PMID:17161201 PMID:18082712

NCBI chr 7:27,194,364...27,200,091
Ensembl chr 7:27,193,503...27,200,091

G

homeobox D13

decreases expression

Ethylenethiourea results in decreased expression of HOXD13 mRNA

PMID:17161201 PMID:18082712

NCBI chr 2:176,087,487...176,095,944
Ensembl chr 2:176,092,721...176,095,944

G

interferon induced protein with tetratricopeptide repeats 3

decreases expression

Ethylenethiourea results in decreased expression of IFIT3 mRNA

NCBI chr10:89,327,997...89,340,968
Ensembl chr10:89,327,307...89,377,473

G

interleukin 1 beta

multiple interactions

[aminomethylphosphonic acid (AMPA) co-treated with 2,4-Dichlorophenoxyacetic Acid metabolite co-treated with Ethylenethiourea co-treated with desethylatrazine] results in decreased expression of IL1B protein

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

inhibin subunit alpha

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of INHA mRNA
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of INHA mRNA

NCBI chr 2:219,572,310...219,575,711
Ensembl chr 2:219,569,162...219,575,711

G

inositol polyphosphate-5-phosphatase J

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of INPP5J mRNA

NCBI chr22:31,122,614...31,134,697
Ensembl chr22:31,122,731...31,134,697

G

jagged canonical Notch ligand 1

increases expression

Ethylenethiourea results in increased expression of JAG1 mRNA alternative form

NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999

G

marker of proliferation Ki-67

increases expression

Ethylenethiourea results in increased expression of MKI67 protein

NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423

G

p21 (RAC1) activated kinase 2

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of PAK2 mRNA

NCBI chr 3:196,739,857...196,832,647
Ensembl chr 3:196,739,857...196,832,647

G

POM121 transmembrane nucleoporin like 2

decreases expression

Ethylenethiourea results in decreased expression of POM121L2 mRNA

NCBI chr 6:27,308,377...27,312,273
Ensembl chr 6:27,285,903...27,312,273

G

POU class 5 homeobox 1

multiple interactions
decreases expression

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]
Ethylenethiourea results in decreased expression of POU5F1 mRNA

NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731

G

receptor accessory protein 6

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of REEP6 mRNA

NCBI chr19:1,491,181...1,497,927
Ensembl chr19:1,491,166...1,497,927

G

RUNX family transcription factor 2

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of RUNX2 mRNA

NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349

G

sonic hedgehog signaling molecule

decreases expression

Ethylenethiourea results in decreased expression of SHH mRNA

PMID:16369776 PMID:17161201 PMID:18082712

NCBI chr 7:155,799,980...155,812,463
Ensembl chr 7:155,799,980...155,812,463

G

SRY-box transcription factor 9

increases expression
decreases expression
multiple interactions

Ethylenethiourea results in increased expression of SOX9 protein
Ethylenethiourea results in decreased expression of SOX9 mRNA
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of SOX9 mRNA

PMID:34571837 PMID:35930101

NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416

G

steroidogenic acute regulatory protein

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of STAR mRNA
Ethylenethiourea results in decreased expression of STAR mRNA

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

stimulated by retinoic acid 8

multiple interactions
decreases expression

[Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA
Ethylenethiourea results in decreased expression of STRA8 mRNA

NCBI chr 7:135,231,915...135,258,663
Ensembl chr 7:135,231,979...135,258,663

G

synaptonemal complex protein 1

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of SYCP1 mRNA
[Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA

NCBI chr 1:114,854,088...114,995,370
Ensembl chr 1:114,854,863...114,995,370

G

terminal nucleotidyltransferase 5D

decreases expression

Ethylenethiourea results in decreased expression of TENT5D mRNA

NCBI chr X:80,335,504...80,445,309
Ensembl chr X:80,335,504...80,445,311

G

thyroglobulin

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of TG mRNA
Ethylenethiourea results in decreased expression of TG mRNA

NCBI chr 8:132,866,958...133,134,899
Ensembl chr 8:132,866,958...133,134,903

G

thyroid hormone receptor alpha

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of THRA mRNA
Ethylenethiourea results in decreased expression of THRA mRNA

NCBI chr17:40,062,193...40,093,867
Ensembl chr17:40,058,290...40,093,867

G

thyroid hormone receptor beta

multiple interactions
decreases expression

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]
Ethylenethiourea results in decreased expression of THRB mRNA

NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756

G

thyroid hormone responsive

multiple interactions
decreases expression

[Ethylenethiourea co-treated with Triiodothyronine] results in increased expression of THRSP mRNA
Ethylenethiourea results in decreased expression of THRSP mRNA

NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351

G

thyroid peroxidase

decreases activity
affects activity

Ethylenethiourea results in decreased activity of TPO protein
Ethylenethiourea affects the activity of TPO protein

PMID:7626075 PMID:9248629 PMID:31629072

NCBI chr 2:1,374,047...1,543,673
Ensembl chr 2:1,374,066...1,543,711

G

Wnt family member 4

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of WNT4 mRNA
Ethylenethiourea results in decreased expression of WNT4 mRNA

NCBI chr 1:22,117,313...22,143,097
Ensembl chr 1:22,117,313...22,143,969

G

ZFP36 ring finger protein like 2

decreases expression

Ethylenethiourea results in decreased expression of ZFP36L2 mRNA

NCBI chr 2:43,222,402...43,226,606
Ensembl chr 2:43,222,402...43,226,606

G

zinc finger protein 362

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of ZFP362 mRNA

NCBI chr 1:33,127,522...33,300,719
Ensembl chr 1:33,256,492...33,300,719

G

zinc finger protein 524

decreases expression

Ethylenethiourea results in decreased expression of ZFP524 mRNA

NCBI chr19:55,599,574...55,603,138
Ensembl chr19:55,600,022...55,603,138

G

zinc finger protein 703

decreases expression

Ethylenethiourea results in decreased expression of ZFP703 mRNA

NCBI chr 8:37,695,782...37,700,019
Ensembl chr 8:37,695,782...37,700,019

Hydroxymephenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily C member 19

increases chemical synthesis
multiple interactions

CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin
[CYP2C19 protein results in increased hydroxylation of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; [CYP2C19 protein results in increased metabolism of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]

PMID:12401345 PMID:15155557 PMID:21915887 PMID:23850985 PMID:25084468 More...

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

imidacloprid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase (Yt blood group)

increases activity
increases expression

imidacloprid results in increased activity of ACHE protein
imidacloprid results in increased expression of ACHE protein

PMID:18080902 PMID:26024013 PMID:37648049

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

acyl-CoA thioesterase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ACOT2 gene

NCBI chr14:73,567,620...73,575,658
Ensembl chr14:73,567,620...73,575,658

G

acyl-CoA thioesterase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACOT4 mRNA

NCBI chr14:73,591,873...73,595,766
Ensembl chr14:73,591,873...73,595,766

G

aminoacylase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACY1 mRNA

NCBI chr 3:51,983,535...51,989,197
Ensembl chr 3:51,983,340...51,989,197

G

ADAM metallopeptidase domain 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAM15 gene

NCBI chr 1:155,051,316...155,062,775
Ensembl chr 1:155,050,566...155,062,775

G

ADAMTS like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAMTSL3 gene

NCBI chr15:83,654,123...84,039,842
Ensembl chr15:83,654,088...84,039,842

G

adenylate cyclase 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ADCY6 mRNA

NCBI chr12:48,766,194...48,789,974
Ensembl chr12:48,766,194...48,789,089

G

ADRM1 26S proteasome ubiquitin receptor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ADRM1 mRNA

NCBI chr20:62,302,896...62,308,862
Ensembl chr20:62,302,093...62,308,862

G

alpha fetoprotein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AFP mRNA

NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174

G

angiotensinogen

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AGT mRNA

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

aryl hydrocarbon receptor

affects expression

imidacloprid affects the expression of AHR mRNA

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

androgen induced 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of AIG1 gene

NCBI chr 6:143,059,213...143,343,883
Ensembl chr 6:143,060,496...143,341,058

G

A-kinase anchoring protein 8

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8 mRNA

NCBI chr19:15,353,385...15,379,787
Ensembl chr19:15,353,385...15,379,815

G

A-kinase anchoring protein 8 like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8L mRNA

NCBI chr19:15,380,050...15,418,988
Ensembl chr19:15,380,050...15,419,141

G

albumin

multiple interactions
decreases expression

[imidacloprid co-treated with sodium arsenate] results in decreased expression of ALB protein
imidacloprid results in decreased expression of ALB protein

PMID:30033815 PMID:34993831

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

aldehyde dehydrogenase 9 family member A1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALDH9A1 mRNA

NCBI chr 1:165,662,216...165,698,562
Ensembl chr 1:165,662,216...165,698,562

G

ALG2 alpha-1,3/1,6-mannosyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALG2 mRNA

NCBI chr 9:99,216,425...99,221,942
Ensembl chr 9:99,216,425...99,221,942

G

adenosine monophosphate deaminase 1

decreases expression

imidacloprid results in decreased expression of AMPD1 mRNA

NCBI chr 1:114,673,098...114,695,546
Ensembl chr 1:114,673,090...114,695,618

G

angiopoietin like 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANGPTL4 mRNA

NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370

G

ankyrin repeat and sterile alpha motif domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ANKS3 mRNA

NCBI chr16:4,696,511...4,734,271
Ensembl chr16:4,696,510...4,734,378

G

annexin A11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANXA11 mRNA

NCBI chr10:80,150,889...80,205,808
Ensembl chr10:80,150,889...80,205,572

G

APC regulator of WNT signaling pathway

affects methylation
multiple interactions

imidacloprid affects the methylation of APC promoter
LIF protein affects the reaction [imidacloprid affects the methylation of APC promoter]

NCBI chr 5:112,707,498...112,846,239
Ensembl chr 5:112,707,518...112,846,239

G

aprataxin and PNKP like factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APLF mRNA

NCBI chr 2:68,467,585...68,580,162
Ensembl chr 2:68,467,572...68,655,862

G

apolipoprotein F

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APOF mRNA

NCBI chr12:56,360,568...56,362,857
Ensembl chr12:56,360,568...56,362,857

G

androgen receptor

decreases expression
affects expression

imidacloprid results in decreased expression of AR mRNA; imidacloprid results in decreased expression of AR protein
imidacloprid affects the expression of AR mRNA

PMID:31780179 PMID:35457321

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

ADP ribosylation factor like GTPase 17B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ARF2 mRNA

NCBI chr17:46,274,184...46,361,787
Ensembl chr17:46,274,784...46,361,766
Ensembl chr17:46,274,784...46,361,766

G

actin related protein 2/3 complex subunit 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ARPC1A gene

NCBI chr 7:99,325,898...99,366,262
Ensembl chr 7:99,325,898...99,366,262

G

ankyrin repeat and SOCS box containing 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ASB7 mRNA

NCBI chr15:100,602,589...100,651,701
Ensembl chr15:100,602,589...100,651,701

G

argininosuccinate synthase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ASS1 mRNA

NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274

G

atos homolog A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ATOSA mRNA

NCBI chr15:52,581,321...52,709,815
Ensembl chr15:52,581,317...52,709,817

G

ATP synthase membrane subunit c locus 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP5MC1 mRNA

NCBI chr17:48,892,787...48,895,871
Ensembl chr17:48,892,765...48,895,871

G

ATPase H+ transporting V0 subunit d1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP6V0D1 mRNA

NCBI chr16:67,438,019...67,481,157
Ensembl chr16:67,438,014...67,481,181

G

BAG cochaperone 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BAG3 mRNA

NCBI chr10:119,651,380...119,677,819
Ensembl chr10:119,651,380...119,677,819

G

BTG3 associated nuclear protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BANP mRNA

NCBI chr16:87,949,238...88,077,318
Ensembl chr16:87,949,244...88,077,318

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

imidacloprid results in increased expression of BAX mRNA; imidacloprid results in increased expression of BAX protein
Thymol inhibits the reaction [imidacloprid results in increased expression of BAX mRNA]

PMID:27914857 PMID:34171690

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

butyrylcholinesterase

increases activity

imidacloprid results in increased activity of BCHE protein

NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

imidacloprid results in decreased expression of BCL2 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of BCL2 mRNA]

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL9 transcription coactivator

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of BCL9 mRNA

NCBI chr 1:147,541,501...147,626,216
Ensembl chr 1:147,541,501...147,626,216

G

betaine--homocysteine S-methyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BHMT mRNA

NCBI chr 5:79,111,809...79,132,288
Ensembl chr 5:79,111,809...79,132,288

G

chromosome 11 open reading frame 54

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C8H11ORF54 mRNA

NCBI chr11:93,741,672...93,764,749
Ensembl chr11:93,741,591...93,764,749

G

complement C1q C chain

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C1QC mRNA

NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,014...22,648,110

G

calcium voltage-gated channel subunit alpha1 H

increases expression

imidacloprid results in increased expression of CACNA1H mRNA

NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169

G

calcium voltage-gated channel auxiliary subunit gamma 1

decreases expression

imidacloprid results in decreased expression of CACNG1 mRNA

NCBI chr17:67,044,554...67,056,797
Ensembl chr17:67,044,554...67,056,797

G

calcium/calmodulin dependent protein kinase II gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAMK2G mRNA

NCBI chr10:73,812,501...73,874,555
Ensembl chr10:73,812,501...73,874,591

G

calcium/calmodulin dependent protein kinase kinase 2

decreases expression
multiple interactions

imidacloprid results in decreased expression of CAMKK2 protein
Dietary Fats promotes the reaction [imidacloprid results in decreased expression of CAMKK2 protein]

NCBI chr12:121,237,692...121,297,819
Ensembl chr12:121,237,675...121,298,308

G

cyclase associated actin cytoskeleton regulatory protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CAP1 mRNA

NCBI chr 1:40,040,240...40,072,648
Ensembl chr 1:40,040,233...40,072,649

G

calcyphosine 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAPS2 mRNA

NCBI chr12:75,275,979...75,390,901
Ensembl chr12:75,275,979...75,390,928

G

caspase 3

increases expression
multiple interactions

imidacloprid results in increased expression of CASP3 mRNA; imidacloprid results in increased expression of CASP3 protein
Thymol inhibits the reaction [imidacloprid results in increased expression of CASP3 mRNA]; Thymol inhibits the reaction [imidacloprid results in increased expression of CASP3 protein]

PMID:34171690 PMID:34993831 PMID:37648049

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

catalase

decreases activity
decreases expression
multiple interactions

imidacloprid results in decreased activity of CAT protein
imidacloprid results in decreased expression of CAT protein
imidacloprid promotes the reaction [sodium arsenate results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [imidacloprid results in decreased expression of CAT protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of CAT protein]; Thymol inhibits the reaction [imidacloprid results in decreased activity of CAT protein]

PMID:20686345 PMID:30033815 PMID:30456172 PMID:34171690 PMID:35398170

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cystathionine beta-synthase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CBS mRNA

NCBI chr21:43,053,191...43,076,873
Ensembl chr21:43,053,191...43,076,943

G

coiled-coil domain containing 125

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCDC125 mRNA

NCBI chr 5:69,273,039...69,332,801
Ensembl chr 5:69,280,175...69,332,809

G

coiled-coil domain containing 81

increases expression

imidacloprid results in increased expression of CCDC81 mRNA

NCBI chr11:86,374,887...86,423,106
Ensembl chr11:86,374,736...86,423,109

G

cyclin L1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCNL1 mRNA

NCBI chr 3:157,143,121...157,160,147
Ensembl chr 3:157,146,508...157,160,760

G

CD36 molecule (CD36 blood group)

increases expression

imidacloprid results in increased expression of CD36 mRNA

NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277

G

cadherin 1

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of CDH1 promoter]

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

cyclin dependent kinase inhibitor 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CDKN1A mRNA

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

cyclin dependent kinase inhibitor 2A

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of CDKN2A promoter]

NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301

G

CCAAT enhancer binding protein delta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CEBPD mRNA

NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164

G

CUGBP Elav-like family member 6

increases expression

imidacloprid results in increased expression of CELF6 mRNA

NCBI chr15:72,284,727...72,320,157
Ensembl chr15:72,284,727...72,320,157

G

centrosomal protein 85

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CEP85 mRNA

NCBI chr 1:26,234,200...26,278,808
Ensembl chr 1:26,234,200...26,278,808

G

ceramide kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CERK mRNA

NCBI chr22:46,684,410...46,738,252
Ensembl chr22:46,684,410...46,738,252

G

complement factor B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFB mRNA

NCBI chr 6:31,946,095...31,952,084
Ensembl chr 6:31,945,650...31,952,086

G

cofilin 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFL1 mRNA

NCBI chr11:65,854,673...65,858,180
Ensembl chr11:65,823,022...65,862,026

G

coiled-coil-helix-coiled-coil-helix domain containing 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CHCHD10 mRNA

NCBI chr22:23,765,834...23,767,972
Ensembl chr22:23,765,834...23,767,972

G

checkpoint kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CHEK2 mRNA

NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422

G

cholinergic receptor muscarinic 1

increases expression

imidacloprid results in increased expression of CHRM1 mRNA

NCBI chr11:62,908,679...62,921,878
Ensembl chr11:62,908,679...62,921,807

G

cholinergic receptor muscarinic 2

increases expression

imidacloprid results in increased expression of CHRM2 protein

NCBI chr 7:136,868,652...137,020,213
Ensembl chr 7:136,868,652...137,020,255

G

cholinergic receptor nicotinic alpha 1 subunit

multiple interactions

imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]; LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]; LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]

NCBI chr 2:174,747,592...174,764,472
Ensembl chr 2:174,747,592...174,787,935

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

imidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr15:78,593,052...78,620,996
Ensembl chr15:78,593,052...78,621,295

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein]
imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein]

PMID:10377228 PMID:10728888 PMID:21538459 PMID:34628512

NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401

G

cholinergic receptor nicotinic alpha 7 subunit

increases activity

imidacloprid metabolite results in increased activity of CHRNA7 protein; imidacloprid results in increased activity of CHRNA7 protein

NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

[NACHRA8 protein co-treated with CHRNB2 protein] affects the susceptibility to imidacloprid; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRA1 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRA2 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA1 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA2 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA3 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA1 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA1 protein co-treated with NACHRA2 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA2 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]; LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]
imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:10377228 PMID:10728888 PMID:16291090 PMID:16981889 PMID:18824080 More...

NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

imidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein]

NCBI chr15:78,624,111...78,661,641
Ensembl chr15:78,624,111...78,727,754

G

cold inducible RNA binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CIRBP mRNA

NCBI chr19:1,269,332...1,274,880
Ensembl chr19:1,259,384...1,274,880

G

cardiotrophin like cytokine factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLCF1 mRNA

NCBI chr11:67,364,168...67,374,177
Ensembl chr11:67,364,168...67,374,177

G

claudin 1

decreases expression

imidacloprid results in decreased expression of CLDN1 mRNA

NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446

G

clusterin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CLU mRNA

NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700

G

carnosine dipeptidase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CNDP2 mRNA

NCBI chr18:74,496,363...74,523,454
Ensembl chr18:74,495,816...74,523,454

G

carnitine palmitoyltransferase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CPT2 mRNA

NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197

G

crumbs cell polarity complex component 3

increases expression

imidacloprid results in increased expression of CRB3 mRNA

NCBI chr19:6,463,777...6,467,221
Ensembl chr19:6,463,777...6,467,221

G

cryptochrome circadian regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CRY1 mRNA

NCBI chr12:106,991,364...107,093,549
Ensembl chr12:106,991,364...107,093,549

G

centrosome and spindle pole associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSPP1 mRNA

NCBI chr 8:67,064,368...67,196,614
Ensembl chr 8:67,062,417...67,196,778

G

cysteine and serine rich nuclear protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSRNP1 mRNA

NCBI chr 3:39,141,855...39,154,641
Ensembl chr 3:39,141,855...39,154,562

G

cystathionine gamma-lyase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of CTH gene

NCBI chr 1:70,411,268...70,439,851
Ensembl chr 1:70,411,218...70,439,851

G

catenin alpha like 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CTNNAL1 mRNA

NCBI chr 9:108,942,577...109,013,499
Ensembl chr 9:108,942,569...109,013,522

G

catenin delta 1

increases expression

imidacloprid results in increased expression of CTNND1 mRNA

NCBI chr11:57,761,802...57,819,540
Ensembl chr11:57,753,243...57,819,546

G

cut like homeobox 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CUX2 mRNA

NCBI chr12:111,034,165...111,350,554
Ensembl chr12:111,034,165...111,350,554

G

cytochrome P450 family 11 subfamily A member 1

decreases expression
multiple interactions

imidacloprid results in decreased expression of CYP11A1 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP11A1 mRNA]

PMID:31780179 PMID:34171690

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

cytochrome P450 family 17 subfamily A member 1

decreases expression
multiple interactions

imidacloprid results in decreased expression of CYP17A1 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP17A1 mRNA]

PMID:27782041 PMID:31780179 PMID:34171690

NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472

G

cytochrome P450 family 19 subfamily A member 1

increases activity
multiple interactions
decreases expression
affects expression

imidacloprid results in increased activity of CYP19A1 protein
Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP19A1 mRNA]
imidacloprid affects the expression of CYP19A1 mRNA
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [imidacloprid affects the expression of CYP19A1 mRNA]

PMID:28750898 PMID:29701941 PMID:34171690

NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601

G

cytochrome P450 family 2 subfamily B member 6

increases expression

imidacloprid results in increased expression of CYP2B10 mRNA

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily E member 1

increases expression

imidacloprid results in increased expression of CYP2E1 mRNA

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions

[NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 3 subfamily A member 7

multiple interactions
increases expression

Estriol inhibits the reaction [imidacloprid results in increased expression of CYP3A7]

NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196

G

cytochrome P450 family 4 subfamily A member 22

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4A1 mRNA

NCBI chr 1:47,137,441...47,149,727
Ensembl chr 1:47,137,435...47,149,727

G

cytochrome P450 family 4 subfamily F member 12

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4F1 mRNA

NCBI chr19:15,673,087...15,697,174
Ensembl chr19:15,673,018...15,697,174

G

cytochrome P450 family 4 subfamily F member 3

increases expression

imidacloprid results in increased expression of CYP4F18 mRNA

NCBI chr19:15,640,897...15,662,825
Ensembl chr19:15,640,897...15,662,825

G

cytohesin 1 interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CYTIP mRNA

NCBI chr 2:157,414,619...157,444,089
Ensembl chr 2:157,414,619...157,488,961

G

D-box binding PAR bZIP transcription factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DBP mRNA

NCBI chr19:48,630,030...48,637,379
Ensembl chr19:48,630,030...48,637,379

G

DNA cross-link repair 1C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DCLRE1C mRNA

NCBI chr10:14,897,359...14,954,432
Ensembl chr10:14,897,359...14,954,432

G

DEAD-box helicase 20

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX20 mRNA

NCBI chr 1:111,755,901...111,768,000
Ensembl chr 1:111,754,832...111,775,602

G

DEAD-box helicase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX5 mRNA

NCBI chr17:64,498,254...64,506,866
Ensembl chr17:64,498,254...64,508,199

G

DNA fragmentation factor subunit beta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DFFB mRNA

NCBI chr 1:3,857,476...3,885,429
Ensembl chr 1:3,857,267...3,885,429

G

discs large MAGUK scaffold protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DLG2 gene

NCBI chr11:83,455,012...85,628,373
Ensembl chr11:83,455,012...85,628,335

G

delta like canonical Notch ligand 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DLL1 mRNA

NCBI chr 6:170,282,206...170,291,078
Ensembl chr 6:170,282,206...170,306,565

G

doublesex and mab-3 related transcription factor 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DMRT3 gene

NCBI chr 9:976,655...991,732
Ensembl chr 9:976,655...991,732

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB1 mRNA

NCBI chr19:14,514,769...14,560,391
Ensembl chr19:14,514,769...14,560,391

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB9 mRNA

NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850

G

dipeptidyl peptidase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DPP4 mRNA

NCBI chr 2:161,992,245...162,074,215
Ensembl chr 2:161,992,245...162,074,394

G

dual specificity phosphatase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP1 mRNA

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

dual specificity phosphatase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DUSP5 gene

NCBI chr10:110,497,907...110,511,533
Ensembl chr10:110,497,907...110,511,533

G

dual specificity phosphatase 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP6 mRNA

NCBI chr12:89,347,235...89,352,501
Ensembl chr12:89,347,235...89,352,501

G

DAZ interacting zinc finger protein 1 like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DZIP1L gene

NCBI chr 3:138,061,990...138,115,608
Ensembl chr 3:138,061,990...138,115,818

G

elastin microfibril interfacer 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of EMILIN1 mRNA

NCBI chr 2:27,078,615...27,086,403
Ensembl chr 2:27,078,615...27,086,403

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ENPP3 mRNA

NCBI chr 6:131,637,302...131,747,410
Ensembl chr 6:131,628,442...131,747,418

G

erythrocyte membrane protein band 4.1 like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of EPB41L3 gene

NCBI chr18:5,392,386...5,630,663
Ensembl chr18:5,392,381...5,630,700

G

EPM2A interacting protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of EPM2AIP1 mRNA

NCBI chr 3:36,985,043...36,993,131
Ensembl chr 3:36,985,043...36,993,131

G

ETS2 repressor factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ERF mRNA

NCBI chr19:42,247,569...42,255,128
Ensembl chr19:42,247,569...42,255,128

G

esterase D

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ESD mRNA

NCBI chr13:46,771,256...46,797,700
Ensembl chr13:46,771,256...46,797,420

G

estrogen receptor 1

increases expression

imidacloprid results in increased expression of ESR1 mRNA

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

affects expression

imidacloprid affects the expression of ESR2 mRNA

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

coagulation factor II thrombin receptor like 2

increases expression

imidacloprid results in increased expression of F2RL2 mRNA

NCBI chr 5:76,615,482...76,623,403
Ensembl chr 5:76,615,482...76,623,413

G

family with sequence similarity 135 member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM135A mRNA

NCBI chr 6:70,413,508...70,561,174
Ensembl chr 6:70,412,941...70,561,174

G

family with sequence similarity 177 member A1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM177A1 gene

NCBI chr14:35,044,907...35,083,383
Ensembl chr14:35,045,117...35,116,630

G

family with sequence similarity 204 member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM204A mRNA

NCBI chr10:118,297,925...118,342,324
Ensembl chr10:118,297,925...118,342,328

G

family with sequence similarity 53 member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM53A gene

NCBI chr 4:1,574,062...1,686,017
Ensembl chr 4:1,617,915...1,684,313

G

FIC domain protein adenylyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FICD mRNA

NCBI chr12:108,515,277...108,521,210
Ensembl chr12:108,515,277...108,525,837

G

FKBP prolyl isomerase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FKBP4 mRNA

NCBI chr12:2,794,970...2,805,423
Ensembl chr12:2,794,970...2,805,423

G

FKBP prolyl isomerase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of FKBP5 gene

NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583

G

formin 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FMN1 mRNA

NCBI chr15:32,765,544...33,194,714
Ensembl chr15:32,765,544...33,194,714

G

FERM domain containing 4B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FRMD4B mRNA

NCBI chr 3:69,168,782...69,542,586
Ensembl chr 3:69,168,782...69,542,583

G

follicle stimulating hormone subunit beta

increases expression
multiple interactions

imidacloprid results in increased expression of FSHB protein
Thymol inhibits the reaction [imidacloprid results in increased expression of FSHB protein]

NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261

G

frizzled class receptor 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FZD6 mRNA

NCBI chr 8:103,298,494...103,332,866
Ensembl chr 8:103,298,433...103,332,866

G

growth arrest and DNA damage inducible gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GADD45G mRNA

NCBI chr 9:89,605,012...89,606,555
Ensembl chr 9:89,605,012...89,606,555

G

polypeptide N-acetylgalactosaminyltransferase 7

increases expression

imidacloprid results in increased expression of GALNT7 mRNA

NCBI chr 4:173,168,811...173,323,967
Ensembl chr 4:173,168,811...173,323,967

G

glutamine amidotransferase class 1 domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GATD3A mRNA

NCBI chr21:44,133,683...44,145,711
Ensembl chr21:44,133,610...44,210,114

G

growth differentiation factor 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GDF15 mRNA

NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176

G

glial fibrillary acidic protein

increases expression

imidacloprid results in increased expression of GFAP protein

NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937

G

gypsy retrotransposon integrase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIN1 mRNA

NCBI chr 5:103,086,000...103,120,138
Ensembl chr 5:103,086,000...103,120,138

G

GIT ArfGAP 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIT2 mRNA

NCBI chr12:109,929,804...110,000,164
Ensembl chr12:109,929,804...109,996,389

G

gap junction protein alpha 1

decreases expression

imidacloprid results in decreased expression of GJA1 mRNA

NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727

G

galactosidase beta 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GLB1 mRNA

NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202

G

glucosamine-6-phosphate deaminase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GNPDA2 mRNA

NCBI chr 4:44,701,795...44,726,556
Ensembl chr 4:44,682,200...44,726,588

G

G protein-coupled receptor associated sorting protein family member 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GPRASP3 mRNA

NCBI chr X:102,720,743...102,753,540
Ensembl chr X:102,720,688...102,753,540

G

glutamic--pyruvic transaminase

increases activity
increases expression
multiple interactions

imidacloprid results in increased activity of GPT protein
imidacloprid results in increased expression of GPT protein
[imidacloprid co-treated with fipronil co-treated with Glyphosate] results in increased activity of and results in increased secretion of GPT protein
[imidacloprid co-treated with sodium arsenate] results in increased activity of GPT protein

PMID:30033815 PMID:34993831 PMID:35850439

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

GRAM domain containing 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GRAMD1A mRNA

NCBI chr19:34,994,727...35,026,469
Ensembl chr19:34,994,784...35,026,471

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GRIA1 gene

NCBI chr 5:153,489,615...153,813,869
Ensembl chr 5:153,489,615...153,813,869

G

glutamate ionotropic receptor NMDA type subunit associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GRINA mRNA

NCBI chr 8:143,990,056...143,993,415
Ensembl chr 8:143,990,056...143,993,415

G

gasdermin A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GSDMA gene

NCBI chr17:39,963,004...39,977,768
Ensembl chr17:39,953,263...39,977,768

G

glutathione-disulfide reductase

decreases activity
multiple interactions

imidacloprid results in decreased activity of GSR protein
imidacloprid promotes the reaction [sodium arsenate results in decreased activity of GSR protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of GSR protein]

PMID:30033815 PMID:30456172

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

glutathione S-transferase kappa 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GSTK1 mRNA

NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854

G

hydroxyacid oxidase 1

decreases expression

imidacloprid results in decreased expression of HAO1 mRNA

NCBI chr20:7,882,985...7,940,458
Ensembl chr20:7,882,985...7,940,458

G

HUWE1 associated protein modifying stress responses 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of HAPSTR2 gene

NCBI chr X:140,091,678...140,092,911
Ensembl chr X:140,091,678...140,092,911

G

histidyl-tRNA synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HARS1 mRNA

NCBI chr 5:140,673,905...140,691,370
Ensembl chr 5:140,673,035...140,691,537

G

heme binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HEBP1 mRNA

NCBI chr12:12,974,870...13,000,265
Ensembl chr12:12,974,870...13,000,265

G

hes family bHLH transcription factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HES1 mRNA

NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732

G

hemojuvelin BMP co-receptor

decreases expression

imidacloprid results in decreased expression of HJV mRNA

NCBI chr 1:146,017,470...146,021,735
Ensembl chr 1:146,017,468...146,036,746

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases expression

imidacloprid results in decreased expression of HMGCR mRNA

NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001

G

heme oxygenase 1

increases expression

imidacloprid results in increased expression of HMOX1 mRNA

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HS3ST3B1 mRNA

NCBI chr17:14,301,081...14,349,404
Ensembl chr17:14,301,081...14,349,404

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD11B2 mRNA

NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553

G

hydroxysteroid 17-beta dehydrogenase 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD17B10 mRNA

NCBI chr X:53,431,258...53,434,376
Ensembl chr X:53,431,258...53,434,370

G

hydroxysteroid 17-beta dehydrogenase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HSD17B2 mRNA

NCBI chr16:82,035,253...82,098,534
Ensembl chr16:82,035,004...82,098,534

G

hydroxysteroid 17-beta dehydrogenase 3

multiple interactions
decreases expression

Thymol inhibits the reaction [imidacloprid results in decreased expression of HSD17B3 mRNA]

NCBI chr 9:96,235,306...96,302,176
Ensembl chr 9:96,235,306...96,302,176

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

decreases expression

imidacloprid results in decreased expression of HSD3B2 mRNA

NCBI chr 1:119,414,931...119,423,034
Ensembl chr 1:119,414,931...119,423,035

G

heat shock protein 90 beta family member 1

decreases expression

imidacloprid results in decreased expression of HSP90B1 protein

NCBI chr12:103,930,410...103,947,926
Ensembl chr12:103,930,107...103,953,931

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPA1B mRNA

NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254

G

heat shock protein family A (Hsp70) member 5

decreases expression

imidacloprid results in decreased expression of HSPA5 protein

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

heat shock protein family B (small) member 1

decreases expression

imidacloprid results in decreased expression of HSPB1 protein

NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295

G

heat shock protein family B (small) member 7

decreases expression

imidacloprid results in decreased expression of HSPB7 mRNA

NCBI chr 1:16,014,029...16,019,594
Ensembl chr 1:16,014,028...16,019,594

G

HSPA (Hsp70) binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPBP1 mRNA

NCBI chr19:55,262,223...55,280,383
Ensembl chr19:55,262,223...55,280,381

G

5-hydroxytryptamine receptor 2C

increases expression

imidacloprid results in increased expression of HTR2C mRNA

NCBI chr X:114,584,086...114,910,061
Ensembl chr X:114,584,078...114,910,061

G

immediate early response 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IER3 mRNA

NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548

G

insulin like growth factor binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IGFBP1 mRNA

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

interleukin 10

multiple interactions
decreases expression

Plant Extracts inhibits the reaction [imidacloprid results in decreased expression of IL10 mRNA]

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 beta

multiple interactions
increases expression

Plant Extracts inhibits the reaction [imidacloprid results in increased expression of IL1B mRNA]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions
increases expression

Plant Extracts inhibits the reaction [imidacloprid results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

inositol polyphosphate-5-phosphatase F

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of INPP5F mRNA

NCBI chr10:119,726,050...119,829,147
Ensembl chr10:119,726,042...119,829,147

G

INS-IGF2 readthrough

multiple interactions
decreases expression
increases secretion

Dietary Fats promotes the reaction [imidacloprid results in increased secretion of INS1 protein]; imidacloprid promotes the reaction [Dietary Fats results in increased secretion of INS1 protein]
imidacloprid results in decreased expression of INS1 protein

PMID:27960282 PMID:28850943

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

IQ motif containing B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IQCB1 mRNA

NCBI chr 3:121,769,761...121,835,060
Ensembl chr 3:121,769,761...121,835,079

G

interferon regulatory factor 2 binding protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IRF2BP2 mRNA

NCBI chr 1:234,604,269...234,610,178
Ensembl chr 1:234,604,269...234,610,178

G

inositol 1,4,5-trisphosphate receptor interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ITPRIP mRNA

NCBI chr10:104,309,700...104,338,465
Ensembl chr10:104,309,698...104,338,465

G

ITPRIP like 1

decreases expression

imidacloprid results in decreased expression of ITPRIPL1 mRNA

NCBI chr 2:96,325,317...96,330,507
Ensembl chr 2:96,325,317...96,330,517

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of JUNB mRNA

NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315

G

katanin interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KATNIP gene

NCBI chr16:27,550,144...27,780,344
Ensembl chr16:27,550,133...27,780,344

G

kelch like ECH associated protein 1

decreases expression

imidacloprid results in decreased expression of KEAP1 mRNA

NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558

G

KH domain containing 4, pre-mRNA splicing factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KHDC4 mRNA

NCBI chr 1:155,913,045...155,934,413
Ensembl chr 1:155,913,045...155,934,413

G

KLF transcription factor 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KLF10 mRNA

NCBI chr 8:102,648,784...102,655,725
Ensembl chr 8:102,648,784...102,655,725

G

KLF transcription factor 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of KLF2 mRNA

NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685

G

kelch like family member 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KLHL10 gene

NCBI chr17:41,835,685...41,848,384
Ensembl chr17:41,835,685...41,848,384

G

kallikrein 1

decreases expression

imidacloprid results in decreased expression of KLK1 mRNA

NCBI chr19:50,819,146...50,823,787
Ensembl chr19:50,819,146...50,823,787

G

keratin 5

decreases expression

imidacloprid results in decreased expression of KRT5 mRNA

NCBI chr12:52,514,575...52,520,394
Ensembl chr12:52,514,575...52,520,530

G

leptin

increases secretion
multiple interactions

imidacloprid results in increased secretion of LEP protein
Dietary Fats promotes the reaction [imidacloprid results in increased secretion of LEP protein]; imidacloprid promotes the reaction [Dietary Fats results in increased secretion of LEP protein]

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

galectin like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LGALSL mRNA

NCBI chr 2:64,454,162...64,461,381
Ensembl chr 2:64,453,969...64,461,381

G

luteinizing hormone subunit beta

increases expression
multiple interactions

imidacloprid results in increased expression of LHB protein
Thymol inhibits the reaction [imidacloprid results in increased expression of LHB protein]

NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091

G

LIM homeobox 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of LHX2 gene

NCBI chr 9:124,011,768...124,033,301
Ensembl chr 9:124,001,670...124,033,301

G

LIF interleukin 6 family cytokine

multiple interactions

LIF protein affects the reaction [imidacloprid affects the methylation of APC promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of CDH1 promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of CDKN2A promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of MLH1 promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of RARB promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of TIMP3 promoter]

NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759

G

leukocyte immunoglobulin like receptor B3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LILRB3 mRNA

NCBI chr19:54,216,278...54,223,007
Ensembl chr19:54,216,278...54,223,506

G

lipopolysaccharide induced TNF factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LITAF mRNA

NCBI chr16:11,547,722...11,640,317
Ensembl chr16:11,547,722...11,636,381

G

ligand of numb-protein X 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LNX2 mRNA

NCBI chr13:27,545,913...27,621,107
Ensembl chr13:27,545,913...27,620,529

G

lysyl oxidase like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LOXL3 gene

NCBI chr 2:74,532,258...74,555,702
Ensembl chr 2:74,532,258...74,555,690

G

lysophosphatidylcholine acyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPCAT1 gene

NCBI chr 5:1,461,427...1,523,960
Ensembl chr 5:1,456,480...1,523,962

G

lysophosphatidylglycerol acyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPGAT1 gene

NCBI chr 1:211,743,457...211,830,763
Ensembl chr 1:211,743,457...211,830,763

G

lipin 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LPIN3 mRNA

NCBI chr20:41,340,821...41,360,582
Ensembl chr20:41,340,821...41,360,582

G

leukotriene A4 hydrolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LTA4H mRNA

NCBI chr12:96,000,753...96,043,520
Ensembl chr12:96,000,753...96,043,520

G

leucine rich adaptor protein 1 like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LURAP1L gene

NCBI chr 9:12,775,020...12,823,060
Ensembl chr 9:12,775,020...12,823,060

G

Ly6/neurotoxin 1

multiple interactions

LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]

NCBI chr 8:142,771,197...142,777,872
Ensembl chr 8:142,771,197...142,777,810

G

LY6/PLAUR domain containing 1

multiple interactions

LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]

NCBI chr 2:132,643,286...132,671,526
Ensembl chr 2:132,643,286...132,671,579

G

lysozyme

multiple interactions
decreases activity

Plant Extracts inhibits the reaction [imidacloprid results in decreased activity of LYZ protein]

NCBI chr12:69,348,381...69,354,234
Ensembl chr12:69,348,381...69,354,234

G

MAGE family member L2

increases expression

imidacloprid results in increased expression of MAGEL2 mRNA

NCBI chr15:23,643,549...23,647,867
Ensembl chr15:23,643,549...23,647,867

G

mitogen-activated protein kinase 1

increases phosphorylation

imidacloprid results in increased phosphorylation of MAPK1 protein

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

increases phosphorylation

imidacloprid results in increased phosphorylation of MAPK3 protein

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

mitogen-activated protein kinase 8

increases expression

imidacloprid results in increased expression of MAPK8 mRNA

NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360

G

MAPK activated protein kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MAPKAPK2 mRNA

NCBI chr 1:206,684,905...206,734,281
Ensembl chr 1:206,684,905...206,734,281

G

meiosis regulator and mRNA stability factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MARF1 mRNA

NCBI chr16:15,594,387...15,643,154
Ensembl chr16:15,594,387...15,643,154

G

myoglobin

decreases expression

imidacloprid results in decreased expression of MB mRNA

NCBI chr22:35,606,764...35,623,354
Ensembl chr22:35,606,764...35,637,951

G

mediator complex subunit 12L

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MED12L mRNA

NCBI chr 3:151,085,664...151,436,653
Ensembl chr 3:151,085,286...151,437,072

G

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of METTL14 mRNA

NCBI chr 4:118,685,392...118,715,430
Ensembl chr 4:118,685,392...118,715,433

G

microfibril associated protein 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of MFAP5 gene

NCBI chr12:8,645,943...8,662,826
Ensembl chr12:8,637,346...8,662,888

G

macrophage migration inhibitory factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIF mRNA

NCBI chr22:23,894,383...23,895,223
Ensembl chr22:23,894,383...23,895,227

G

microRNA 122

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR122 mRNA

NCBI chr18:58,451,074...58,451,158
Ensembl chr18:58,451,074...58,451,158

G

microRNA 130a

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR130A mRNA

NCBI chr11:57,641,198...57,641,286
Ensembl chr11:57,641,198...57,641,286

G

microRNA 146a

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR146A mRNA

NCBI chr 5:160,485,352...160,485,450
Ensembl chr 5:160,485,352...160,485,450

G

microRNA 22

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR22 mRNA

NCBI chr17:1,713,903...1,713,987
Ensembl chr17:1,713,903...1,713,987

G

microRNA 32

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR32 mRNA

NCBI chr 9:109,046,229...109,046,298
Ensembl chr 9:109,046,229...109,046,298

G

microRNA 33a

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR33 mRNA

NCBI chr22:41,900,944...41,901,012
Ensembl chr22:41,900,944...41,901,012

G

microRNA 486-1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR486 mRNA

NCBI chr 8:41,660,441...41,660,508
Ensembl chr 8:41,660,441...41,660,508

G

mutL homolog 1

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of MLH1 promoter]

NCBI chr 3:36,993,466...37,050,846
Ensembl chr 3:36,993,226...37,050,896

G

malonyl-CoA decarboxylase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MLYCD mRNA

NCBI chr16:83,899,115...83,927,031
Ensembl chr16:83,899,115...83,951,445

G

molybdenum cofactor synthesis 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA

NCBI chr 5:53,095,679...53,109,757
Ensembl chr 5:53,095,679...53,110,063

G

MORC family CW-type zinc finger 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MORC3 mRNA

NCBI chr21:36,320,197...36,376,632
Ensembl chr21:36,320,189...36,386,148

G

myeloperoxidase

increases expression

imidacloprid results in increased expression of MPO protein

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

MRG domain binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRGBP mRNA

NCBI chr20:62,796,473...62,801,729
Ensembl chr20:62,796,473...62,801,729

G

MRN complex interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRNIP mRNA

NCBI chr 5:179,837,276...179,858,817
Ensembl chr 5:179,835,133...179,862,173

G

mitochondrial ribosomal protein L44

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPL44 mRNA

NCBI chr 2:223,950,854...223,967,714
Ensembl chr 2:223,957,463...223,967,714

G

mitochondrial ribosomal protein S18B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPS18B mRNA

NCBI chr 6:30,617,840...30,626,392
Ensembl chr 6:30,617,840...30,626,395

G

mitochondrial amidoxime reducing component 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MTARC1 mRNA

NCBI chr 1:220,786,913...220,819,659
Ensembl chr 1:220,786,352...220,819,659

G

myosin binding protein C2

increases expression

imidacloprid results in increased expression of MYBPC2 mRNA

NCBI chr19:50,432,892...50,466,321
Ensembl chr19:50,432,892...50,466,321

G

myosin X

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MYO10 mRNA

NCBI chr 5:16,661,907...16,936,288
Ensembl chr 5:16,661,907...16,936,288

G

myopalladin

decreases expression

imidacloprid results in decreased expression of MYPN mRNA

NCBI chr10:68,087,897...68,212,017
Ensembl chr10:68,087,897...68,212,017

G

NEDD4 binding protein 2 like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of N4BP2L2 mRNA

NCBI chr13:32,432,485...32,538,868
Ensembl chr13:32,432,417...32,538,885

G

NEDD8 activating enzyme E1 subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NAE1 mRNA

NCBI chr16:66,802,878...66,830,976
Ensembl chr16:66,802,875...66,873,256

G

NADH:ubiquinone oxidoreductase complex assembly factor 2

decreases expression

imidacloprid results in decreased expression of NDUFAF2 mRNA

NCBI chr 5:60,945,205...61,153,026
Ensembl chr 5:60,945,177...61,154,531

G

NADH:ubiquinone oxidoreductase subunit B11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of NDUFB11 gene

NCBI chr X:47,142,216...47,145,491
Ensembl chr X:47,142,071...47,145,466

G

neurogenin 3

decreases expression

imidacloprid results in decreased expression of NEUROG3 mRNA

NCBI chr10:69,571,485...69,573,422
Ensembl chr10:69,571,698...69,573,422

G

nuclear factor, erythroid 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NFE2 mRNA

NCBI chr12:54,292,111...54,301,015
Ensembl chr12:54,292,111...54,301,015

G

nuclear factor, interleukin 3 regulated

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NFIL3 mRNA

NCBI chr 9:91,409,045...91,483,497
Ensembl chr 9:91,409,045...91,423,832

G

nuclear receptor subfamily 0 group B member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR0B2 mRNA

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

nuclear receptor subfamily 1 group D member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D1 mRNA

NCBI chr17:40,092,793...40,100,589
Ensembl chr17:40,092,793...40,100,589

G

nuclear receptor subfamily 1 group D member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D2 mRNA

NCBI chr 3:23,945,286...23,980,617
Ensembl chr 3:23,945,286...23,980,617

G

nuclear receptor subfamily 1 group I member 3

decreases abundance

NR1I3 results in decreased abundance of imidacloprid

NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244

G

nuclear receptor subfamily 5 group A member 1

decreases expression

imidacloprid results in decreased expression of NR5A1 mRNA

NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420

G

nuclear casein kinase and cyclin dependent kinase substrate 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NUCKS1 mRNA

NCBI chr 1:205,712,822...205,750,182
Ensembl chr 1:205,712,822...205,750,182

G

2'-5'-oligoadenylate synthetase like

increases expression

imidacloprid results in increased expression of OASL mRNA

NCBI chr12:121,017,761...121,039,246
Ensembl chr12:121,017,763...121,039,246

G

8-oxoguanine DNA glycosylase

increases expression

imidacloprid results in increased expression of OGG1 mRNA

NCBI chr 3:9,749,952...9,783,108
Ensembl chr 3:9,749,944...9,788,219

G

5-oxoprolinase, ATP-hydrolysing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of OPLAH mRNA

NCBI chr 8:144,050,322...144,063,961
Ensembl chr 8:144,051,266...144,063,965

G

ORAI calcium release-activated calcium modulator 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ORAI3 gene

NCBI chr16:30,949,068...30,954,938
Ensembl chr16:30,949,068...30,956,461

G

PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PABIR1 gene

NCBI chr 9:68,780,065...68,785,566
Ensembl chr 9:68,780,065...68,785,566

G

PARP1 binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene

NCBI chr12:102,120,183...102,197,520
Ensembl chr12:102,120,183...102,197,520

G

phosphoenolpyruvate carboxykinase 2, mitochondrial

increases expression
multiple interactions

imidacloprid results in increased expression of PCK2 mRNA
Dietary Fats promotes the reaction [imidacloprid results in increased expression of PCK2 mRNA]; imidacloprid promotes the reaction [Dietary Fats results in increased expression of PCK2 mRNA]

NCBI chr14:24,094,171...24,104,125
Ensembl chr14:24,094,053...24,110,598

G

proliferating cell nuclear antigen

decreases expression
multiple interactions

imidacloprid results in decreased expression of PCNA protein
Thymol inhibits the reaction [imidacloprid results in decreased expression of PCNA protein]

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

pyruvate dehydrogenase kinase 4

increases expression

imidacloprid results in increased expression of PDK4 mRNA

NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516

G

PDZ and LIM domain 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PDLIM1 mRNA

NCBI chr10:95,237,572...95,291,003
Ensembl chr10:95,237,572...95,291,012

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PDP1 mRNA

NCBI chr 8:93,916,923...93,926,068
Ensembl chr 8:93,857,807...93,926,068

G

PDZ domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PDZD2 gene

NCBI chr 5:31,639,131...32,110,932
Ensembl chr 5:31,639,131...32,110,932

G

period circadian regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PER1 mRNA

NCBI chr17:8,140,472...8,152,404
Ensembl chr17:8,140,472...8,156,506

G

period circadian regulator 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PER3 mRNA

NCBI chr 1:7,784,291...7,845,177
Ensembl chr 1:7,784,291...7,845,177

G

phosphoglycerate kinase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PGK1 mRNA

NCBI chr X:78,104,248...78,129,295
Ensembl chr X:77,910,739...78,129,295

G

progesterone receptor

affects expression

imidacloprid affects the expression of PGR mRNA

NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813

G

protein inhibitor of activated STAT 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIAS3 mRNA

NCBI chr 1:145,848,522...145,859,081
Ensembl chr 1:145,848,522...145,859,836

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIP4P1 mRNA

NCBI chr14:20,457,681...20,461,434
Ensembl chr14:20,457,681...20,461,465

G

pleckstrin homology and RhoGEF domain containing G5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLEKHG5 mRNA

NCBI chr 1:6,467,122...6,520,092
Ensembl chr 1:6,467,122...6,520,074

G

polo like kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLK2 mRNA

NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139

G

phospholipid phosphatase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PLPP4 gene

NCBI chr10:120,456,954...120,592,065
Ensembl chr10:120,457,227...120,592,065

G

phosphomevalonate kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PMVK mRNA

NCBI chr 1:154,924,740...154,942,658
Ensembl chr 1:154,924,740...154,936,719

G

PNKD metallo-beta-lactamase domain containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNKD mRNA

NCBI chr 2:218,270,519...218,346,793
Ensembl chr 2:218,269,651...218,346,793

G

phenylethanolamine N-methyltransferase

multiple interactions
increases expression

imidacloprid promotes the reaction [Nicotine results in increased expression of PNMT protein]
imidacloprid results in increased expression of PNMT protein

NCBI chr17:39,668,019...39,670,475
Ensembl chr17:39,667,981...39,670,475

G

proline rich nuclear receptor coactivator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNRC1 mRNA

NCBI chr 6:89,080,751...89,085,160
Ensembl chr 6:89,080,751...89,085,160

G

cytochrome p450 oxidoreductase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of POR gene

NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855

G

peroxisome proliferator activated receptor alpha

decreases expression

imidacloprid results in decreased expression of PPARA mRNA

NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755

G

peroxisome proliferator activated receptor delta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PPARD mRNA

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

PPARG coactivator 1 alpha

decreases expression

imidacloprid results in decreased expression of PPARGC1A protein

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

PR/SET domain 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRDM15 mRNA

NCBI chr21:41,798,225...41,879,344
Ensembl chr21:41,798,225...41,879,482

G

PRELI domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELID2 mRNA

NCBI chr 5:145,228,985...145,835,342
Ensembl chr 5:145,471,799...145,835,369

G

proline and arginine rich end leucine rich repeat protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELP mRNA

NCBI chr 1:203,475,806...203,491,352
Ensembl chr 1:203,475,806...203,491,352

G

prolactin

multiple interactions

[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein

NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826

G

proline and serine rich 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PROSER2 mRNA

NCBI chr10:11,823,356...11,872,277
Ensembl chr10:11,823,339...11,872,277

G

pre-mRNA processing factor 39

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRPF39 mRNA

NCBI chr14:45,084,116...45,116,282
Ensembl chr14:45,084,107...45,116,282

G

proteasome 26S subunit, ATPase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC2 mRNA

NCBI chr 7:103,347,524...103,369,395
Ensembl chr 7:103,328,570...103,370,346

G

proteasome 26S subunit, ATPase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC4 mRNA

NCBI chr19:39,971,165...39,981,764
Ensembl chr19:39,971,165...39,981,764

G

proteasome 26S subunit, ATPase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC5 mRNA

NCBI chr17:63,827,431...63,832,019
Ensembl chr17:63,827,152...63,832,026

G

protein phosphatase 2 phosphatase activator

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PTPA mRNA

NCBI chr 9:129,110,950...129,148,946
Ensembl chr 9:129,110,950...129,148,946

G

pseudouridine synthase 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PUS10 mRNA

NCBI chr 2:60,940,223...61,018,259
Ensembl chr 2:60,940,222...61,018,259

G

rabaptin, RAB GTPase binding effector protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABEP1 mRNA

NCBI chr17:5,282,284...5,386,340
Ensembl chr17:5,282,265...5,386,340

G

RAB, member of RAS oncogene family like 2B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABL2 mRNA

NCBI chr22:50,767,506...50,783,636
Ensembl chr22:50,767,501...50,783,667

G

RNA guanine-7 methyltransferase activating subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RAMAC gene

NCBI chr15:82,986,210...82,991,057
Ensembl chr15:82,986,210...82,991,057

G

Ran GTPase activating protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RANGAP1 mRNA

NCBI chr22:41,244,779...41,302,369
Ensembl chr22:41,244,779...41,286,187

G

retinoic acid receptor beta

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of RARB promoter]

NCBI chr 3:24,829,321...25,597,932
Ensembl chr 3:24,687,887...25,597,932

G

arginyl-tRNA synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RARS1 mRNA

NCBI chr 5:168,486,471...168,519,301
Ensembl chr 5:168,486,451...168,519,301

G

RNA binding fox-1 homolog 2

increases expression

imidacloprid results in increased expression of RBFOX2 mRNA

NCBI chr22:35,738,736...36,028,824
Ensembl chr22:35,738,736...36,028,824

G

RNA binding motif protein 14

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RBM14 mRNA

NCBI chr11:66,616,630...66,629,934
Ensembl chr11:66,616,626...66,629,934

G

RNA binding motif protein 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RBM3 mRNA

NCBI chr X:48,574,484...48,581,162
Ensembl chr X:48,574,449...48,581,162

G

RNA binding protein, mRNA processing factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RBPMS gene

NCBI chr 8:30,384,541...30,572,256
Ensembl chr 8:30,384,511...30,572,256

G

RELA proto-oncogene, NF-kB subunit

increases expression

imidacloprid results in increased expression of RELA protein

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

retroelement silencing factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RESF1 mRNA

NCBI chr12:31,959,415...31,993,107
Ensembl chr12:31,959,370...31,993,107

G

REV1 DNA directed polymerase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of REV1 mRNA

NCBI chr 2:99,400,477...99,490,202
Ensembl chr 2:99,400,475...99,490,035

G

regulatory factor X7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RFX7 mRNA

NCBI chr15:56,087,280...56,245,082
Ensembl chr15:56,087,280...56,245,082

G

regulator of cell cycle

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RGCC gene

NCBI chr13:41,457,550...41,470,871
Ensembl chr13:41,457,550...41,470,871

G

regulator of G protein signaling 16

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RGS16 mRNA

NCBI chr 1:182,598,623...182,604,389
Ensembl chr 1:182,598,623...182,604,389

G

Rho related BTB domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RHOBTB3 mRNA

NCBI chr 5:95,717,624...95,796,361
Ensembl chr 5:95,713,522...95,824,383

G

ribonuclease A family member 10 (inactive)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RNASE10 gene

NCBI chr14:20,504,233...20,513,884
Ensembl chr14:20,505,537...20,513,884

G

Rho family GTPase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RND3 gene; [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RND3 mRNA

NCBI chr 2:150,468,193...150,487,695
Ensembl chr 2:150,468,195...150,539,011

G

RAR related orphan receptor C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RORC mRNA

NCBI chr 1:151,806,071...151,831,802
Ensembl chr 1:151,806,071...151,831,845

G

ribitol xylosyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RXYLT1 gene

NCBI chr12:63,779,909...63,809,562
Ensembl chr12:63,779,833...63,809,792

G

spalt like transcription factor 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SALL4 gene

NCBI chr20:51,782,331...51,802,521
Ensembl chr20:51,782,331...51,802,521

G

sarcosine dehydrogenase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SARDH mRNA

NCBI chr 9:133,659,418...133,739,955
Ensembl chr 9:133,663,560...133,739,955

G

sodium channel epithelial 1 subunit alpha

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SCNN1A mRNA

NCBI chr12:6,346,847...6,377,359
Ensembl chr12:6,346,843...6,377,730

G

short chain dehydrogenase/reductase family 42E, member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SDR42E1 mRNA

NCBI chr16:81,988,855...82,011,470
Ensembl chr16:81,988,855...82,011,481

G

serpin family A member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SERPINA1 mRNA

NCBI chr14:94,376,747...94,390,635
Ensembl chr14:94,376,747...94,390,693

G

sestrin 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SESN2 mRNA

NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491

G

SET domain containing 6, protein lysine methyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SETD6 mRNA

NCBI chr16:58,515,479...58,523,842
Ensembl chr16:58,515,479...58,523,842

G

secreted frizzled related protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SFRP2 gene

NCBI chr 4:153,780,591...153,789,083
Ensembl chr 4:153,780,591...153,789,083

G

SH3 domain binding protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SH3BP2 mRNA

NCBI chr 4:2,793,085...2,841,096
Ensembl chr 4:2,793,071...2,841,098

G

single Ig and TIR domain containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SIGIRR mRNA

NCBI chr11:405,716...417,397
Ensembl chr11:405,716...417,455

G

salt inducible kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SIK2 mRNA

NCBI chr11:111,602,449...111,730,855
Ensembl chr11:111,602,449...111,730,855

G

sirtuin 1

decreases expression

imidacloprid results in decreased expression of SIRT1 protein

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

solute carrier family 12 member 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC12A6 mRNA

NCBI chr15:34,229,784...34,338,057
Ensembl chr15:34,229,784...34,338,060

G

solute carrier family 20 member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC20A1 mRNA

NCBI chr 2:112,645,939...112,663,825
Ensembl chr 2:112,645,939...112,663,825

G

solute carrier family 22 member 1

increases activity

imidacloprid results in increased activity of SLC22A1 protein

NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718

G

solute carrier family 22 member 2

decreases activity

imidacloprid results in decreased activity of SLC22A2 protein

NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638

G

solute carrier family 22 member 8

decreases activity

imidacloprid results in decreased activity of SLC22A8 protein

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier family 25 member 39

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC25A39 mRNA

NCBI chr17:44,319,628...44,324,823
Ensembl chr17:44,319,625...44,324,870

G

solute carrier family 26 member 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC26A6 mRNA

NCBI chr 3:48,625,723...48,635,461
Ensembl chr 3:48,625,723...48,635,493

G

solute carrier family 2 member 2

increases expression

imidacloprid results in increased expression of SLC2A2 mRNA

NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743

G

solute carrier family 2 member 3

increases expression

imidacloprid results in increased expression of SLC2A3 mRNA

NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007

G

solute carrier family 2 member 4

decreases expression

imidacloprid results in decreased expression of SLC2A4 mRNA
imidacloprid results in decreased expression of SLC2A4 mRNA; imidacloprid results in decreased expression of SLC2A4 protein

PMID:27960282 PMID:28850943 PMID:32685429

NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257

G

solute carrier family 37 member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC37A2 mRNA

NCBI chr11:125,063,305...125,090,516
Ensembl chr11:125,063,302...125,090,516

G

STE20 like kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SLK gene

NCBI chr10:103,967,140...104,029,233
Ensembl chr10:103,967,140...104,029,233

G

SMAD family member 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SMAD7 mRNA

NCBI chr18:48,919,853...48,950,965
Ensembl chr18:48,919,853...48,950,965

G

small muscle protein X-linked

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SMPX gene

NCBI chr X:21,705,978...21,758,116
Ensembl chr X:21,705,978...21,758,116

G

small nuclear ribonucleoprotein U5 subunit 200

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SNRNP200 mRNA

NCBI chr 2:96,274,338...96,305,546
Ensembl chr 2:96,274,338...96,321,271

G

sorting nexin 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SNX4 mRNA

NCBI chr 3:125,446,650...125,520,202
Ensembl chr 3:125,446,650...125,520,202

G

suppressor of cytokine signaling 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SOCS3 mRNA

NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077

G

superoxide dismutase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SOD3 mRNA

NCBI chr 4:24,795,573...24,800,842
Ensembl chr 4:24,789,912...24,800,842

G

spermatogenesis and oogenesis specific basic helix-loop-helix 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SOHLH1 gene

NCBI chr 9:135,693,407...135,702,112
Ensembl chr 9:135,693,407...135,704,498

G

sperm associated antigen 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SPAG1 mRNA

NCBI chr 8:100,158,038...100,241,904
Ensembl chr 8:100,157,906...100,259,278

G

steroid 5 alpha-reductase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SRD5A2 gene

NCBI chr 2:31,522,480...31,663,009
Ensembl chr 2:31,522,480...31,580,938

G

sterol regulatory element binding transcription factor 1

increases expression

imidacloprid results in increased expression of SREBF1 mRNA

NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002

G

serine/arginine repetitive matrix 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRRM2 mRNA

NCBI chr16:2,752,638...2,771,412
Ensembl chr16:2,752,626...2,772,538

G

serine and arginine rich splicing factor 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRSF5 mRNA

NCBI chr14:69,767,142...69,772,005
Ensembl chr14:69,726,900...69,772,005

G

steroidogenic acute regulatory protein

decreases expression
multiple interactions

imidacloprid results in decreased expression of STAR mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of STAR mRNA]

PMID:31780179 PMID:34171690

NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992

G

StAR related lipid transfer domain containing 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of STARD9 mRNA

NCBI chr15:42,575,606...42,720,998
Ensembl chr15:42,575,606...42,720,998

G

sushi domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SUSD2 mRNA

NCBI chr22:24,181,487...24,189,106
Ensembl chr22:24,181,487...24,189,106

G

symplekin scaffold protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SYMPK mRNA

NCBI chr19:45,815,410...45,863,147
Ensembl chr19:45,815,410...45,863,194

G

tachykinin receptor 3

increases expression

imidacloprid results in increased expression of TACR3 mRNA

NCBI chr 4:103,586,031...103,719,985
Ensembl chr 4:103,586,031...103,719,985

G

transcriptional adaptor 2B

increases expression

imidacloprid results in increased expression of TADA2B mRNA

NCBI chr 4:7,043,372...7,057,952
Ensembl chr 4:7,041,899...7,057,952

G

tyrosine aminotransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TAT mRNA

NCBI chr16:71,565,660...71,577,092
Ensembl chr16:71,565,660...71,577,092

G

tyrosyl-DNA phosphodiesterase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TDP2 mRNA

NCBI chr 6:24,649,979...24,666,899
Ensembl chr 6:24,649,979...24,666,930

G

TEA domain transcription factor 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TEAD2 mRNA

NCBI chr19:49,340,595...49,362,416
Ensembl chr19:49,340,595...49,362,457

G

trans-2,3-enoyl-CoA reductase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TECR mRNA

NCBI chr19:14,527,726...14,565,980
Ensembl chr19:14,517,085...14,565,980

G

TDP-glucose 4,6-dehydratase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TGDS mRNA

NCBI chr13:94,574,054...94,596,273
Ensembl chr13:94,574,054...94,596,242

G

transforming growth factor beta induced

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TGFBI mRNA

NCBI chr 5:136,028,988...136,063,818
Ensembl chr 5:136,028,988...136,063,818

G

tyrosine hydroxylase

multiple interactions
increases expression

[conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; exoenzyme C3, Clostridium botulinum inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; ZM 241385 inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; ZM 241385 inhibits the reaction [imidacloprid results in increased expression of TH mRNA]
imidacloprid results in increased expression of TH mRNA; imidacloprid results in increased expression of TH protein

NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815

G

thyroid hormone receptor beta

affects binding

imidacloprid binds to THRB protein

NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756

G

TIMP metallopeptidase inhibitor 3

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of TIMP3 promoter]

NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041

G

tight junction associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TJAP1 mRNA

NCBI chr 6:43,477,570...43,506,554
Ensembl chr 6:43,477,523...43,506,556

G

tight junction protein 1

decreases expression

imidacloprid results in decreased expression of TJP1 mRNA

NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915

G

thymidine kinase 1

increases mutagenesis

imidacloprid results in increased mutagenesis of TK1 gene

NCBI chr17:78,174,079...78,187,204
Ensembl chr17:78,174,091...78,187,233

G

transketolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TKT mRNA

NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052

G

transmembrane BAX inhibitor motif containing 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMBIM6 mRNA

NCBI chr12:49,741,557...49,764,934
Ensembl chr12:49,707,725...49,764,934

G

transmembrane protein 268

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TMEM268 mRNA

NCBI chr 9:114,603,904...114,646,422
Ensembl chr 9:114,611,206...114,646,422

G

thiol methyltransferase 1B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of METTL7B mRNA

NCBI chr12:55,681,736...55,684,611
Ensembl chr12:55,681,736...55,684,611

G

tumor necrosis factor

multiple interactions
increases expression

Dietary Fats promotes the reaction [imidacloprid results in increased expression of TNF mRNA]; imidacloprid promotes the reaction [Dietary Fats results in increased expression of TNF mRNA]
imidacloprid results in increased expression of TNF mRNA; imidacloprid results in increased expression of TNF protein
Plant Extracts inhibits the reaction [imidacloprid results in increased expression of TNF mRNA]

PMID:27960282 PMID:34993831 PMID:35398170

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF alpha induced protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TNFAIP2 mRNA

NCBI chr14:103,121,469...103,137,439
Ensembl chr14:103,121,476...103,137,439

G

troponin I2, fast skeletal type

decreases expression

imidacloprid results in decreased expression of TNNI2 mRNA

NCBI chr11:1,838,981...1,841,678
Ensembl chr11:1,838,981...1,841,680

G

torsin family 3 member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TOR3A mRNA

NCBI chr 1:179,082,070...179,095,996
Ensembl chr 1:179,082,070...179,098,023

G

TRAF3 interacting protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAF3IP2 mRNA

NCBI chr 6:111,555,381...111,605,878
Ensembl chr 6:111,555,381...111,606,906

G

TRAF-type zinc finger domain containing 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAFD1 mRNA

NCBI chr12:112,125,560...112,153,604
Ensembl chr12:112,125,538...112,153,604

G

tripartite motif containing 34

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRIM34 mRNA

NCBI chr11:5,619,944...5,644,398
Ensembl chr11:5,619,764...5,644,398

G

TSC22 domain family member 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TSC22D3 mRNA

NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342

G

thyroid stimulating hormone subunit beta

multiple interactions

[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein

NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302

G

translocator protein

decreases expression

imidacloprid results in decreased expression of TSPO mRNA

NCBI chr22:43,151,559...43,163,242
Ensembl chr22:43,151,547...43,163,242

G

TXK tyrosine kinase

increases expression

imidacloprid results in increased expression of TXK mRNA

NCBI chr 4:48,066,393...48,134,250
Ensembl chr 4:48,066,393...48,134,250

G

ubiquitin like modifier activating enzyme 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UBA3 mRNA

NCBI chr 3:69,054,730...69,080,373
Ensembl chr 3:69,054,730...69,080,408

G

ubiquitin B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBB mRNA

NCBI chr17:16,380,779...16,382,745
Ensembl chr17:16,380,798...16,382,745

G

ubiquitin C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBC mRNA

NCBI chr12:124,911,646...124,914,650
Ensembl chr12:124,911,604...124,917,368

G

uridine-cytidine kinase 1 like 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UCKL1 mRNA

NCBI chr20:63,939,829...63,956,416
Ensembl chr20:63,939,829...63,956,416

G

unc-45 myosin chaperone A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UNC45A mRNA

NCBI chr15:90,930,180...90,954,093
Ensembl chr15:90,930,180...90,954,093

G

unc-45 myosin chaperone B

decreases expression

imidacloprid results in decreased expression of UNC45B mRNA

NCBI chr17:35,147,817...35,189,345
Ensembl chr17:35,147,817...35,189,345

G

ubiquitin specific peptidase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of USP2 mRNA

NCBI chr11:119,355,215...119,381,690
Ensembl chr11:119,355,215...119,381,711

G

ubiquitin specific peptidase 40

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of USP40 mRNA

NCBI chr 2:233,475,526...233,566,782
Ensembl chr 2:233,475,526...233,566,782

G

vinculin

decreases expression

imidacloprid results in decreased expression of VCL mRNA

NCBI chr10:73,998,116...74,121,363
Ensembl chr10:73,995,193...74,121,363

G

vascular endothelial growth factor A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of VEGFA mRNA

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vanin 3, pseudogene

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VNN3 mRNA

NCBI chr 6:132,722,787...132,734,765
Ensembl chr 6:132,722,784...132,736,935
Ensembl chr 6:132,722,784...132,736,935

G

vitronectin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VTN mRNA

NCBI chr17:28,367,284...28,370,307
Ensembl chr17:28,367,284...28,373,091

G

WD repeat domain 11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of WDR11 gene

NCBI chr10:120,851,362...120,909,524
Ensembl chr10:120,851,305...120,909,524

G

WEE1 G2 checkpoint kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of WEE1 mRNA

NCBI chr11:9,573,670...9,589,985
Ensembl chr11:9,573,670...9,593,457

G

WAP four-disulfide core domain 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of WFDC9 gene

NCBI chr20:45,607,939...45,631,284
Ensembl chr20:45,607,939...45,631,284

G

YOD1 deubiquitinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of YOD1 gene

NCBI chr 1:207,043,849...207,053,116
Ensembl chr 1:207,043,849...207,052,980

G

zinc finger C3H1-type containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFC3H1 mRNA

NCBI chr12:71,609,599...71,663,848
Ensembl chr12:71,609,599...71,667,725

G

ZFP36 ring finger protein like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP36L2 mRNA

NCBI chr 2:43,222,402...43,226,606
Ensembl chr 2:43,222,402...43,226,606

G

zinc finger MYM-type containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM3 mRNA

NCBI chr X:71,239,624...71,255,290
Ensembl chr X:71,239,624...71,255,146

G

zinc finger MYM-type containing 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM6 mRNA

NCBI chr 1:34,986,165...35,031,945
Ensembl chr 1:34,986,165...35,031,945

G

zinc finger protein 22

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP422 mRNA

NCBI chr10:45,000,923...45,005,326
Ensembl chr10:45,000,923...45,005,326

G

zinc finger protein 280D

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP280D mRNA

NCBI chr15:56,630,176...56,733,509
Ensembl chr15:56,630,176...56,734,086

G

zinc finger protein 598, E3 ubiquitin ligase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP598 mRNA

NCBI chr16:1,997,654...2,009,821
Ensembl chr16:1,997,654...2,009,821

G

zinc finger RANBP2-type containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZRANB2 mRNA

NCBI chr 1:71,063,291...71,081,035
Ensembl chr 1:71,063,291...71,081,289

imidapril

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

increases response to substance

ACE2 gene SNP results in increased susceptibility to imidapril

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

carboxylesterase 1

multiple interactions

CES1 protein results in increased hydrolysis of and results in increased activity of imidapril; CES1 protein results in increased metabolism of and results in increased activity of imidapril; Dust inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; tert-butylphenyl diphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; triphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]

PMID:9300133 PMID:31268531

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

cytochrome P450 family 11 subfamily B member 2

affects response to substance

CYP11B2 gene polymorphism affects the susceptibility to imidapril

NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843

imidaprilat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein]

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

protein kinase C alpha

multiple interactions

imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein]

NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743

imiprothrin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

decreases expression

imiprothrin results in decreased expression of CAT protein

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cytochrome P450 family 1 subfamily A member 2

increases expression

imiprothrin results in increased expression of CYP1A2 mRNA

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

glutamic--pyruvic transaminase

increases expression

imiprothrin results in increased expression of GPT protein

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

iprodione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

iprodione binds to and results in increased activity of AHR protein

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

aldehyde dehydrogenase 2 family member

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532

G

annexin A10

increases expression

iprodione results in increased expression of ANXA10 mRNA

NCBI chr 4:168,092,537...168,187,736
Ensembl chr 4:168,092,537...168,187,736

G

androgen receptor

multiple interactions
affects binding

[iprodione binds to and results in decreased activity of AR protein] inhibits the reaction [Metribolone binds to AR protein]; iprodione inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; iprodione inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]
iprodione binds to AR protein

PMID:19564212 PMID:33049310

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

iprodione results in decreased expression of BCL2 protein
Chlorpyrifos promotes the reaction [iprodione results in decreased expression of BCL2 protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of BCL2 protein]

PMID:33586219 PMID:34060014

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

increases expression
multiple interactions

iprodione results in increased expression of CASP3 protein
Chlorpyrifos promotes the reaction [iprodione results in increased expression of CASP3 protein]; iprodione promotes the reaction [Chlorpyrifos results in increased expression of CASP3 protein]

PMID:33586219 PMID:34060014

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

cadherin 1

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

claudin 11

multiple interactions
increases expression

[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein
iprodione results in increased expression of CLDN11 protein

NCBI chr 3:170,418,868...170,434,691
Ensembl chr 3:170,418,868...170,454,733

G

cytochrome P450 family 19 subfamily A member 1

increases activity

iprodione results in increased activity of CYP19A1 protein

NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601

G

cytochrome P450 family 1 subfamily A member 1

increases expression

iprodione results in increased expression of CYP1A1 mRNA; iprodione results in increased expression of CYP1A1 protein

PMID:16696176 PMID:32194361

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 2 subfamily C member 19

decreases expression

iprodione results in decreased expression of CYP2C19 protein

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of CYP3A4 mRNA

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

iprodione results in decreased expression of CYP7A1 protein

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

DNA damage inducible transcript 3

increases expression

iprodione results in increased expression of DDIT3 mRNA

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

estrogen receptor 1

multiple interactions

iprodione binds to and results in increased activity of ESR1 protein

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions

iprodione binds to and results in increased activity of ESR2 protein

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

iprodione results in increased expression of FOS mRNA

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

follicle stimulating hormone subunit beta

multiple interactions
decreases expression

Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of FSHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of FSHB protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of FSHB protein]

PMID:33586219 PMID:34060014

NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261

G

growth arrest and DNA damage inducible alpha

increases expression

iprodione results in increased expression of GADD45A mRNA

NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334

G

gap junction protein alpha 1

multiple interactions

[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein

NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727

G

glutathione S-transferase alpha 2

increases expression

iprodione results in increased expression of GSTA2 mRNA

NCBI chr 6:52,750,087...52,763,475
Ensembl chr 6:52,750,087...52,763,475

G

H2A.X variant histone

multiple interactions

[fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein

PMID:22389207 PMID:34503147 PMID:34830855

NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465

G

hydroxysteroid 17-beta dehydrogenase 3

multiple interactions
decreases expression

[Chlorpyrifos co-treated with iprodione] results in decreased expression of HSD17B3 mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of HSD17B3 mRNA
iprodione results in decreased expression of HSD17B3 mRNA

PMID:33586219 PMID:34060014

NCBI chr 9:96,235,306...96,302,176
Ensembl chr 9:96,235,306...96,302,176

G

heat shock protein family A (Hsp70) member 5

increases expression

iprodione results in increased expression of HSPA5 mRNA

NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382

G

luteinizing hormone subunit beta

decreases expression
multiple interactions

iprodione results in decreased expression of LHB protein
Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of LHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of LHB protein]

NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091

G

nuclear receptor subfamily 1 group I member 2

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein; iprodione binds to and results in increased activity of NR1I2 protein

PMID:25028461 PMID:33049310

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

G

nuclear receptor subfamily 5 group A member 1

decreases expression
multiple interactions

iprodione results in decreased expression of NR5A1 mRNA
[iprodione co-treated with Chlorpyrifos] results in decreased expression of NR5A1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of NR5A1 mRNA]

PMID:33586219 PMID:34060014

NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420

G

peroxisome proliferator activated receptor gamma

increases activity
multiple interactions

iprodione results in increased activity of PPARG protein
iprodione binds to and results in increased activity of PPARG protein

PMID:20143881 PMID:33049310

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

PPARG coactivator 1 alpha

decreases expression
multiple interactions

iprodione results in decreased expression of PPARGC1A mRNA
Chlorpyrifos promotes the reaction [iprodione results in decreased expression of PPARGC1A mRNA]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of PPARGC1A mRNA]

PMID:33586219 PMID:34060014

NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089

G

S100 calcium binding protein P

increases expression

iprodione results in increased expression of S100P mRNA; iprodione results in increased expression of S100P protein

NCBI chr 4:6,693,878...6,697,170
Ensembl chr 4:6,693,878...6,697,170

G

sirtuin 1

multiple interactions
decreases expression

[iprodione co-treated with Chlorpyrifos] results in decreased expression of SIRT1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of SIRT1 mRNA]
iprodione results in decreased expression of SIRT1 mRNA

PMID:33586219 PMID:34060014

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

stathmin 1

increases expression

iprodione results in increased expression of STMN1 mRNA

NCBI chr 1:25,884,179...25,906,880
Ensembl chr 1:25,884,181...25,906,991

G

telomerase reverse transcriptase

multiple interactions
decreases expression

[Chlorpyrifos co-treated with iprodione] results in decreased expression of TERT mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of TERT mRNA
iprodione results in decreased expression of TERT mRNA

PMID:33586219 PMID:34060014

NCBI chr 5:1,253,167...1,295,068
Ensembl chr 5:1,253,147...1,295,068

G

thyroid hormone receptor alpha

multiple interactions

iprodione binds to and results in increased activity of THRA protein

NCBI chr17:40,062,193...40,093,867
Ensembl chr17:40,058,290...40,093,867

G

thyroid hormone receptor beta

multiple interactions

iprodione binds to and results in increased activity of THRB protein

NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756

G

tumor necrosis factor

multiple interactions

Acetylcysteine inhibits the reaction [iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53 binding protein 1

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein

NCBI chr15:43,403,061...43,510,640
Ensembl chr15:43,403,061...43,510,728

mephenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 1 subfamily B member 1

decreases activity

Mephenytoin results in decreased activity of CYP1B1 protein

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

cytochrome P450 family 2 subfamily A member 7

decreases activity

Mephenytoin results in decreased activity of CYP2A4 protein

NCBI chr19:40,875,439...40,882,231
Ensembl chr19:40,875,439...40,882,752

G

cytochrome P450 family 2 subfamily B member 6

decreases methylation
multiple interactions
increases metabolic processing
decreases activity

CYP2B6 protein results in decreased methylation of Mephenytoin
Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein]; Mephenytoin inhibits the reaction [CYP2B6 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Mephenytoin inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin]
CYP2B6 protein results in increased metabolism of Mephenytoin
Mephenytoin results in decreased activity of CYP2B10 protein
Mephenytoin results in decreased activity of CYP2B6 protein

PMID:9241656 PMID:12433797 PMID:12464242 PMID:18420780 PMID:25500267

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

increases metabolic processing
affects metabolic processing
decreases activity
increases hydroxylation
increases oxidation
affects hydroxylation
multiple interactions

CYP2C19 protein results in increased metabolism of Mephenytoin
CYP2C19 protein affects the metabolism of Mephenytoin
Mephenytoin results in decreased activity of CYP2C19 protein
CYP2C19 protein results in increased hydroxylation of Mephenytoin; CYP2C19 protein results in increased hydroxylation of Mephenytoin analog
CYP2C19 protein results in increased oxidation of Mephenytoin
CYP2C19 gene SNP affects the hydroxylation of Mephenytoin; CYP2C19 protein affects the hydroxylation of Mephenytoin
4-amino-2-phenoxymethanesulfonanilide inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin]; [CYP2C19 protein results in increased hydroxylation of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; [CYP2C19 protein results in increased metabolism of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; [Mephenytoin results in decreased activity of CYP2C19 protein] which results in decreased degradation of vanoxerine; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; GH1 protein inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Mephenytoin inhibits the reaction [CYP2C19 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]; methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin analog]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Pantoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; perfluorooctane sulfonic acid inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin]; rabeprazole-thioether inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Resveratrol inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; sitaxsentan inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Tranylcypromine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ursolic Acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]

PMID:3577206 PMID:9170147 PMID:11502731 PMID:11907490 PMID:12401345 More...

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 8

decreases activity

Mephenytoin results in decreased activity of CYP2C29 protein

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

decreases activity

Mephenytoin results in decreased activity of CYP2C9 protein

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily E member 1

decreases activity

Mephenytoin results in decreased activity of CYP2E1 protein

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

growth hormone 1

multiple interactions

GH1 protein inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]

NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839

G

nuclear receptor subfamily 1 group I member 2

multiple interactions

Mephenytoin binds to and results in increased activity of NR1I2 protein

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

nilutamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases expression

nilutamide results in increased expression of AKT1 protein

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

androgen receptor

affects binding
increases response to substance
decreases activity
multiple interactions

nilutamide binds to AR protein
AR protein mutant form results in increased susceptibility to nilutamide
nilutamide results in decreased activity of AR protein
[AR protein mutant form results in increased susceptibility to nilutamide] which results in increased activity of AR protein mutant form; nilutamide analog binds to and affects the localization of AR protein; nilutamide binds to and results in decreased activity of AR protein; nilutamide inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; nilutamide inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; nilutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; nilutamide inhibits the reaction [Metribolone results in increased activity of AR protein]; nilutamide inhibits the reaction [mibolerone affects the localization of AR protein]

PMID:15509168 PMID:16125883 PMID:16857237 PMID:18324785 PMID:18973785 More...

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

cyclin dependent kinase inhibitor 1B

decreases expression

nilutamide results in decreased expression of CDKN1B protein

NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369

G

cytochrome P450 family 1 subfamily B member 1

decreases activity

nilutamide results in decreased activity of CYP1B1 protein

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

estrogen receptor 1

multiple interactions

nilutamide binds to and results in increased activity of ESR1 protein

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

nilutamide inhibits the reaction [Dihydrotestosterone results in decreased activity of GAPDH protein]

NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374

G

growth regulating estrogen receptor binding 1

multiple interactions

nilutamide inhibits the reaction [Testosterone results in increased expression of GREB1 mRNA]

NCBI chr 2:11,482,888...11,642,788
Ensembl chr 2:11,482,341...11,642,788

G

insulin like growth factor 1 receptor

multiple interactions

nilutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of IGF1R protein]

NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530

G

nuclear receptor subfamily 1 group I member 2

multiple interactions

nilutamide binds to and results in increased activity of NR1I2 protein

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

G

peroxisome proliferator activated receptor gamma

multiple interactions

nilutamide binds to and results in increased activity of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

thyroid hormone receptor beta

multiple interactions

nilutamide binds to and results in increased activity of THRB protein

NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756

nitrofurantoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Nitrofurantoin results in decreased activity of ABCB11 protein

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily B member 4

decreases activity

Nitrofurantoin results in decreased activity of ABCB4 protein

NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435

G

ATP binding cassette subfamily G member 2 (JR blood group)

affects transport
affects abundance
multiple interactions
increases secretion
increases transport
affects response to substance
increases export

ABCG2 protein affects the transport of Nitrofurantoin
ABCG2 protein affects the abundance of Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein affects the transport of Nitrofurantoin]; Elacridar inhibits the reaction [ABCG2 protein affects the transport of Nitrofurantoin]
ABCG2 protein results in increased secretion of Nitrofurantoin
ABCG2 protein results in increased transport of Nitrofurantoin
ABCG2 results in increased secretion of Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein results in increased transport of Nitrofurantoin]
ABCG2 affects the susceptibility to Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein results in increased transport of Nitrofurantoin]; Nitrofurantoin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]
ABCG2 protein results in increased export of Nitrofurantoin

PMID:15709111 PMID:15722455 PMID:17093006 PMID:17785426 PMID:18799806 More...

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

angiotensinogen

decreases activity

Nitrofurantoin results in decreased activity of AGT protein

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

aldolase, fructose-bisphosphate A

increases expression

Nitrofurantoin results in increased expression of ALDOA mRNA; Nitrofurantoin results in increased expression of ALDOA protein

NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457

G

catalase

decreases activity

Nitrofurantoin results in decreased activity of CAT protein

PMID:1313237 PMID:9000262

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

ciliary neurotrophic factor

multiple interactions

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]]

NCBI chr11:58,622,665...58,625,733
Ensembl chr11:58,622,665...58,625,733

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

Nitrofurantoin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

multiple interactions

Nitrofurantoin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

glutamate-cysteine ligase catalytic subunit

increases expression
multiple interactions

Nitrofurantoin results in increased expression of GCLC protein
NFE2L2 protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; POR protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutathione-disulfide reductase

decreases activity
multiple interactions

Nitrofurantoin results in decreased activity of GSR protein
[Nitrofurantoin co-treated with GSR protein] affects the metabolism of Glucose

PMID:1313237 PMID:1901343 PMID:9000262

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

hypoxia inducible factor 1 subunit alpha

increases activity

Nitrofurantoin results in increased activity of HIF1A protein

NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259

G

heme oxygenase 1

increases expression

Nitrofurantoin results in increased expression of HMOX1 mRNA

PMID:7626009 PMID:11841787

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heat shock transcription factor 1

increases activity

Nitrofurantoin results in increased activity of HSF1 protein

NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720

G

heat shock protein family A (Hsp70) member 8

increases expression

Nitrofurantoin results in increased expression of HSPA8 mRNA

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Nitrofurantoin results in increased expression of JUN mRNA

PMID:7626009 PMID:11841787

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

LIM and cysteine rich domains 1

increases expression

Nitrofurantoin results in increased expression of LMCD1 mRNA

NCBI chr 3:8,501,823...8,574,668
Ensembl chr 3:8,501,807...8,574,668

G

NFE2 like bZIP transcription factor 2

multiple interactions

NFE2L2 protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; Nitrofurantoin results in increased expression of and affects the localization of NFE2L2 protein; POR protein affects the reaction [Nitrofurantoin results in increased expression of NFE2L2 protein]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NAD(P)H quinone dehydrogenase 1

increases response to substance
affects reduction

NQO1 protein results in increased susceptibility to Nitrofurantoin
NQO1 protein affects the reduction of Nitrofurantoin

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

orosomucoid 1

increases expression

Nitrofurantoin results in increased expression of ORM1 mRNA; Nitrofurantoin results in increased expression of ORM1 protein

NCBI chr 9:114,323,098...114,326,479
Ensembl chr 9:114,323,098...114,326,479

G

cytochrome p450 oxidoreductase

increases metabolic processing
multiple interactions
affects metabolic processing

POR protein results in increased metabolism of Nitrofurantoin
POR protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; POR protein affects the reaction [Nitrofurantoin results in increased expression of NFE2L2 protein]
diphenyleneiodonium inhibits the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; Nitrofurantoin inhibits the reaction [POR protein results in increased metabolism of Misonidazole]

PMID:6802140 PMID:18206659 PMID:34021431

NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855

G

signal transducer and activator of transcription 1

multiple interactions

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]]

NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960

G

signal transducer and activator of transcription 3

multiple interactions
increases activity
increases expression

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]]
Nitrofurantoin results in increased activity of STAT3 protein
Nitrofurantoin results in increased expression of STAT3 mRNA

PMID:11841787 PMID:15748169

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

transforming growth factor beta 2

increases expression

Nitrofurantoin results in increased expression of TGFB2 mRNA

NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619

G

transmembrane serine protease 2

increases expression

Nitrofurantoin results in increased expression of TMPRSS2 mRNA

NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116

phenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aladin WD repeat nucleoporin

decreases expression

Phenytoin results in decreased expression of AAAS mRNA

NCBI chr12:53,307,460...53,321,610
Ensembl chr12:53,307,456...53,324,864

G

ATP binding cassette subfamily A member 1

decreases expression

Phenytoin results in decreased expression of ABCA1 mRNA

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 1

affects response to substance
multiple interactions
increases expression
increases transport
affects abundance
decreases activity
increases metabolic processing

ABCB1 protein affects the susceptibility to Phenytoin
Amino Acids, Peptides, and Proteins inhibits the reaction [Phenytoin results in increased expression of ABCB1 protein]; Phenytoin results in increased expression of and results in increased activity of ABCB1A protein
ABCB1A protein results in increased transport of Phenytoin
ABCB1 protein affects the abundance of Phenytoin
Phenytoin results in decreased activity of ABCB1 protein
ABCB1 protein results in increased metabolism of Phenytoin

PMID:8001500 PMID:10580886 PMID:14749549 PMID:15569486 PMID:16220110 More...

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

multiple interactions
increases expression

KN 62 inhibits the reaction [Phenytoin results in increased expression of ABCC1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Phenytoin results in increased expression of ABCC1 protein]

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily C member 2

affects transport
multiple interactions
increases expression
affects response to substance

ABCC2 protein affects the transport of Phenytoin
KN 62 inhibits the reaction [Phenytoin results in increased expression of ABCC2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Phenytoin results in increased expression of ABCC2 protein]
ABCC2 protein affects the susceptibility to Phenytoin

PMID:12663688 PMID:14636316 PMID:17376120 PMID:18473823

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

increases expression

Phenytoin results in increased expression of ABCC3 mRNA

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

ATP binding cassette subfamily G member 1

decreases expression

Phenytoin results in decreased expression of ABCG1 mRNA

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244

G

abhydrolase domain containing 5, lysophosphatidic acid acyltransferase

increases expression

Phenytoin results in increased expression of ABHD5 mRNA

NCBI chr 3:43,690,870...43,734,371
Ensembl chr 3:43,690,108...43,734,371

G

actin binding LIM protein 1

decreases expression

Phenytoin results in decreased expression of ABLIM1 mRNA

NCBI chr10:114,431,110...114,801,373
Ensembl chr10:114,431,112...114,768,061

G

angiotensin converting enzyme 2

decreases expression

Phenytoin results in decreased expression of ACE2 mRNA

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

acetylcholinesterase (Yt blood group)

increases activity

Phenytoin results in increased activity of ACHE protein

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

ADAM metallopeptidase domain 8

decreases expression

Phenytoin results in decreased expression of ADAM8 mRNA

NCBI chr10:133,262,423...133,276,868
Ensembl chr10:133,262,420...133,276,868

G

ADAM metallopeptidase with thrombospondin type 1 motif 9

increases expression

Phenytoin results in increased expression of ADAMTS9 mRNA

NCBI chr 3:64,515,654...64,688,000
Ensembl chr 3:64,515,654...64,688,000

G

adhesion G protein-coupled receptor B3

increases expression

Phenytoin results in increased expression of ADGRB3 mRNA

NCBI chr 6:68,635,282...69,389,506
Ensembl chr 6:68,635,282...69,390,571

G

adrenoceptor beta 3

decreases expression

Phenytoin results in decreased expression of ADRB3 mRNA

NCBI chr 8:37,962,990...37,966,599
Ensembl chr 8:37,962,990...37,966,599

G

alpha fetoprotein

decreases expression

Phenytoin results in decreased expression of AFP mRNA

PMID:14741686 PMID:26272751

NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 3

decreases expression

Phenytoin results in decreased expression of AGAP3 mRNA

NCBI chr 7:151,085,867...151,144,434
Ensembl chr 7:151,085,831...151,144,436

G

aryl hydrocarbon receptor

multiple interactions
increases expression

CYP3A11 protein affects the reaction [Phenytoin results in increased expression of AHR mRNA]
Ketoconazole inhibits the reaction [Phenytoin results in increased expression of AHR protein]

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

A-kinase anchoring protein 10

increases expression

Phenytoin results in increased expression of AKAP10 mRNA

NCBI chr17:19,904,302...19,977,828
Ensembl chr17:19,904,302...19,978,343

G

aldo-keto reductase family 7 member A3

decreases expression
increases expression

Phenytoin results in decreased expression of AKR7A3 mRNA
Phenytoin results in increased expression of AKR7A3 mRNA

NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770

G

aldehyde dehydrogenase 1 family member A1

increases expression

Phenytoin results in increased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

aldehyde dehydrogenase 1 family member A2

decreases expression

Phenytoin results in decreased expression of ALDH1A2 mRNA

NCBI chr15:57,953,429...58,065,711
Ensembl chr15:57,953,424...58,497,866

G

antagonist of mitotic exit network 1 homolog

increases expression

Phenytoin results in increased expression of AMN1 mRNA

NCBI chr12:31,671,137...31,729,174
Ensembl chr12:31,671,142...31,729,121

G

annexin A4

increases expression

Phenytoin results in increased expression of ANXA4 mRNA

NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112

G

annexin A5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA

NCBI chr 4:121,667,946...121,696,980
Ensembl chr 4:121,667,946...121,696,995

G

apolipoprotein A1

increases expression

Phenytoin results in increased expression of APOA1 mRNA

NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622

G

apolipoprotein A4

increases expression

Phenytoin results in increased expression of APOA4 mRNA

NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304

G

apolipoprotein E

increases expression

Phenytoin results in increased expression of APOE mRNA

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

androgen receptor

multiple interactions
increases expression
increases activity

[Phenytoin co-treated with Prednisolone] results in increased expression of AR protein
Phenytoin results in increased expression of AR protein
Ketoconazole inhibits the reaction [Phenytoin results in increased expression of AR protein]
Phenytoin results in increased expression of AR mRNA; Phenytoin results in increased expression of AR protein
Phenytoin results in increased activity of AR protein

PMID:19226368 PMID:19490052

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

ADP ribosylation factor interacting protein 1

increases expression

Phenytoin results in increased expression of ARFIP1 mRNA

NCBI chr 4:152,779,954...152,912,357
Ensembl chr 4:152,779,937...152,918,463

G

Rho GTPase activating protein 39

increases expression

Phenytoin results in increased expression of ARHGAP39 mRNA

NCBI chr 8:144,529,179...144,700,362
Ensembl chr 8:144,529,179...144,685,846

G

armadillo repeat containing 8

increases expression

Phenytoin results in increased expression of ARMC8 mRNA

NCBI chr 3:138,187,248...138,298,389
Ensembl chr 3:138,187,248...138,298,384

G

ATM serine/threonine kinase

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein

NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102

G

ATP synthase mitochondrial F1 complex assembly factor 1

decreases expression

Phenytoin results in decreased expression of ATPAF1 mRNA

NCBI chr 1:46,632,737...46,668,557
Ensembl chr 1:46,632,737...46,673,867

G

beta-1,4-galactosyltransferase 7

decreases expression

Phenytoin results in decreased expression of B4GALT7 mRNA

NCBI chr 5:177,600,132...177,610,330
Ensembl chr 5:177,600,132...177,610,330

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

Phenytoin results in increased expression of and affects the localization of BCL2 protein
Phenytoin results in decreased expression of BCL2 mRNA

PMID:9118846 PMID:10695937

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA

NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989

G

bone morphogenetic protein 1

decreases expression

Phenytoin results in decreased expression of BMP1 mRNA

NCBI chr 8:22,165,372...22,212,326
Ensembl chr 8:22,165,140...22,212,326

G

bone morphogenetic protein 4

increases expression

Phenytoin results in increased expression of BMP4 mRNA

NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761

G

complement C2

decreases expression

Phenytoin results in decreased expression of C2 mRNA

NCBI chr 6:31,897,783...31,945,672
Ensembl chr 6:31,897,785...31,945,673

G

carbonic anhydrase 6

increases expression

Phenytoin results in increased expression of CAR6 mRNA

NCBI chr 1:8,945,868...8,975,092
Ensembl chr 1:8,945,867...8,975,092

G

calcyclin binding protein

increases expression

Phenytoin results in increased expression of CACYBP mRNA

NCBI chr 1:174,999,435...175,012,027
Ensembl chr 1:174,999,163...175,012,027

G

calcitonin related polypeptide alpha

decreases expression

Phenytoin results in decreased expression of CALCA protein

NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354

G

calmodulin 2

decreases expression

Phenytoin results in decreased expression of CALM2 mRNA

NCBI chr 2:47,160,082...47,176,936
Ensembl chr 2:47,160,084...47,176,921

G

calpain 5

decreases expression

Phenytoin results in decreased expression of CAPN5 mRNA

NCBI chr11:77,066,971...77,126,155
Ensembl chr11:77,066,961...77,126,155

G

CASK interacting protein 1

affects expression

Phenytoin affects the expression of CASKIN1 mRNA

NCBI chr16:2,177,180...2,196,605
Ensembl chr16:2,177,180...2,196,605

G

caspase 10

increases expression

Phenytoin results in increased expression of CASP10 mRNA

NCBI chr 2:201,183,141...201,229,406
Ensembl chr 2:201,182,872...201,229,428

G

catalase

decreases response to substance

CAT protein results in decreased susceptibility to Phenytoin

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

Cbl proto-oncogene like 1

increases expression

Phenytoin results in increased expression of CBLL1 mRNA

NCBI chr 7:107,744,142...107,761,667
Ensembl chr 7:107,743,073...107,761,667

G

C-C motif chemokine ligand 2

increases expression

Phenytoin results in increased expression of CCL2 protein

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

cyclin C

increases expression

Phenytoin results in increased expression of CCNC mRNA

NCBI chr 6:99,542,387...99,568,814
Ensembl chr 6:99,542,387...99,568,825

G

cyclin D1

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA
Phenytoin results in decreased expression of CCND1 mRNA

PMID:14741686 PMID:21224054

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

cyclin G1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA

NCBI chr 5:163,437,571...163,457,640
Ensembl chr 5:163,437,569...163,446,151

G

CD47 molecule

decreases expression

Phenytoin results in decreased expression of CD47 mRNA

NCBI chr 3:108,043,091...108,091,031
Ensembl chr 3:108,043,091...108,091,862

G

cadherin 2

decreases expression

Phenytoin results in decreased expression of CDH2 mRNA

NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946

G

cyclin dependent kinase 1

decreases expression

Phenytoin results in decreased expression of CDK1 mRNA

NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852

G

cyclin dependent kinase inhibitor 1A

decreases expression
multiple interactions

Phenytoin results in decreased expression of CDKN1A mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein

PMID:14741686 PMID:21224054

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

caudal type homeobox 2

increases expression

Phenytoin results in increased expression of CDX2 mRNA

NCBI chr13:27,960,918...27,969,315
Ensembl chr13:27,960,918...27,969,315

G

chymotrypsin like elastase 2A

decreases expression

Phenytoin results in decreased expression of CELA2A mRNA

NCBI chr 1:15,456,732...15,472,091
Ensembl chr 1:15,456,728...15,472,091

G

centrosomal protein 57

increases expression

Phenytoin results in increased expression of CEP57 mRNA

NCBI chr11:95,790,498...95,832,693
Ensembl chr11:95,789,965...95,832,693

G

cerberus 1, DAN family BMP antagonist

decreases expression

Phenytoin results in decreased expression of CER1 mRNA

NCBI chr 9:14,717,326...14,722,733
Ensembl chr 9:14,719,724...14,722,733

G

checkpoint kinase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA

NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422

G

creatine kinase, M-type

increases expression

Phenytoin results in increased expression of CKM protein

NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875

G

chloride voltage-gated channel 6

decreases expression

Phenytoin results in decreased expression of CLCN6 mRNA

NCBI chr 1:11,806,191...11,843,130
Ensembl chr 1:11,806,096...11,848,079

G

cytidine/uridine monophosphate kinase 1

increases expression

Phenytoin results in increased expression of CMPK1 mRNA

NCBI chr 1:47,333,790...47,378,839
Ensembl chr 1:47,333,790...47,394,866

G

CCR4-NOT transcription complex subunit 7

increases expression

Phenytoin results in increased expression of CNOT7 mRNA

NCBI chr 8:17,224,966...17,246,857
Ensembl chr 8:17,224,966...17,246,878

G

collagen type XI alpha 1 chain

increases expression

Phenytoin results in increased expression of COL11A1 mRNA

NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872

G

collagen type XVIII alpha 1 chain

decreases expression

Phenytoin results in decreased expression of COL18A1 mRNA

NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720

G

collagen type I alpha 1 chain

multiple interactions
increases expression
decreases expression

Phenytoin inhibits the reaction [IL1B protein results in decreased expression of COL1A1 mRNA]
Phenytoin results in increased expression of COL1A1 mRNA
Phenytoin results in decreased expression of COL1A1 mRNA

PMID:8971655 PMID:14741686

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type I alpha 2 chain

increases expression
affects expression

Phenytoin results in increased expression of COL1A2 mRNA
Phenytoin affects the expression of COL1A2 mRNA

PMID:14741686 PMID:24704097

NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227

G

collagen type VI alpha 1 chain

decreases expression
increases expression

Phenytoin results in decreased expression of COL6A1 mRNA
Phenytoin results in increased expression of COL6A1 mRNA

PMID:8224229 PMID:14741686

NCBI chr21:45,981,770...46,005,048
Ensembl chr21:45,981,770...46,005,050

G

collagen type VI alpha 2 chain

increases expression

Phenytoin results in increased expression of COL6A2 mRNA

NCBI chr21:46,098,112...46,132,848
Ensembl chr21:46,098,112...46,132,848

G

collagen type VI alpha 3 chain

increases expression

Phenytoin results in increased expression of COL6A3 mRNA

NCBI chr 2:237,324,018...237,414,164
Ensembl chr 2:237,324,003...237,414,328

G

ceruloplasmin

decreases expression

Phenytoin results in decreased expression of CP mRNA

NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829

G

cleavage and polyadenylation specific factor 6

increases expression

Phenytoin results in increased expression of CPSF6 mRNA

NCBI chr12:69,239,569...69,274,358
Ensembl chr12:69,239,569...69,274,358

G

corticotropin releasing hormone

affects expression

Phenytoin affects the expression of CRH mRNA

NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464

G

CDP-L-ribitol pyrophosphorylase A

increases expression

Phenytoin results in increased expression of CRPPA mRNA

NCBI chr 7:16,087,525...16,421,538
Ensembl chr 7:16,087,525...16,502,504

G

cathepsin B

increases expression
decreases activity

Phenytoin results in increased expression of CTSB mRNA
Phenytoin results in decreased activity of CTSB protein

PMID:10914799 PMID:14741686

NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533

G

cathepsin L

decreases activity
increases expression

Phenytoin results in decreased activity of CTSL protein
Phenytoin results in increased expression of CTSL mRNA

NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469

G

cullin 4A

increases expression

Phenytoin results in increased expression of CUL4A mRNA

NCBI chr13:113,208,193...113,267,108
Ensembl chr13:113,208,193...113,267,108

G

C-X3-C motif chemokine ligand 1

increases expression

Phenytoin results in increased expression of CX3CL1 mRNA

NCBI chr16:57,372,490...57,385,044
Ensembl chr16:57,372,477...57,385,044

G

C-X-C motif chemokine ligand 10

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 2

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA]

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

cytochrome P450 family 19 subfamily A member 1

decreases activity

Phenytoin results in decreased activity of CYP19A1 protein

NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601

G

cytochrome P450 family 1 subfamily A member 1

increases expression

Phenytoin results in increased expression of CYP1A1 mRNA

PMID:9860486 PMID:17381134

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

multiple interactions

[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 1 subfamily B member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

cytochrome P450 family 2 subfamily A member 6

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA

NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447

G

cytochrome P450 family 2 subfamily B member 6

multiple interactions
decreases expression
increases expression
increases activity

[Phenytoin results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; NOC 18 inhibits the reaction [Phenytoin results in increased expression of CYP2B6 protein]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; Phenytoin results in increased expression of and results in increased activity of CYP2B6 protein; pimagedine inhibits the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]
Phenytoin results in decreased expression of CYP2B10 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA
Phenytoin results in increased expression of CYP2B6 mRNA; Phenytoin results in increased expression of CYP2B6 protein
Phenytoin results in increased activity of CYP2B6 protein

PMID:12571232 PMID:12695351 PMID:14977870 PMID:15123723 PMID:17041008 More...

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

decreases hydroxylation
increases metabolic processing
multiple interactions
decreases metabolic processing
increases hydroxylation
affects metabolic processing

CYP2C19 gene polymorphism results in decreased hydroxylation of Phenytoin
CYP2C19 protein results in increased metabolism of Phenytoin
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin
CYP2C19 gene polymorphism results in decreased metabolism of Phenytoin
CYP2C19 protein results in increased hydroxylation of Phenytoin
CYP2C19 protein affects the metabolism of Phenytoin

PMID:9146858 PMID:9333104 PMID:9579299 PMID:9860067 PMID:15569425 More...

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 8

affects expression
multiple interactions
increases expression

Phenytoin affects the expression of CYP2C29 mRNA
[Phenytoin results in decreased activity of CYP2C29 protein] which results in decreased reduction of and results in decreased oxidation of 9-anthraldehyde; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C29 mRNA]
Phenytoin results in increased expression of CYP2C protein; Phenytoin results in increased expression of CYP2C29 mRNA; Phenytoin results in increased expression of CYP2C29 protein

PMID:12051692 PMID:15155833 PMID:19136022 PMID:19903449 PMID:21766881

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions
increases metabolic processing
increases activity
increases hydroxylation
decreases metabolic processing
decreases hydroxylation
increases expression
increases response to substance
affects metabolic processing

[Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin; [CYP2C9 protein results in increased hydroxylation of Phenytoin] which results in increased abundance of hydroxyphenytoin; Miconazole inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Phenytoin] which results in increased abundance of hydroxyphenytoin]; Miconazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Phenytoin]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP2C9 mRNA]
CYP2C9 protein results in increased metabolism of Phenytoin
Phenytoin results in increased activity of CYP2C9 protein
CYP2C9 5' UTR polymorphism results in decreased metabolism of Phenytoin; CYP2C9 gene polymorphism results in decreased metabolism of Phenytoin
CYP2C9 gene polymorphism results in decreased hydroxylation of Phenytoin
CYP2C9 gene polymorphism results in increased susceptibility to Phenytoin
CYP2C9 protein affects the metabolism of Phenytoin; CYP2C9 protein alternative form affects the metabolism of Phenytoin

PMID:2025243 PMID:9110362 PMID:9860067 PMID:10208645 PMID:10510154 More...

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily D member 6

multiple interactions

[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin

NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865

G

cytochrome P450 family 2 subfamily E member 1

multiple interactions
decreases expression
increases expression

NOC 18 inhibits the reaction [Phenytoin results in increased expression of CYP2E1 mRNA]
Phenytoin results in decreased expression of CYP2E1 mRNA
Phenytoin results in increased expression of CYP2E1 mRNA; Phenytoin results in increased expression of CYP2E1 protein

PMID:17381134 PMID:18206661

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions
increases expression
increases activity

[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NOC 18 inhibits the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; NR3C1 protein promotes the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; Phenytoin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol]; Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]
Phenytoin results in increased expression of CYP3A2 mRNA; Phenytoin results in increased expression of CYP3A2 protein
Ketoconazole inhibits the reaction [Phenytoin results in increased expression of CYP3A2 protein]
Phenytoin results in increased activity of CYP3A4 protein
Phenytoin results in increased expression of CYP3A4 mRNA; Phenytoin results in increased expression of CYP3A4 protein

PMID:9512926 PMID:10219967 PMID:12065438 PMID:12505310 PMID:12673034 More...

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 3 subfamily A member 5

increases expression

Phenytoin results in increased expression of CYP3A5 mRNA
Phenytoin results in increased expression of CYP3A13 mRNA

PMID:12673034 PMID:19903449

NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996

G

cytochrome P450 family 3 subfamily A member 7

increases expression

Phenytoin results in increased expression of CYP3A7 mRNA
Phenytoin results in increased expression of CYP3A13 mRNA

PMID:12673034 PMID:19903449

NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196

G

cytochrome P450 family 4 subfamily A member 22

decreases expression

Phenytoin results in decreased expression of CYP4A1 mRNA

NCBI chr 1:47,137,441...47,149,727
Ensembl chr 1:47,137,435...47,149,727

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

increases expression

Phenytoin results in increased expression of CYP7B1 mRNA

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

death associated protein 3

increases expression

Phenytoin results in increased expression of DAP3 mRNA

NCBI chr 1:155,687,948...155,739,010
Ensembl chr 1:155,687,960...155,739,010

G

death associated protein kinase 2

decreases expression

Phenytoin results in decreased expression of DAPK2 mRNA

NCBI chr15:63,907,036...64,046,485
Ensembl chr15:63,907,036...64,072,033

G

DNA damage inducible transcript 3

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA

NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737

G

DExH-box helicase 9

increases expression

Phenytoin results in increased expression of DHX9 mRNA

NCBI chr 1:182,839,347...182,887,982
Ensembl chr 1:182,839,347...182,887,982

G

dematin actin binding protein

decreases expression

Phenytoin results in decreased expression of DMTN mRNA

NCBI chr 8:22,048,931...22,082,525
Ensembl chr 8:22,048,995...22,082,527

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA

NCBI chr 9:33,025,273...33,039,907
Ensembl chr 9:33,025,273...33,039,907

G

E2F transcription factor 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

EBP like

increases expression

Phenytoin results in increased expression of EBPL mRNA

NCBI chr13:49,660,674...49,691,487
Ensembl chr13:49,660,674...49,691,486

G

early growth response 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

early growth response 3

increases expression

Phenytoin results in increased expression of EGR3 mRNA

NCBI chr 8:22,687,659...22,693,480
Ensembl chr 8:22,687,659...22,693,480

G

empty spiracles homeobox 2

decreases expression

Phenytoin results in decreased expression of EMX2 mRNA

NCBI chr10:117,542,746...117,549,546
Ensembl chr10:117,542,445...117,549,546

G

glutamyl aminopeptidase

decreases expression
increases expression

Phenytoin results in decreased expression of ENPEP mRNA
Phenytoin results in increased expression of ENPEP mRNA

NCBI chr 4:110,476,155...110,565,285
Ensembl chr 4:110,365,733...110,565,285

G

eomesodermin

increases expression

Phenytoin results in increased expression of EOMES mRNA

NCBI chr 3:27,715,953...27,722,713
Ensembl chr 3:27,715,949...27,722,711

G

epoxide hydrolase 1

affects response to substance
increases expression

EPHX1 gene polymorphism affects the susceptibility to Phenytoin
Phenytoin results in increased expression of EPHX1 mRNA

PMID:17381134 PMID:19952982

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

epoxide hydrolase 2

decreases expression

Phenytoin results in decreased expression of EPHX2 mRNA

NCBI chr 8:27,491,143...27,548,626
Ensembl chr 8:27,490,781...27,545,564

G

estrogen receptor 1

increases expression

Phenytoin results in increased expression of ESR1 mRNA; Phenytoin results in increased expression of ESR1 protein

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

Phenytoin results in decreased expression of EYA1 mRNA

NCBI chr 8:71,197,433...71,548,094
Ensembl chr 8:71,197,433...71,592,025

G

coagulation factor X

decreases expression

Phenytoin results in decreased expression of F10 mRNA

NCBI chr13:113,122,799...113,149,529
Ensembl chr13:113,122,799...113,149,529

G

coagulation factor II, thrombin

multiple interactions

[clobazam co-treated with Phenytoin] results in increased expression of [F2 protein binds to SERPINC1 protein]

NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506

G

Fas ligand

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA
Phenytoin results in decreased expression of FASL mRNA

PMID:21224054 PMID:23986454

NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876

G

F-box and leucine rich repeat protein 3

increases expression

Phenytoin results in increased expression of FBXL3 mRNA

NCBI chr13:77,005,260...77,027,159
Ensembl chr13:76,992,598...77,027,195

G

F-box protein 30

increases expression

Phenytoin results in increased expression of FBXO30 mRNA

NCBI chr 6:145,793,502...145,814,795
Ensembl chr 6:145,793,502...145,814,795

G

fibroblast growth factor 12

increases expression

Phenytoin results in increased expression of FGF12 mRNA

NCBI chr 3:192,139,390...192,727,541
Ensembl chr 3:192,139,390...192,767,764

G

fibroblast growth factor 5

increases expression

Phenytoin results in increased expression of FGF5 mRNA

NCBI chr 4:80,266,588...80,291,017
Ensembl chr 4:80,266,639...80,336,680

G

fibroblast growth factor 8

increases expression

Phenytoin results in increased expression of FGF8 mRNA

NCBI chr10:101,770,109...101,780,369
Ensembl chr10:101,770,109...101,780,371

G

fibroblast growth factor 9

increases expression

Phenytoin results in increased expression of FGF9 mRNA

NCBI chr13:21,671,073...21,704,498
Ensembl chr13:21,671,073...21,704,498

G

fibroblast growth factor receptor 2

increases expression

Phenytoin results in increased expression of FGFR2 mRNA; Phenytoin results in increased expression of FGFR2 protein

NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458

G

fibronectin leucine rich transmembrane protein 2

increases expression

Phenytoin results in increased expression of FLRT2 mRNA

NCBI chr14:85,530,144...85,654,428
Ensembl chr14:85,530,144...85,654,428

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA

NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978

G

flavin containing dimethylaniline monoxygenase 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA

NCBI chr 1:171,314,183...171,342,084
Ensembl chr 1:171,314,183...171,342,084

G

fibromodulin

decreases expression

Phenytoin results in decreased expression of FMOD mRNA

NCBI chr 1:203,340,628...203,351,122
Ensembl chr 1:203,340,628...203,351,758

G

fragile X messenger ribonucleoprotein 1

increases expression

Phenytoin results in increased expression of FMR1 mRNA

NCBI chr X:147,911,919...147,951,125
Ensembl chr X:147,911,919...147,951,125

G

fibronectin 1

increases expression

Phenytoin results in increased expression of FN1 mRNA

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

fibronectin type III domain containing 3A

increases expression

Phenytoin results in increased expression of FNDC3A mRNA

NCBI chr13:48,975,291...49,209,779
Ensembl chr13:48,975,912...49,209,779

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression

[Phenytoin co-treated with Drugs, Chinese Herbal] inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]
Phenytoin results in decreased expression of FOS protein

PMID:7789465 PMID:8758711

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

forkhead box C2

decreases expression

Phenytoin results in decreased expression of FOXC2 mRNA

NCBI chr16:86,566,829...86,569,728
Ensembl chr16:86,566,829...86,569,728

G

forkhead box P3

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA
Phenytoin results in decreased expression of FOXP3 mRNA

NCBI chr X:49,250,438...49,264,710
Ensembl chr X:49,250,438...49,264,800

G

fibroblast growth factor receptor substrate 3

decreases expression

Phenytoin results in decreased expression of FRS3 mRNA

NCBI chr 6:41,770,176...41,779,900
Ensembl chr 6:41,770,176...41,786,542

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Phenytoin results in decreased expression of G6PC1 mRNA

NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438

G

glucose-6-phosphate dehydrogenase

affects response to substance

G6PDX protein affects the susceptibility to Phenytoin

NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572

G

growth arrest and DNA damage inducible alpha

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA

NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334

G

GATA binding protein 3

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA
Phenytoin results in decreased expression of GATA3 mRNA

NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198

G

glutamate-cysteine ligase modifier subunit

increases expression

Phenytoin results in increased expression of GCLM mRNA

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

glutamate-ammonia ligase

decreases activity

Phenytoin results in decreased activity of GLUL protein

NCBI chr 1:182,378,098...182,391,790
Ensembl chr 1:182,378,098...182,392,206

G

G protein nucleolar 2

increases expression

Phenytoin results in increased expression of GNL2 mRNA

NCBI chr 1:37,566,816...37,595,937
Ensembl chr 1:37,566,816...37,595,937

G

glucosamine-6-phosphate deaminase 2

increases expression

Phenytoin results in increased expression of GNPDA2 mRNA

NCBI chr 4:44,701,795...44,726,556
Ensembl chr 4:44,682,200...44,726,588

G

glycoprotein M6A

increases expression

Phenytoin results in increased expression of GPM6A mRNA

NCBI chr 4:175,632,937...176,002,691
Ensembl chr 4:175,632,934...176,002,664

G

glutathione peroxidase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

G

glutamate ionotropic receptor NMDA type subunit 1

increases expression

Phenytoin results in increased expression of GRIN1 mRNA

NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756

G

glutathione S-transferase alpha 1

increases expression

Phenytoin results in increased expression of GSTA1 mRNA

NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860

G

glutathione S-transferase alpha 2

increases expression
decreases expression

Phenytoin results in increased expression of GSTA2 mRNA
Phenytoin results in decreased expression of GSTA2 mRNA

NCBI chr 6:52,750,087...52,763,475
Ensembl chr 6:52,750,087...52,763,475

G

glutathione S-transferase kappa 1

decreases expression

Phenytoin results in decreased expression of GSTK1 mRNA

NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854

G

glutathione S-transferase mu 1

increases expression
multiple interactions

Phenytoin results in increased expression of GSTM1 mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein

PMID:17381134 PMID:21224054

NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039

G

glutathione S-transferase mu 2

increases expression

Phenytoin results in increased expression of GSTM2 mRNA

NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551

G

glutathione S-transferase mu 3

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA

NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038

G

glutathione S-transferase omega 1

decreases expression

Phenytoin results in decreased expression of GSTO1 mRNA

NCBI chr10:104,254,173...104,267,455
Ensembl chr10:104,235,356...104,267,459

G

glucuronidase beta

multiple interactions
decreases activity

Phenytoin inhibits the reaction [Misonidazole results in increased activity of GUSB protein]
Phenytoin results in decreased activity of GUSB protein

NCBI chr 7:65,960,684...65,982,213
Ensembl chr 7:65,960,684...65,982,215

G

histone deacetylase 7

increases expression

Phenytoin results in increased expression of HDAC7 mRNA

NCBI chr12:47,782,722...47,821,344
Ensembl chr12:47,782,722...47,833,132

G

helicase with zinc finger

increases expression

Phenytoin results in increased expression of HELZ mRNA

NCBI chr17:67,070,444...67,245,989
Ensembl chr17:67,070,444...67,245,989

G

HEXIM P-TEFb complex subunit 1

increases expression

Phenytoin results in increased expression of HEXIM1 mRNA

NCBI chr17:45,148,475...45,152,099
Ensembl chr17:45,148,475...45,152,099

G

major histocompatibility complex, class I, B

affects response to substance

HLA-B gene polymorphism affects the susceptibility to Phenytoin

NCBI chr 6:31,353,875...31,357,179
Ensembl chr 6:31,353,872...31,367,067

G

high mobility group box 1

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein

NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597

G

heme oxygenase 1

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA
Phenytoin results in increased expression of HMOX1 mRNA

PMID:17381134 PMID:21224054

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

heterogeneous nuclear ribonucleoprotein A2/B1

increases expression

Phenytoin results in increased expression of HNRNPA2B1 mRNA

NCBI chr 7:26,189,927...26,200,746
Ensembl chr 7:26,171,151...26,201,529

G

hook microtubule tethering protein 3

increases expression

Phenytoin results in increased expression of HOOK3 mRNA

NCBI chr 8:42,896,978...43,030,535
Ensembl chr 8:42,896,946...43,030,535

G

homeobox A2

decreases expression

Phenytoin results in decreased expression of HOXA2 mRNA; Phenytoin results in decreased expression of HOXA2 protein

NCBI chr 7:27,100,354...27,102,683
Ensembl chr 7:27,100,354...27,102,686

G

homeobox B7

increases expression

Phenytoin results in increased expression of HOXB7 mRNA

NCBI chr17:48,607,232...48,611,017
Ensembl chr17:48,607,232...48,633,572

G

homeobox B9

increases expression

Phenytoin results in increased expression of HOXB9 mRNA

NCBI chr17:48,621,156...48,626,358
Ensembl chr17:48,621,156...48,626,358

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA

NCBI chr 6:31,809,619...31,815,283
Ensembl chr 6:31,809,619...31,815,283

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

heat shock protein family B (small) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA

NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295

G

heat shock protein family D (Hsp60) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA

NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737

G

heat shock protein family E (Hsp10) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA

NCBI chr 2:197,500,379...197,503,449
Ensembl chr 2:197,500,140...197,503,449

G

interferon gamma

decreases expression

Phenytoin results in decreased expression of IFNG protein

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interferon gamma receptor 1

increases expression

Phenytoin results in increased expression of IFNGR1 mRNA

NCBI chr 6:137,197,484...137,219,385
Ensembl chr 6:137,197,483...137,219,449

G

interferon gamma receptor 2

increases expression

Phenytoin results in increased expression of IFNGR2 mRNA

NCBI chr21:33,402,882...33,437,516
Ensembl chr21:33,403,413...33,479,348

G

insulin like growth factor 1

decreases expression

Phenytoin results in decreased expression of IGF1 mRNA

NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744

G

insulin like growth factor 2

increases expression

Phenytoin results in increased expression of IGF2 mRNA

NCBI chr11:2,129,117...2,149,566
Ensembl chr11:2,129,112...2,158,391

G

Indian hedgehog signaling molecule

increases expression

Phenytoin results in increased expression of IHH mRNA

NCBI chr 2:219,054,424...219,060,921
Ensembl chr 2:219,054,424...219,060,921

G

interleukin 17A

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein

NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638

G

interleukin 18

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA

NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096

G

interleukin 1 beta

multiple interactions

Phenytoin inhibits the reaction [IL1B protein results in decreased expression of COL1A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein

PMID:8971655 PMID:21224054 PMID:23986454

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 23 subunit alpha

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA

NCBI chr12:56,338,884...56,340,410
Ensembl chr12:56,334,174...56,340,410

G

interleukin 6

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA
Phenytoin results in increased expression of IL6 mRNA

PMID:21224054 PMID:23986454

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

interleukin 6 receptor

decreases expression

Phenytoin results in decreased expression of IL6RA mRNA

NCBI chr 1:154,405,343...154,469,450
Ensembl chr 1:154,405,193...154,469,450

G

inositol polyphosphate-5-phosphatase F

increases expression

Phenytoin results in increased expression of INPP5F mRNA

NCBI chr10:119,726,050...119,829,147
Ensembl chr10:119,726,042...119,829,147

G

insulin receptor

increases expression

Phenytoin results in increased expression of INSR mRNA

NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414

G

intracisternal A particle-promoted polypeptide

increases expression

Phenytoin results in increased expression of IPP mRNA

NCBI chr 1:45,694,324...45,750,653
Ensembl chr 1:45,694,324...45,750,653

G

interferon regulatory factor 9

increases expression

Phenytoin results in increased expression of IRF9 mRNA

NCBI chr14:24,161,265...24,166,565
Ensembl chr14:24,161,234...24,168,043

G

integrin subunit alpha 2

decreases expression

Phenytoin results in decreased expression of ITGA2 protein

NCBI chr 5:52,989,352...53,094,779
Ensembl chr 5:52,989,340...53,094,779

G

integrin subunit alpha 8

increases expression

Phenytoin results in increased expression of ITGA8 mRNA

NCBI chr10:15,513,954...15,719,922
Ensembl chr10:15,513,954...15,719,922

G

integrin subunit beta 1

decreases expression

Phenytoin results in decreased expression of ITGB1 protein

NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792

G

integrin subunit beta 3 binding protein

increases expression

Phenytoin results in increased expression of ITGB3BP mRNA

NCBI chr 1:63,440,770...63,529,187
Ensembl chr 1:63,440,770...63,593,721

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

Phenytoin results in decreased expression of JUN mRNA

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

potassium voltage-gated channel subfamily D member 2

increases expression

Phenytoin results in increased expression of KCND2 mRNA

NCBI chr 7:120,272,908...120,750,337
Ensembl chr 7:120,273,175...120,750,337

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Phenytoin results in decreased activity of KCNH2 protein

NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321

G

potassium channel tetramerization domain containing 3

increases expression

Phenytoin results in increased expression of KCTD3 mRNA

NCBI chr 1:215,567,304...215,621,807
Ensembl chr 1:215,567,304...215,621,807

G

kinase insert domain receptor

increases expression

Phenytoin results in increased expression of KDR mRNA

NCBI chr 4:55,078,481...55,125,595
Ensembl chr 4:55,078,481...55,125,595

G

KH RNA binding domain containing, signal transduction associated 2

increases expression

Phenytoin results in increased expression of KHDRBS2 mRNA

NCBI chr 6:61,542,670...62,286,225
Ensembl chr 6:61,679,961...62,286,225

G

KLF transcription factor 2

increases expression

Phenytoin results in increased expression of KLF2 mRNA

NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685

G

kelch like family member 2

increases expression

Phenytoin results in increased expression of KLHL2 mRNA

NCBI chr 4:165,207,561...165,323,156
Ensembl chr 4:165,207,561...165,323,156

G

kelch like family member 7

increases expression

Phenytoin results in increased expression of KLHL7 mRNA

NCBI chr 7:23,105,785...23,177,914
Ensembl chr 7:23,105,758...23,177,914

G

KRIT1 ankyrin repeat containing

increases expression

Phenytoin results in increased expression of KRIT1 mRNA

NCBI chr 7:92,198,969...92,246,100
Ensembl chr 7:92,197,498...92,246,166

G

keratin 2

increases expression

Phenytoin results in increased expression of KRT2 mRNA

NCBI chr12:52,644,558...52,652,211
Ensembl chr12:52,644,558...52,652,211

G

kynurenine aminotransferase 1

increases activity

Phenytoin results in increased activity of KYAT1 protein

NCBI chr 9:128,832,942...128,882,523
Ensembl chr 9:128,832,942...128,882,494
Ensembl chr 9:128,832,942...128,882,494

G

laminin subunit alpha 2

increases expression

Phenytoin results in increased expression of LAMA2 mRNA

NCBI chr 6:128,883,138...129,516,566
Ensembl chr 6:128,883,138...129,516,566

G

leucine aminopeptidase 3

affects expression

Phenytoin affects the expression of LAP3 mRNA

NCBI chr 4:17,577,198...17,607,970
Ensembl chr 4:17,577,198...17,607,972

G

lecithin-cholesterol acyltransferase

increases expression

Phenytoin results in increased expression of LCAT mRNA

NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131

G

LIM domain binding 2

increases expression

Phenytoin results in increased expression of LDB2 mRNA

NCBI chr 4:16,501,541...16,898,645
Ensembl chr 4:16,501,541...16,898,678

G

lipin 1

increases expression

Phenytoin results in increased expression of LPIN1 mRNA

NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409

G

LPS responsive beige-like anchor protein

increases expression

Phenytoin results in increased expression of LRBA mRNA

NCBI chr 4:150,264,435...151,015,727
Ensembl chr 4:150,264,435...151,015,727

G

LSM1 homolog, mRNA degradation associated

decreases expression

Phenytoin results in decreased expression of LSM1 mRNA

NCBI chr 8:38,163,321...38,176,730
Ensembl chr 8:38,163,335...38,176,730

G

latent transforming growth factor beta binding protein 4

increases expression

Phenytoin results in increased expression of LTBP4 mRNA

NCBI chr19:40,593,166...40,629,820
Ensembl chr19:40,592,883...40,629,818

G

lysophospholipase 1

increases expression

Phenytoin results in increased expression of LYPLA1 mRNA

NCBI chr 8:54,046,367...54,101,947
Ensembl chr 8:54,046,367...54,102,017

G

microtubule associated protein 1B

increases expression

Phenytoin results in increased expression of MAP1B mRNA

NCBI chr 5:72,107,475...72,209,565
Ensembl chr 5:72,107,234...72,209,565

G

mitogen-activated protein kinase kinase kinase 4

increases expression

Phenytoin results in increased expression of MAP3K4 mRNA

NCBI chr 6:160,991,769...161,117,380
Ensembl chr 6:160,991,727...161,117,385

G

mitogen-activated protein kinase 1

decreases phosphorylation

Phenytoin results in decreased phosphorylation of MAPK1 protein

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

decreases phosphorylation

Phenytoin results in decreased phosphorylation of MAPK3 protein

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

microtubule associated protein RP/EB family member 3

increases expression

Phenytoin results in increased expression of MAPRE3 mRNA

NCBI chr 2:26,970,637...27,027,219
Ensembl chr 2:26,970,637...27,027,219

G

mannose binding lectin 1, pseudogene

decreases expression

Phenytoin results in decreased expression of MBL1 mRNA

NCBI chr10:79,920,178...79,923,119
Ensembl chr10:79,920,327...79,923,032
Ensembl chr10:79,920,327...79,923,032

G

midkine

increases expression

Phenytoin results in increased expression of MDK mRNA

NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837

G

MDM2 proto-oncogene

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA

NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544

G

malic enzyme 1

increases expression

Phenytoin results in increased expression of ME1 mRNA

NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051

G

mesenchyme homeobox 1

decreases expression

Phenytoin results in decreased expression of MEOX1 mRNA

NCBI chr17:43,640,389...43,661,922
Ensembl chr17:43,640,389...43,661,922

G

mesoderm posterior bHLH transcription factor 1

increases expression

Phenytoin results in increased expression of MESP1 mRNA

NCBI chr15:89,732,446...89,751,249
Ensembl chr15:89,749,875...89,751,249

G

mex-3 RNA binding family member D

increases expression

Phenytoin results in increased expression of MEX3D mRNA

NCBI chr19:1,554,672...1,568,325
Ensembl chr19:1,554,672...1,568,325

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

increases expression

Phenytoin results in increased expression of MGAT2 mRNA

NCBI chr14:49,620,799...49,623,481
Ensembl chr14:49,620,799...49,623,481

G

O-6-methylguanine-DNA methyltransferase

increases methylation

Phenytoin results in increased methylation of MGMT promoter

NCBI chr10:129,467,241...129,770,983
Ensembl chr10:129,467,190...129,770,983

G

marker of proliferation Ki-67

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein

NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423

G

matrix metallopeptidase 1

decreases expression
increases expression

Phenytoin results in decreased expression of MMP1 mRNA
Phenytoin results in increased expression of MMP1 mRNA

PMID:10914799 PMID:14741686 PMID:15948689

NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160

G

matrix metallopeptidase 2

decreases expression

Phenytoin results in decreased expression of MMP2 mRNA

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

matrix metallopeptidase 3

decreases expression

Phenytoin results in decreased expression of MMP3 mRNA

NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609

G

mitochondrial ribosomal protein S18C

increases expression

Phenytoin results in increased expression of MRPS18C mRNA

NCBI chr 4:83,456,058...83,462,298
Ensembl chr 4:83,455,932...83,469,735

G

metal response element binding transcription factor 2

increases expression

Phenytoin results in increased expression of MTF2 mRNA

NCBI chr 1:93,079,283...93,139,076
Ensembl chr 1:93,079,235...93,139,079

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like

increases expression

Phenytoin results in increased expression of MTHFD1L mRNA

NCBI chr 6:150,865,702...151,101,887
Ensembl chr 6:150,865,679...151,101,887

G

metaxin 2

increases expression

Phenytoin results in increased expression of MTX2 mRNA

NCBI chr 2:176,269,442...176,338,025
Ensembl chr 2:176,269,395...176,338,025

G

MYC proto-oncogene, bHLH transcription factor

increases expression
decreases expression

Phenytoin results in increased expression of MYC protein
Phenytoin results in decreased expression of MYC mRNA

PMID:10695937 PMID:26272751

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

myosin IE

increases expression

Phenytoin results in increased expression of MYO1E mRNA

NCBI chr15:59,132,434...59,372,871
Ensembl chr15:59,132,434...59,372,871

G

nucleosome assembly protein 1 like 2

affects expression

Phenytoin affects the expression of NAP1L2 mRNA

NCBI chr X:73,212,299...73,214,851
Ensembl chr X:73,212,299...73,214,851

G

neurocan

increases expression

Phenytoin results in increased expression of NCAN mRNA

NCBI chr19:19,211,958...19,252,233
Ensembl chr19:19,211,958...19,252,233

G

nucleolin

decreases expression

Phenytoin results in decreased expression of NCL mRNA

NCBI chr 2:231,453,531...231,464,484
Ensembl chr 2:231,453,531...231,483,641

G

nuclear receptor coactivator 1

multiple interactions

Phenytoin promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]

NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,254...24,770,702

G

negative elongation factor complex member A

decreases expression

Phenytoin results in decreased expression of NELFA mRNA

NCBI chr 4:1,982,723...2,008,974
Ensembl chr 4:1,982,717...2,041,903

G

nestin

decreases expression

Phenytoin results in decreased expression of NES mRNA

NCBI chr 1:156,668,763...156,677,407
Ensembl chr 1:156,668,763...156,677,407

G

neurogenin 2

increases expression

Phenytoin results in increased expression of NEUROG2 mRNA

NCBI chr 4:112,513,516...112,516,180
Ensembl chr 4:112,513,516...112,516,180

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression

Phenytoin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased localization of and results in increased activity of NFKB1 protein]
Phenytoin results in increased expression of NFKB1 mRNA

PMID:10700573 PMID:14741686

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

NFKB inhibitor alpha

decreases degradation

Phenytoin results in decreased degradation of NFKBIA protein

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

N-glycanase 1

increases expression

Phenytoin results in increased expression of NGLY1 mRNA

NCBI chr 3:25,718,944...25,790,039
Ensembl chr 3:25,718,944...25,790,039

G

NLR family pyrin domain containing 3

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA

NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108

G

nitric oxide synthase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

neuronal PAS domain protein 2

increases expression

Phenytoin results in increased expression of NPAS2 mRNA

NCBI chr 2:100,818,723...100,996,829
Ensembl chr 2:100,820,139...100,996,829

G

NAD(P)H quinone dehydrogenase 1

increases expression

Phenytoin results in increased expression of NQO1 mRNA

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 1 group I member 2

multiple interactions
affects activity
increases expression
increases activity

Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; Phenytoin binds to and results in increased activity of NR1I2 protein; Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]
Phenytoin affects the activity of NR1I2 protein
Phenytoin results in increased expression of NR1I2 protein
Phenytoin results in increased activity of NR1I2 protein

PMID:12065438 PMID:12695340 PMID:12695351 PMID:14600250 PMID:14977870 More...

NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487

G

nuclear receptor subfamily 1 group I member 3

multiple interactions
increases expression
increases activity
increases localization

[Phenytoin results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; Phenytoin promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]
Phenytoin results in increased expression of NR1I3 protein
NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C29 mRNA]; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C37 mRNA]
Phenytoin results in increased localization of NR1I3 protein

PMID:15123723 PMID:15155833 PMID:15849716 PMID:16936065 PMID:17041008 More...

NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244

G

nuclear receptor subfamily 2 group F member 1

increases expression

Phenytoin results in increased expression of NR2F1 mRNA

NCBI chr 5:93,583,222...93,594,611
Ensembl chr 5:93,583,222...93,594,611

G

nuclear receptor subfamily 3 group C member 1

multiple interactions
increases expression

Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]
Phenytoin results in increased expression of NR3C1 mRNA

PMID:10219967 PMID:12695351 PMID:20345932

NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512

G

neuronal cell adhesion molecule

decreases expression

Phenytoin results in decreased expression of NRCAM mRNA

NCBI chr 7:108,147,649...108,456,720
Ensembl chr 7:108,147,623...108,456,717

G

NSE3 homolog, SMC5-SMC6 complex component

increases expression

Phenytoin results in increased expression of NSMCE3 mRNA

NCBI chr15:29,264,989...29,269,822
Ensembl chr15:29,264,989...29,269,822

G

5'-nucleotidase domain containing 1

increases expression

Phenytoin results in increased expression of NT5DC1 mRNA

NCBI chr 6:116,100,853...116,249,497
Ensembl chr 6:116,100,851...116,249,497

G

neurotrophin 3

decreases expression

Phenytoin results in decreased expression of NTF3 mRNA

NCBI chr12:5,430,332...5,495,299
Ensembl chr12:5,432,108...5,521,536

G

nucleoporin 153

increases expression

Phenytoin results in increased expression of NUP153 mRNA

NCBI chr 6:17,615,037...17,706,925
Ensembl chr 6:17,615,035...17,706,925

G

oligodendrocyte transcription factor 3

increases expression

Phenytoin results in increased expression of OLIG3 mRNA

NCBI chr 6:137,492,199...137,494,394
Ensembl chr 6:137,492,199...137,494,394

G

opioid receptor mu 1

multiple interactions

[cyprodime binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Phenytoin

NCBI chr 6:154,010,496...154,246,867
Ensembl chr 6:154,010,496...154,246,867

G

platelet activating factor acetylhydrolase 1b regulatory subunit 1

decreases expression

Phenytoin results in decreased expression of PAFAH1B1 mRNA

NCBI chr17:2,593,183...2,685,615
Ensembl chr17:2,593,210...2,685,615

G

platelet activating factor acetylhydrolase 1b catalytic subunit 2

decreases expression

Phenytoin results in decreased expression of PAFAH1B2 mRNA

NCBI chr11:117,144,287...117,178,173
Ensembl chr11:117,144,284...117,176,894

G

par-6 family cell polarity regulator gamma

increases expression

Phenytoin results in increased expression of PARD6G mRNA

NCBI chr18:80,157,232...80,247,514
Ensembl chr18:80,157,232...80,247,514

G

poly(ADP-ribose) glycohydrolase

increases expression

Phenytoin results in increased expression of PARG mRNA

NCBI chr10:49,818,279...49,942,027
Ensembl chr10:49,818,279...49,970,203

G

paired box 3

decreases expression

Phenytoin results in decreased expression of PAX3 mRNA

PMID:9118846 PMID:31711903

NCBI chr 2:222,199,887...222,298,998
Ensembl chr 2:222,199,887...222,298,998

G

paired box 6

increases expression

Phenytoin results in increased expression of PAX6 mRNA

NCBI chr11:31,789,026...31,817,961
Ensembl chr11:31,784,779...31,817,961

G

PBX homeobox 1

increases expression

Phenytoin results in increased expression of PBX1 mRNA

NCBI chr 1:164,559,184...164,886,047
Ensembl chr 1:164,555,584...164,899,296

G

prenylcysteine oxidase 1

increases expression

Phenytoin results in increased expression of PCYOX1 mRNA

NCBI chr 2:70,257,915...70,281,185
Ensembl chr 2:70,257,386...70,281,185

G

platelet derived growth factor subunit A

increases expression

Phenytoin results in increased expression of PDGFA mRNA

NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296

G

platelet derived growth factor subunit B

increases expression

Phenytoin results in increased expression of PDGFB mRNA; Phenytoin results in increased expression of PDGFB protein

PMID:8463938 PMID:9029455 PMID:14741686

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

progesterone receptor membrane component 1

increases expression

Phenytoin results in increased expression of PGRMC1 mRNA

NCBI chr X:119,236,285...119,244,466
Ensembl chr X:119,236,245...119,244,466

G

PHD finger protein 14

increases expression

Phenytoin results in increased expression of PHF14 mRNA

NCBI chr 7:10,973,872...11,169,618
Ensembl chr 7:10,973,336...11,169,623

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

increases expression

Phenytoin results in increased expression of PIP4K2A mRNA

NCBI chr10:22,534,854...22,714,578
Ensembl chr10:22,534,854...22,714,578

G

plasminogen activator, urokinase receptor

decreases expression

Phenytoin results in decreased expression of PLAUR mRNA

NCBI chr19:43,646,095...43,670,169
Ensembl chr19:43,646,095...43,670,547

G

phospholipase C like 1 (inactive)

increases expression

Phenytoin results in increased expression of PLCL1 mRNA

NCBI chr 2:197,804,593...198,149,863
Ensembl chr 2:197,804,593...198,572,581

G

plectin

increases expression

Phenytoin results in increased expression of PLEC mRNA

NCBI chr 8:143,915,153...143,976,745
Ensembl chr 8:143,915,153...143,976,734

G

phospholipid transfer protein

increases expression

Phenytoin results in increased expression of PLTP mRNA

NCBI chr20:45,898,620...45,912,155
Ensembl chr20:45,898,621...45,912,155

G

plexin B2

decreases expression

Phenytoin results in decreased expression of PLXNB2 mRNA

NCBI chr22:50,274,979...50,307,646
Ensembl chr22:50,274,979...50,307,646

G

pinin, desmosome associated protein

increases expression

Phenytoin results in increased expression of PNN mRNA

NCBI chr14:39,175,254...39,183,220
Ensembl chr14:39,175,183...39,183,220

G

paraoxonase 1

decreases expression
affects activity

Phenytoin results in decreased expression of PON1 mRNA
Phenytoin affects the activity of PON1 protein

PMID:15136057 PMID:28032682

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

cytochrome p450 oxidoreductase

increases activity

Phenytoin results in increased activity of POR protein

NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855

G

POU class 3 homeobox 1

increases expression

Phenytoin results in increased expression of POU3F1 protein

NCBI chr 1:38,043,829...38,046,793
Ensembl chr 1:38,043,829...38,046,793

G

peptidylprolyl isomerase like 4

increases expression

Phenytoin results in increased expression of PPIL4 mRNA

NCBI chr 6:149,504,495...149,546,043
Ensembl chr 6:149,504,495...149,546,043

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]

NCBI chr 8:47,773,111...47,960,136
Ensembl chr 8:47,773,111...47,960,178

G

prolactin

decreases expression

Phenytoin results in decreased expression of PRL mRNA; Phenytoin results in decreased expression of PRL protein

NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826

G

protein arginine methyltransferase 3

increases expression

Phenytoin results in increased expression of PRMT3 mRNA

NCBI chr11:20,387,716...20,509,338
Ensembl chr11:20,387,558...20,509,338

G

serine protease 12

increases expression

Phenytoin results in increased expression of PRSS12 mRNA

NCBI chr 4:118,280,038...118,353,003
Ensembl chr 4:118,280,038...118,353,003

G

PC4 and SRSF1 interacting protein 1

increases expression

Phenytoin results in increased expression of PSIP1 mRNA

NCBI chr 9:15,464,066...15,510,970
Ensembl chr 9:15,464,066...15,510,995

G

proteasome 26S subunit, ATPase 6

increases expression

Phenytoin results in increased expression of PSMC6 mRNA

NCBI chr14:52,707,200...52,728,590
Ensembl chr14:52,707,178...52,728,590

G

proteasome 26S subunit, non-ATPase 12

increases expression

Phenytoin results in increased expression of PSMD12 mRNA

NCBI chr17:67,337,916...67,366,577
Ensembl chr17:67,337,916...67,366,605

G

polypyrimidine tract binding protein 2

increases expression

Phenytoin results in increased expression of PTBP2 mRNA

NCBI chr 1:96,721,784...96,823,739
Ensembl chr 1:96,721,665...96,823,738

G

patched 1

increases expression

Phenytoin results in increased expression of PTCH1 mRNA

NCBI chr 9:95,442,980...95,516,971
Ensembl chr 9:95,442,980...95,517,057

G

prostaglandin-endoperoxide synthase 2

increases expression

Phenytoin results in increased expression of PTGS2 mRNA

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

parathyroid hormone

increases expression

Phenytoin results in increased expression of PTH protein

NCBI chr11:13,492,054...13,496,181
Ensembl chr11:13,492,054...13,496,181

G

RAD50 double strand break repair protein

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA

NCBI chr 5:132,556,977...132,646,349
Ensembl chr 5:132,556,019...132,646,349

G

retinoic acid induced 1

increases expression

Phenytoin results in increased expression of RAI1 mRNA

NCBI chr17:17,681,458...17,811,453
Ensembl chr17:17,681,458...17,811,453

G

RAN binding protein 6

increases expression

Phenytoin results in increased expression of RANBP6 mRNA

NCBI chr 9:6,011,025...6,015,624
Ensembl chr 9:6,011,025...6,015,625

G

Rap guanine nucleotide exchange factor 4

increases expression

Phenytoin results in increased expression of RAPGEF4 mRNA

NCBI chr 2:172,735,318...173,052,893
Ensembl chr 2:172,735,274...173,052,893

G

retinoic acid receptor alpha

increases expression
decreases expression

Phenytoin results in increased expression of RARA mRNA
Phenytoin results in decreased expression of RARA mRNA

PMID:9118846 PMID:9988880

NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643

G

retinoic acid receptor beta

increases expression

Phenytoin results in increased expression of RARB mRNA

NCBI chr 3:24,829,321...25,597,932
Ensembl chr 3:24,687,887...25,597,932

G

retinoic acid receptor gamma

increases expression

Phenytoin results in increased expression of RARG mRNA

NCBI chr12:53,210,569...53,232,209
Ensembl chr12:53,210,567...53,232,980

G

RNA binding motif protein 12

increases expression

Phenytoin results in increased expression of RBM12 mRNA

NCBI chr20:35,648,925...35,664,900
Ensembl chr20:35,648,925...35,664,956

G

RNA binding motif protein 3

increases expression

Phenytoin results in increased expression of RBM3 mRNA

NCBI chr X:48,574,484...48,581,162
Ensembl chr X:48,574,449...48,581,162

G

RNA binding motif protein 34

increases expression

Phenytoin results in increased expression of RBM34 mRNA

NCBI chr 1:235,131,183...235,161,250
Ensembl chr 1:235,131,183...235,161,283

G

retinol binding protein 2

increases expression

Phenytoin results in increased expression of RBP2 mRNA

NCBI chr 3:139,452,884...139,476,516
Ensembl chr 3:139,452,884...139,480,747

G

retinol dehydrogenase 14

increases expression

Phenytoin results in increased expression of RDH14 mRNA

NCBI chr 2:18,554,723...18,560,653
Ensembl chr 2:18,554,723...18,560,679

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases activity

Phenytoin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased localization of and results in increased activity of RELA protein]
Phenytoin results in increased activity of RELA protein

PMID:10700573 PMID:15322231

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

ras homolog family member A

decreases expression

Phenytoin results in decreased expression of RHOA mRNA

NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998

G

RIO kinase 2

increases expression

Phenytoin results in increased expression of RIOK2 mRNA

NCBI chr 5:97,160,867...97,183,247
Ensembl chr 5:97,160,867...97,183,247

G

ribonuclease H1

decreases expression

Phenytoin results in decreased expression of RNASEH1 mRNA

NCBI chr 2:3,531,813...3,558,333
Ensembl chr 2:3,541,430...3,558,333

G

Rho family GTPase 1

increases expression

Phenytoin results in increased expression of RND1 mRNA

NCBI chr12:48,857,145...48,865,870
Ensembl chr12:48,857,145...48,865,870

G

ring finger protein 115

increases expression

Phenytoin results in increased expression of RNF115 mRNA

NCBI chr 1:145,738,868...145,824,095
Ensembl chr 1:145,738,868...145,824,095

G

ribulose-5-phosphate-3-epimerase

increases expression

Phenytoin results in increased expression of RPE mRNA

NCBI chr 2:210,002,638...210,022,260
Ensembl chr 2:210,002,565...210,022,260

G

ribosomal protein L28

increases expression

Phenytoin results in increased expression of RPL28 mRNA

NCBI chr19:55,385,932...55,403,342
Ensembl chr19:55,385,932...55,403,250

G

ribosomal protein S6 kinase A3

increases expression

Phenytoin results in increased expression of RPS6KA3 mRNA

NCBI chr X:20,149,911...20,267,097
Ensembl chr X:20,149,911...20,267,519

G

ribosomal protein SA

increases expression

Phenytoin results in increased expression of RPSA mRNA

NCBI chr 3:39,406,720...39,412,542
Ensembl chr 3:39,406,716...39,426,255

G

arginine and serine rich coiled-coil 1

decreases expression

Phenytoin results in decreased expression of RSRC1 mRNA

NCBI chr 3:158,110,089...158,545,730
Ensembl chr 3:158,105,855...158,545,730

G

ryanodine receptor 2

increases expression

Phenytoin results in increased expression of RYR2 mRNA

NCBI chr 1:237,042,184...237,833,988
Ensembl chr 1:237,042,184...237,833,988

G

S100 calcium binding protein A10

increases expression

Phenytoin results in increased expression of S100A10 mRNA

NCBI chr 1:151,982,915...151,993,859
Ensembl chr 1:151,982,915...151,993,859

G

S100 calcium binding protein A4

increases expression

Phenytoin results in increased expression of S100A4 mRNA

NCBI chr 1:153,543,621...153,545,806
Ensembl chr 1:153,543,613...153,550,136

G

S100 calcium binding protein A8

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

S100 calcium binding protein A9

multiple interactions
increases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA
Phenytoin results in increased expression of S100A9 mRNA

NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023

G

spliceosome associated factor 3, U4/U6 recycling protein

increases expression

Phenytoin results in increased expression of SART3 mRNA

NCBI chr12:108,522,214...108,561,173
Ensembl chr12:108,522,214...108,561,400

G

sterol-C5-desaturase

increases expression

Phenytoin results in increased expression of SC5D mRNA

NCBI chr11:121,292,771...121,313,410
Ensembl chr11:121,292,681...121,313,410

G

SR-related CTD associated factor 1

increases expression

Phenytoin results in increased expression of SCAF1 mRNA

NCBI chr19:49,640,465...49,658,642
Ensembl chr19:49,642,209...49,658,642

G

scavenger receptor class B member 1

decreases expression

Phenytoin results in decreased expression of SCARB1 mRNA

NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668

G

sodium voltage-gated channel alpha subunit 1

affects response to substance

SCN1A gene polymorphism affects the susceptibility to Phenytoin; SCN1A protein affects the susceptibility to Phenytoin

PMID:15805193 PMID:17001291

NCBI chr 2:165,984,641...166,149,161
Ensembl chr 2:165,984,641...166,149,214

G

sodium voltage-gated channel beta subunit 1

affects binding
decreases response to substance
multiple interactions

Phenytoin binds to [SCN1B protein binds to SCN3A protein]
SCN1B protein mutant form results in decreased susceptibility to Phenytoin
Phenytoin results in decreased activity of [SCN1B protein binds to SCN3A protein]

NCBI chr19:35,030,470...35,040,449
Ensembl chr19:35,030,470...35,040,449

G

sodium voltage-gated channel alpha subunit 2

decreases activity

Phenytoin results in decreased activity of SCN2A protein

NCBI chr 2:165,239,414...165,392,304
Ensembl chr 2:165,194,993...165,392,310

G

sodium voltage-gated channel alpha subunit 3

multiple interactions
affects binding

Phenytoin results in decreased activity of [SCN1B protein binds to SCN3A protein]
Phenytoin binds to [SCN1B protein binds to SCN3A protein]

NCBI chr 2:165,087,526...165,204,050
Ensembl chr 2:165,087,526...165,204,050

G

syndecan 4

decreases expression

Phenytoin results in decreased expression of SDC4 mRNA

NCBI chr20:45,325,288...45,348,424
Ensembl chr20:45,325,288...45,348,424

G

selectin E

multiple interactions

[clobazam co-treated with Phenytoin] results in increased expression of SELE protein

NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705

G

SUMO specific peptidase 7

increases expression

Phenytoin results in increased expression of SENP7 mRNA

NCBI chr 3:101,324,205...101,513,212
Ensembl chr 3:101,324,205...101,513,241

G

serpin family C member 1

multiple interactions

[clobazam co-treated with Phenytoin] results in increased expression of [F2 protein binds to SERPINC1 protein]

NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327

G

serpin family E member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

SH3 and SYLF domain containing 1

increases expression

Phenytoin results in increased expression of SH3YL1 mRNA

NCBI chr 2:218,136...264,824
Ensembl chr 2:217,730...266,398

G

sonic hedgehog signaling molecule

increases expression

Phenytoin results in increased expression of SHH mRNA

NCBI chr 7:155,799,980...155,812,463
Ensembl chr 7:155,799,980...155,812,463

G

siah E3 ubiquitin protein ligase 1

increases expression

Phenytoin results in increased expression of SIAH1A mRNA

NCBI chr16:48,360,531...48,387,246
Ensembl chr16:48,356,364...48,448,402

G

signal induced proliferation associated 1 like 1

increases expression

Phenytoin results in increased expression of SIPA1L1 mRNA

NCBI chr14:71,320,476...71,741,209
Ensembl chr14:71,320,449...71,741,229

G

solute carrier family 22 member 7

decreases expression

Phenytoin results in decreased expression of SLC22A7 mRNA

NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538

G

solute carrier family 4 member 3

increases expression

Phenytoin results in increased expression of SLC4A3 mRNA

NCBI chr 2:219,627,630...219,641,971
Ensembl chr 2:219,627,394...219,641,980

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1

increases expression

Phenytoin results in increased expression of SMARCA1 mRNA

NCBI chr X:129,446,506...129,523,490
Ensembl chr X:129,446,501...129,523,500

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5

increases expression

Phenytoin results in increased expression of SMARCA5 mRNA

NCBI chr 4:143,513,702...143,557,486
Ensembl chr 4:143,513,702...143,557,486

G

structural maintenance of chromosomes 2

increases expression

Phenytoin results in increased expression of SMC2 mRNA

NCBI chr 9:104,088,263...104,141,419
Ensembl chr 9:104,094,260...104,141,419

G

structural maintenance of chromosomes 3

increases expression

Phenytoin results in increased expression of SMC3 mRNA

NCBI chr10:110,567,695...110,606,048
Ensembl chr10:110,567,684...110,606,048

G

structural maintenance of chromosomes 5

increases expression

Phenytoin results in increased expression of SMC5 mRNA

NCBI chr 9:70,258,978...70,354,873
Ensembl chr 9:70,258,978...70,354,873

G

sorting nexin 2

increases expression

Phenytoin results in increased expression of SNX2 mRNA

NCBI chr 5:122,774,996...122,834,543
Ensembl chr 5:122,775,079...122,834,543

G

Sp3 transcription factor

increases expression

Phenytoin results in increased expression of SP3 mRNA

NCBI chr 2:173,900,775...173,965,702
Ensembl chr 2:173,880,850...173,965,373

G

ST13 Hsp70 interacting protein

increases expression

Phenytoin results in increased expression of ST13 mRNA

NCBI chr22:40,824,535...40,856,639
Ensembl chr22:40,824,535...40,856,639

G

signal transducer and activator of transcription 4

decreases expression

Phenytoin results in decreased expression of STAT4 mRNA

NCBI chr 2:191,029,576...191,151,596
Ensembl chr 2:191,029,576...191,151,596

G

sulfotransferase family 1A member 1

decreases expression

Phenytoin results in decreased expression of SULT1A1 mRNA

PMID:9566755 PMID:17381134

NCBI chr16:28,605,258...28,623,375
Ensembl chr16:28,605,196...28,610,044

G

sulfotransferase family 2A member 1

decreases expression

Phenytoin results in decreased expression of SULT2A1 mRNA

NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315

G

synapsin I

decreases expression
multiple interactions

Phenytoin results in decreased expression of SYN1 mRNA
Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYN1 mRNA]

NCBI chr X:47,571,901...47,619,857
Ensembl chr X:47,571,901...47,619,857

G

synaptophysin

decreases expression
multiple interactions

Phenytoin results in decreased expression of SYP mRNA
Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYP mRNA]

NCBI chr X:49,187,815...49,200,193
Ensembl chr X:49,187,815...49,200,218

G

synaptophysin like 1

increases expression

Phenytoin results in increased expression of SYPL1 mRNA

NCBI chr 7:106,090,505...106,112,576
Ensembl chr 7:106,090,505...106,112,589

G

TATA-box binding protein associated factor 9b

increases expression

Phenytoin results in increased expression of TAF9B mRNA

NCBI chr X:78,129,748...78,139,650
Ensembl chr X:78,129,748...78,139,650

G

T-box transcription factor 21

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TBX21 mRNA
Phenytoin results in decreased expression of TBX21 mRNA

NCBI chr17:47,733,236...47,746,122
Ensembl chr17:47,733,236...47,746,122

G

transcription elongation factor A like 1

increases expression

Phenytoin results in increased expression of TCEAL1 mRNA

NCBI chr X:103,628,716...103,630,953
Ensembl chr X:103,628,704...103,630,953

G

transcription factor 15

decreases expression

Phenytoin results in decreased expression of TCF15 mRNA

NCBI chr20:604,257...610,309
Ensembl chr20:604,257...610,309

G

telomeric repeat binding factor 1

increases expression

Phenytoin results in increased expression of TERF1 mRNA

NCBI chr 8:73,008,864...73,048,123
Ensembl chr 8:73,008,856...73,048,123

G

transforming growth factor alpha

increases expression

Phenytoin results in increased expression of TGFA mRNA

NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193

G

transforming growth factor beta 1

increases expression
decreases expression

Phenytoin results in increased expression of TGFB1 mRNA
Phenytoin results in decreased expression of TGFB1 mRNA

PMID:7841657 PMID:9988880 PMID:16141649

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transforming growth factor beta 2

decreases expression

Phenytoin results in decreased expression of TGFB2 mRNA

NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619

G

transforming growth factor beta 3

increases expression

Phenytoin results in increased expression of TGFB3 mRNA

NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011

G

THO complex subunit 6

decreases expression

Phenytoin results in decreased expression of THOC6 mRNA

NCBI chr16:3,024,035...3,027,750
Ensembl chr16:3,024,027...3,027,755

G

TIMP metallopeptidase inhibitor 1

increases expression

Phenytoin results in increased expression of TIMP1 mRNA; Phenytoin results in increased expression of TIMP1 protein

PMID:10914799 PMID:14741686 PMID:15948689

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

transketolase

increases expression

Phenytoin results in increased expression of TKT mRNA

NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052

G

toll like receptor 2

multiple interactions
increases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of TLR2 mRNA
Phenytoin results in increased expression of TLR2 mRNA

NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,070...153,706,260

G

toll like receptor 4

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR4 mRNA
Phenytoin results in decreased expression of TLR4 mRNA

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

toll like receptor 9

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR9 mRNA
Phenytoin results in decreased expression of TLR9 mRNA

NCBI chr 3:52,221,080...52,225,645
Ensembl chr 3:52,221,080...52,225,645

G

tumor necrosis factor

increases expression

Phenytoin results in increased expression of TNF mRNA

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

TNF superfamily member 10

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA

NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475

G

tumor protein p53

increases expression

Phenytoin results in increased expression of TP53 mRNA

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

tumor protein p53 binding protein 2

increases expression

Phenytoin results in increased expression of TRP53BP2 mRNA

NCBI chr 1:223,779,893...223,845,947
Ensembl chr 1:223,779,893...223,845,954

G

TNFRSF1A associated via death domain

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA

NCBI chr16:67,154,185...67,159,909
Ensembl chr16:67,154,185...67,159,909

G

tRNA methyltransferase 10B

increases expression

Phenytoin results in increased expression of TRMT10B mRNA

NCBI chr 9:37,752,901...37,778,972
Ensembl chr 9:37,753,803...37,778,972

G

terminal uridylyl transferase 4

increases expression

Phenytoin results in increased expression of TUT4 mRNA

NCBI chr 1:52,423,275...52,553,463
Ensembl chr 1:52,408,282...52,553,487

G

thioredoxin reductase 1

increases expression

Phenytoin results in increased expression of TXNRD1 mRNA

NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307

G

ubiquitin conjugating enzyme E2 D2

increases expression

Phenytoin results in increased expression of UBE2D2 mRNA

NCBI chr 5:139,526,240...139,628,434
Ensembl chr 5:139,526,431...139,628,434

G

ubiquitin like 5

decreases expression

Phenytoin results in decreased expression of UBL5 mRNA

NCBI chr19:9,827,918...9,830,115
Ensembl chr19:9,827,892...9,830,115

G

ubiquitin protein ligase E3 component n-recognin 1

increases expression

Phenytoin results in increased expression of UBR1 mRNA

NCBI chr15:42,942,897...43,106,038
Ensembl chr15:42,942,897...43,106,113

G

UDP-glucose 6-dehydrogenase

decreases expression

Phenytoin results in decreased expression of UGDH mRNA

NCBI chr 4:39,498,755...39,527,439
Ensembl chr 4:39,498,755...39,528,311

G

UDP glucuronosyltransferase family 1 member A1

affects expression
increases activity
multiple interactions
increases expression

Phenytoin affects the expression of UGT1A1 mRNA
Phenytoin results in increased activity of UGT1A1 protein
Phenytoin results in increased expression of and results in increased activity of UGT1A1 protein
Phenytoin results in increased expression of UGT1A1 mRNA
Phenytoin results in increased expression of UGT1A1 mRNA; Phenytoin results in increased expression of UGT1A1 protein

PMID:10421657 PMID:15849716 PMID:17381134 PMID:27413119

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

UDP glucuronosyltransferase family 1 member A6

increases expression

Phenytoin results in increased expression of UGT1A6 mRNA

NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300

G

UDP glucuronosyltransferase family 2 member B17

increases expression

Phenytoin results in increased expression of UGT2B1 mRNA

NCBI chr 4:68,537,173...68,576,322
Ensembl chr 4:68,537,173...68,576,413

G

UNC homeobox

decreases expression

Phenytoin results in decreased expression of UNCX mRNA

NCBI chr 7:1,232,872...1,237,326
Ensembl chr 7:1,232,872...1,237,326

G

uracil DNA glycosylase

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA

NCBI chr12:109,097,597...109,110,992
Ensembl chr12:109,097,597...109,126,725

G

valyl-tRNA synthetase 2, mitochondrial

increases expression

Phenytoin results in increased expression of VARS2 mRNA

NCBI chr 6:30,914,238...30,926,459
Ensembl chr 6:30,914,205...30,926,459

G

versican

increases expression

Phenytoin results in increased expression of VCAN mRNA

NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303

G

vascular endothelial growth factor B

decreases expression

Phenytoin results in decreased expression of VEGFB mRNA

NCBI chr11:64,234,584...64,239,264
Ensembl chr11:64,234,584...64,239,264

G

vimentin

increases expression

Phenytoin results in increased expression of VIM mRNA

NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593

G

Wnt family member 1

decreases expression

Phenytoin results in decreased expression of WNT1 mRNA

NCBI chr12:48,978,322...48,982,620
Ensembl chr12:48,978,322...48,982,620

G

Wnt family member 3

decreases expression

Phenytoin results in decreased expression of WNT3 mRNA

NCBI chr17:46,762,506...46,818,692
Ensembl chr17:46,762,506...46,833,154

G

Wnt family member 5A

increases expression

Phenytoin results in increased expression of WNT5A mRNA

NCBI chr 3:55,465,715...55,505,263
Ensembl chr 3:55,465,715...55,490,539

G

X-ray repair cross complementing 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA

NCBI chr 5:83,077,547...83,374,473
Ensembl chr 5:83,077,498...83,353,787

G

YME1 like 1 ATPase

increases expression

Phenytoin results in increased expression of YME1L1 mRNA

NCBI chr10:27,110,111...27,154,384
Ensembl chr10:27,110,111...27,155,266

G

zeta chain of T cell receptor associated protein kinase 70

decreases expression

Phenytoin results in decreased expression of ZAP70 mRNA

NCBI chr 2:97,713,576...97,756,364
Ensembl chr 2:97,713,576...97,739,862

G

zinc finger protein 131

increases expression

Phenytoin results in increased expression of ZFP131 mRNA

NCBI chr 5:43,120,914...43,176,324
Ensembl chr 5:43,065,176...43,192,021

G

zinc finger protein 503

increases expression

Phenytoin results in increased expression of ZFP503 mRNA

NCBI chr10:75,279,725...75,401,916
Ensembl chr10:75,397,830...75,401,764

G

zinc finger protein 638

increases expression

Phenytoin results in increased expression of ZFP638 mRNA

NCBI chr 2:71,331,782...71,435,061
Ensembl chr 2:71,276,561...71,435,069

G

zinc finger and SCAN domain containing 21

increases expression

Phenytoin results in increased expression of ZSCAN21 mRNA

NCBI chr 7:100,049,774...100,065,040
Ensembl chr 7:100,049,774...100,065,040

sertindole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

sertindole results in decreased activity of KCNH2 protein
sertindole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

PMID:16278312 PMID:21158687 PMID:24052561

NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321

sorbinil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of ACTA2 mRNA]

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339

G

aldo-keto reductase family 1 member B

decreases activity
multiple interactions

sorbinil results in decreased activity of AKR1B1 protein
[sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Reactive Oxygen Species]; [sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; [sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to Lipopolysaccharides; [sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to TNF protein; sorbinil inhibits the reaction [AKR1B1 protein results in decreased expression of CDH1 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of ACTA2 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 protein]; sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK1 protein]; sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK3 protein]

PMID:21334316 PMID:28137510

NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284

G

aldo-keto reductase family 1 member B10

multiple interactions
decreases activity

sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde]
sorbinil results in decreased activity of AKR1B10 protein

PMID:18325492 PMID:19028477

NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412

G

albumin

multiple interactions

sorbinil inhibits the reaction [[ALB protein binds to Fructosamine] which results in increased secretion of TNF protein]

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

cadherin 1

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in decreased expression of CDH1 mRNA]

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

C-X-C motif chemokine ligand 8

multiple interactions

sorbinil inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; sorbinil inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

fibronectin 1

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 protein]

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

interleukin 6

multiple interactions

sorbinil inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; sorbinil inhibits the reaction [TNF protein results in increased secretion of IL6 protein]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

mitogen-activated protein kinase 1

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

nerve growth factor

multiple interactions

sorbinil inhibits the reaction [Streptozocin results in increased expression of NGF mRNA]

NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770

G

nitric oxide synthase 2

multiple interactions

sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

prostaglandin-endoperoxide synthase 2

multiple interactions

sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

tachykinin precursor 1

multiple interactions

sorbinil inhibits the reaction [Streptozocin results in increased expression of TAC1 mRNA]

NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472

G

tumor necrosis factor

multiple interactions

[sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to TNF protein; sorbinil inhibits the reaction [[ALB protein binds to Fructosamine] which results in increased secretion of TNF protein]; sorbinil inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]; sorbinil inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; sorbinil inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; sorbinil inhibits the reaction [TNF protein results in increased secretion of IL6 protein]
sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; sorbinil inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]

PMID:21334316 PMID:24021941 PMID:30682331

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

vascular endothelial growth factor A

multiple interactions

sorbinil inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	26034
chemical entity	26024
atom	26009
nonmetal atom	25498
nitrogen atom	22541
nitrogen molecular entity	22528
organonitrogen compound	21922
organonitrogen heterocyclic compound	20349
diazolidine	1017
imidazolidines	1007
(3S)-3-hydroxy-L-enduracididine	0
2-[1-(4-chlorophenyl)-5-oxo-3-(2-pyridin-4-ylethyl)-2-sulfanylidene-4-imidazolidinyl]-N-(4-fluorophenyl)acetamide	0
3-(2-fluorophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(2-methylphenyl)-2-(2-thiazolyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(3-bromophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(4-methoxyphenyl)-2-sulfanylidene-5-(thiophen-2-ylmethylidene)-4-imidazolidinone	0
4-(6-imidazolidin-2-yl-1H,3'H-2,5'-bibenzimidazol-2'-yl)phenol	0
4-chloro-N-[3-(4-fluorophenyl)-5-[2-(4-methoxyanilino)-2-oxoethyl]-4-oxo-2-sulfanylidene-1-imidazolidinyl]benzamide	0
8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one	0
Alchorneine	0
Aniquinazoline A	0
Aniquinazoline B	0
Aniquinazoline C	0
Clazolimine	0
Ethylenethiourea	55
Imicyafos	0
L-enduracididine	0
N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide	0
N-(4-ethoxyphenyl)-2-[5-oxo-1-phenyl-3-(2-pyridinylmethyl)-2-sulfanylidene-4-imidazolidinyl]acetamide	0
[(2R,2'S)-2,2'-bipiperidinato(2-)-kappa(2)N(1),N(1')](imidazolidin-1-yl)[(6S)-6-[(2S)-piperidin-2-yl-kappaN]-1,2,3,6-tetrahydropyridinato(2-)-kappaN]ruthenium(2+)	0
bisantrene	0
imidacloprid +	407
imidapril +	5
imidaprilat	2
imidazolidine +	0
imidazolidinone +	619
methylparabanic acid	0
nimazone	0
Path 2
Term	Annotations
CHEBI ontology	26034
subatomic particle	26009
composite particle	26009
hadron	26020
baryon	26009
nucleon	26009
atomic nucleus	26009
atom	26009
main group element atom	25834
p-block element atom	25834
carbon group element atom	25434
carbon atom	25403
organic molecular entity	25392
organic molecule	25222
organic cyclic compound	24274
organic heterocyclic compound	22328
organic heteromonocyclic compound	19212
diazolidine	1017
imidazolidines	1007
(3S)-3-hydroxy-L-enduracididine	0
2-[1-(4-chlorophenyl)-5-oxo-3-(2-pyridin-4-ylethyl)-2-sulfanylidene-4-imidazolidinyl]-N-(4-fluorophenyl)acetamide	0
3-(2-fluorophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(2-methylphenyl)-2-(2-thiazolyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(3-bromophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(4-methoxyphenyl)-2-sulfanylidene-5-(thiophen-2-ylmethylidene)-4-imidazolidinone	0
4-(6-imidazolidin-2-yl-1H,3'H-2,5'-bibenzimidazol-2'-yl)phenol	0
4-chloro-N-[3-(4-fluorophenyl)-5-[2-(4-methoxyanilino)-2-oxoethyl]-4-oxo-2-sulfanylidene-1-imidazolidinyl]benzamide	0
8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one	0
Alchorneine	0
Aniquinazoline A	0
Aniquinazoline B	0
Aniquinazoline C	0
Clazolimine	0
Ethylenethiourea	55
Imicyafos	0
L-enduracididine	0
N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide	0
N-(4-ethoxyphenyl)-2-[5-oxo-1-phenyl-3-(2-pyridinylmethyl)-2-sulfanylidene-4-imidazolidinyl]acetamide	0
[(2R,2'S)-2,2'-bipiperidinato(2-)-kappa(2)N(1),N(1')](imidazolidin-1-yl)[(6S)-6-[(2S)-piperidin-2-yl-kappaN]-1,2,3,6-tetrahydropyridinato(2-)-kappaN]ruthenium(2+)	0
bisantrene	0
imidacloprid +	407
imidapril +	5
imidaprilat	2
imidazolidine +	0
imidazolidinone +	619
methylparabanic acid	0
nimazone	0

paths to the root